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Bronchiectasis is characterized by chronic cough, sputum production and recurrent
chest infections. The pathogenesis is poorly understood but pulmonary pathology
shows excess neutrophilic airways inflammation. Accumulating evidence suggests
that statins have pleiotropic effects, including modulation of innate and adaptive
immune system and anti-inflammatory effects and therefore is a potential novel anti
inflammatory therapy for patients with bronchiectasis.
Aim
The aim of this thesis was to (i) establish if atorvastatin could break the vicious circle
of infection and inflammation in bronchiectasis and (ii) establish the anti
inflammatory mechanisms of statins contributing to this.
Methods
A RCT was conducted to test the hypothesis that aorvastatin could be a potential anti
inflammatory therapy in bronchhiecatsis. In this RCT patients aged 18-79 years were
recruited. Patients had clinically significant bronchiectasis, which is patients with
cough and sputum production when clinically stable, with two or more chest
infections in the preceding year and bronchiectasis confirmed on CT scan of the chest.
We excluded: current smokers or ex-smokers of less than 1 year, those with a greater
than fifteen pack year history or those with predominant emphysema on CT scan;
cystic fibrosis; active allergic bronchopulmonary aspergillosis; active tuberculosis;
poorly controlled asthma; pregnancy or breast feeding; known allergy to statins;
currently on statins or statin use within 1 year; active malignancy; chronic liver
disease; patients on long term oral macrolides; patients chronically colonized with
Pseudomonas aeruginosa.
Sequence generation was done by block randomization of four, by Tayside
pharmaceuticals, NHS Tayside, for 30 patients to receive either atorvastatin 80mg or
30 to receive placebo orally, once daily for 6 months. The placebo (lactose) was not
matched to the atorvastatin in appearance. Pharmacy directly dispensed study
medications to the patients, hence allocation concealment was maintained at all times
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to the study investigators. The primary endpoint of this study was a reduction in
cough at 6 months compared to baseline as measured by the Leicester Cough
Questionnaire (LCQ) score. It is a 19 item self completed quality of life measure of
chronic cough which ranges from 3-21, a lower score indicating a more severe cough.
The minimum clinically important difference (MCID) is 1.3 Units. The LCQ score is
repeatable over 6 months in stable disease. Analysis done was intention to treat.
Secondary outcomes included: forced expired volume in one second, forced vital
capacity; incremental shuttle walk test; qualitative and quantitative sputum
bacteriology; exacerbation frequency; health related quality of life; sputum neutrophil
numbers and apoptosis; sputum myeloperoxidase and free elastase activity; sputum-
interleukin (IL)-8; systemic inflammation- white cell count, C-reactive protein (CRP)
and erythrocyte sedimentation rate, additional systemic inflammatory markers (IL-1(3,
IL-6, IL-8, IL-10, IL-12p70 and tumor necrosis factor-a) and safety of therapy.
Findings
(i) RCT
There was evidence of a difference in baseline to 6-month change in LCQ between
the treatment groups, with a significant improvement in the statin treated group, with
a mean difference 2.2, 95% CI for difference (0.5, 3.9) p=0.01.
When analyzed as proportion of improvement in LCQ, in the statin treated group 40%
patients had a 1.3 Units or more improvement in the LCQ compared with 17% in the
placebo group; difference in proportion 23% (95% CI for difference 1%, 45%),
p=0.04.
There was significantly increased number of apoptotic airway neutrophils [mean
difference of 8.9 (11.7); p=0.04] with a trend towards a decreased total number of
neutrophils in the sputum; p=0.09; in statin treated group.
Ten (33%) patients had an adverse event in the statin group compared to three (10%)
in the placebo, difference in proportion 23% (95% CI for difference 3%, 43%),
p=0.02. There were however no serious adverse events.
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(ii) In vitro studies
Statins enhance apoptosis of neutrophils in vitro and this is consequent to reduction in
stimuli induced increase in calcium flux.
Interpretation
(i) In this proof of concept study, six months of atorvastatin improved cough in
bronchiectasis. Multi-centered studies are now needed to assess whether long-term
statin therapy can reduce exacerbations.
(ii) Further studies are needed to establish if statins regulate Ca2+ flux by altering the
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"This affection of the bronchia is always produced by chronic catarrh, or by some
other disease attended by long, violent, and often repeatedfits ofcoughing. "
R.T.H. Laennec.
1.1.1. DEFINITION AND EPIDEMIOLOGY
Bronchiectasis is a common chronic debilitating respiratory condition. First described
by Laennec in 1819, then by Osier in the late 1800s, and then further detailed by Reid
in 1950s, bronchiectasis has since undergone significant changes in prevalence,
etiology, diagnosis and management (Bilton 2008, Luce 1994). Patients suffer daily
cough, excess sputum production and recurrent chest infections because of inflamed
and permanently damaged airways (Rougin 2008). Pulmonary pathology shows
excess neutrophilic airways inflammation, but despite this over two thirds of patients
are chronically infected with potential pathogenic microorganisms.
Reid defined bronchiectasis as permanent dilatation of the airways, a term that has
stayed with the disease for more than 60 years. Bronchiectasis can be characterised by
the pathologic or radiographic appearances. Cylindrical or tubular bronchiectasis is
characterised by dilated airways; varicose bronchiectasis (so named because its
appearance is similar to that of varicose veins) is characterized by focal constrictive
areas along the dilated airways that result from defects in the bronchial wall; and
saccular or cystic bronchiectasis is characterized by progressive dilatation of the
airways, which leads to formation of large cysts or saccules and always indicative of
the most severe form of bronchiectasis (figure 1) (Reid 1950).
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Varicose Cystic
Figure 1. Bronchial dilatation in bronchiectasis as defined by Reid et al.
There is no systematic data available on the incidence or prevalence of bronchiectasis.
It is generally presumed that with the use of antibiotics in the 20th century there has
been a decline in the incidence of bronchiectasis (Barker
2002Tiavascript:showrefcontentf'refrenceslaver'): Data available suggest that the
prevalence of bronchiectasis reflects the socioeconomic conditions of the population
under study, with significantly lower prevalence in areas where immunizations and
antibiotics are readily available. Hence, bronchiectasis remains a major cause of
morbidity in countries with limited access to medical care and antibiotic therapy
(Singleton et al 2000, Chang et al 2002).
Similarly, in UK there are no recent studies, although chest x-ray features of
bronchiectasis in the 1950s suggested a prevalence of 100/ 100 000 (Reid 1950). This
is perhaps an under estimation of the actual incidence of bronchiectasis as most of
these studies were conducted before the diagnostic methods such as high resolution
CT scans were available (BTS guidelines 2010). For instance, the pathological
changes of bronchiectasis have been identified using HRCT in up to 15- 30% of
patients diagnosed in primary care with chronic bronchitis and chronic obstructive
pulmonary disease (COPD) (Patel et al 2004, O'Brien et al 2000). In international
studies, bronchiectasis is more common in women and the mean age is in the 60's
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although it can affect any age (Reich and Johnson 1992).
1.1.2. PATHOPHYSIOLOGY
The pathogenesis of bronchiectasis is poorly understood. Pulmonary pathology shows
excess neutrophilic airways inflammation (Angrill 2001), but despite this over two
thirds of patients are chronically infected with potential pathogenic organisms
(Angrill 2002). The affected areas may show a variety of changes, including
transmural inflammation, oedema, scarring, and ulceration. Patients suffer daily
cough, daily sputum production and recurrent chest infections, leading to an
inflammatory disease condition. The acute inflammatory response is a protective
mechanism that is evolved to eliminate invading organisms and should ideally be self-
limiting and lead to complete resolution (Serhan 2007, Houck 1979, Mantovani et al
2011, Medzhitov 2010). However there is failure of resolution of inflammation in
bronchiectasis, leading to irreversible damage and dilatation of the bronchial airways
with loss ofmucociliary function. It is assumed there are intrinsic abnormalities of the
innate and adaptive immune systems that predispose to impaired clearance of
respiratory pathogens and exaggerated inflammatory responses secondary to
abnormal immune regulation. Repeated micro-aspiration of upper airway organisms
during recurrent respiratory infections when mucociliary clearance is temporarily
compromised may help establish lower airway infection. The driver for persistent
neutrophilic airway inflammation in bronchiectasis is unknown, but infection is
considered to play a major role (Angrill 2001). This is easy to understand as part of a
'vicious cycle' which was first described by Cole and colleagues and all of our
current management strategies are directed towards breaking this cycle (Cole 1984).
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1.1.3. VICIOUS CIRCLE
Described by PJ Cole in 1984 (Cole 1984), there is a 'vicious circle' (figure 2) of
airways inflammation and bacterial infection in bronchiectasis. The lung is
continuously exposed to inhaled pathogen and it is the primary and secondary defense
of the lung that maintains sterility of the lung. The excessive neutrophilic airways
inflammation leads to damage of the bronchial wall and paradoxically promotes more
airways inflammation and bacterial infection creating a vicious cycle (Barker 2002,
Cole 1984). During natural resolution, polymorphonuclear neutrophils are required for
antimicrobial defense (Medzhitov 2010), but these cells must then apoptose and be
removed from the inflammatory site by macrophages (Henneke and Golenbock 2004,
Rossi et 2006, Dinarello 2010, Schif-Zuck et al 2011). Is this natural resolution














Figure 2. Vicious circle as described by Cole.
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1.1.4. AETIOLOGY
Although there are many different disease processes, bronchiectasis is the final
pathological end point. All the different etiologies ultimately lead to destruction of the
airway epithelium, damage of the mucociliary clearance thereby leading to persistent
infection and inflammation. Part of the assessment of patients with bronchiectasis
involves identifying where possible the primary insult and allowing specific
management. Identifying an underlying cause may limit the need for expensive,
invasive or time-consuming investigations and may direct appropriate management.
Examples include the commencement of immunoglobulin replacement therapy in
patients with common variable immune deficiency and considering oral steroid
treatment in those with allergic bronchopulmonary aspergillosis. A significant
proportion of adults have bronchiectasis secondary to previous pneumonia or other
lower respiratory tract infections but often no cause is identified (BTS guidelines
2010). All other causes are much less frequent. Causes are summarized in table 1.
Etiology Incidence (%) History/
Signs
Investigation Expected findings
Idiopathic 53 Diagnosis of
exclusion










Immune defect 8 Immunoglobulin Decreased values
G, A, M and of
protein immunoglobulins,
electrophoresis. subclasses or








Allergic 7 History of Full blood count; Raised eosinophils,
bronchopulmona asthma and Total IgE, Ig E total IgE and IgE
ry aspergillosis fleeting to aspergillus, specific to
(ABPA) infiltrates or Aspergillus aspergillus.
proximal precipitins; 24 hr CXR or HRCT
bronchiecta sputum for evidence of
sis on CXR aspergillus; fleeting infiltrates
or CT chest HRCT or proximal
bronchiectasis.
Aspiration/ 4 History Bronchoscopy if Foreign body/
Gastro consistent indicated mucus plugging in
oesophageal with (e.g. foreign bronchus
reflux (GORD) aspiration body aspiration)
or reflux
Rheumatoid 3 History of Autoimmune Positive screen
Arthritis (RA) RA screen (Anti
CCP)
Cystic Fibrosis 3 Age <40 CF cytogenetics CFTR mutations
(CF) years, (CFTR gene Positive sweat test:
19
malabsorpti mutations); chloride>60mEq/l
on, male Sweat test
infertility;
diabetes
Ciliary 1.5 History of Ciliary motility Abnormal ciliary
Dysfunction situs assessment from beat pattern





Ulcerative Colitis <1 History of Gastro-intestinal Biopsy suggestive
chronic investigations of inflammatory
productive (colonoscopy bowel disease.







Table 1. Etiology, clinical findings and relevant investigations in brochiectasis.




Lower respiratory tract infections are associated with the etiology of bronchiectasis
and most common is bacterial pneumonia. Pertussis, pulmonary tuberculosis,
mycoplasma and viral pneumonia (particularly adenoviruses and measles but also
influenza and respiratory syncytial viruses) have, in addition, all been linked directly
to permanent lung damage and bronchiectasis (Pasteur et al 2000). Post-tuberculous
bronchiectasis is often segmental or lobar in the area primarily affected (Scala et al
2000). In studies investigating the aetiology of bronchiectasis in those over the age of
50, infection was identified as the etiology in more than a third of the cases (Warner
1935).
1.1.4.2. Mycobacterium tuberculosis and non-tuberculous mycobacteria
Bronchiectasis may result from pulmonary Mycobacterium tuberculosis infection,
with the incidence reflecting the prevalence of tuberculosis in the population. It is also
increasingly recognised that opportunist mycobacteria are associated with localised or
widespread bronchiectasis. Opportunist mycobacteria have been isolated in 2% and
10% of random sputum specimens from patients with bronchiectasis, but the clinical
significance is unclear. Patients with Mycobacterium avium complex (MAC)
infection may develop bronchiectasis over years. Middle-aged or elderly women are
particularly prone to this disease and is known as Lady Windermere disease and this
particularly affects the middle lobe or the lingula (Reich and Johnson 1992).
However, isolation of an opportunist mycobacterial species should not necessarily be
interpreted as pathogenic. Persistent isolation (colonisation) may occur without any
change in clinical status. Careful follow-up is mandatory because colonisation can
change to infection. Patients should be reassessed if there is a change in clinical
features, change in sputum conventional microbial culture, there is a rapid decline in
spirometry, or if there are characteristic HRCT changes (exudative 'tree-in-bud'
bronchiolitis, mucus plugging, cavitating nodules, rapid progression of broncheictasis;
(figure 3)). The species isolated will also influence the likelihood of infection (M
avium complex, M kansasii, M malmoense), for example mycobacteria such as M
gordonae maybe just a contaminant. (BTS guidelines 2010).
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Figure 3. a. HRCT showing tuberculous granuloma in bronchiectasis (as indicated by




Definition of an exacerbation in bronchiectasis
The BTS guidelines recommends antibiotics for exacerbations that present with an
acute deterioration (usually over several days) with worsening local symptoms
(cough, increased sputum volume or change of viscosity, increased sputum purulence











Figure 5. Exacerbations as defined by the BTS guidelines, 2010.
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1.3. SPUTUM MICROBIOLOGY AND COLONIZATION
In bronchiectasis, the normally sterile airways are chronically colonised with
pathogenic organisms in about 70% of patients. In adults, definitions of colonization
have included at least three isolates of an organism over a period of at least 3 months;
and at least two isolates 3 months apart over 1 year (BTS guidelines 2010).
Common gram-positive organisms colonising the airways include Streptococcus
pneumoniae and Staphylococcus aureus (both methicillin-sensitive and methicillin-
resistant). Gram-negative pathogens include uncapsulated nontypable Haemophilus
influenzae, Moraxella catarrhalis, Klebsiella, Enterobacter and non mucoid and
mucoid Pseudomonas aeruginosa (Angrill et al 2002). The type of bacterial infection
is important in the determination of the patient's prognosis. Studies have shown that
patients colonised with Pseudomonas aeruginosa usually have worse symptoms,
worse health-related quality of life and accelerated decline in forced expiratory
volume over one second (FEVi) (Martinez-Garcia et al 2007). Pseudomonas
aeruginosa and other gram-negative organisms are usually found in patients with
more severe bronchiectasis. Patients are encouraged to hand in sputum samples for








Figure 4. Summary of common pathogens isolated from bronchiectasis patients
(Chalmers et al 2012).
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1.3.1. Haemophilus influenzae
In adults, H. influenzae is the most frequently isolated microorganism, with about
35% patients being colonized with it. In bronchiectasis, 39% of the patients are
colonized with Haemophilus influenzae (Chalmers et al). It is a small (1 pm X 0.3
pm), non-motile, pleomorphic, gram-negative coccobacillus. There are both
capsulated and non-capsulated (also known as non typeable) strains. It has now been
recognized that NTHi (non typeable Haemophilus influenzae) is a major cause of
respiratory infection, which tends to be chronic and recurrent and includes sinusitis,
otitis media, tonsillitis, pneumonia and chronic bronchitis and systemic infection
(Murphy 2001). In the context of infection, it has the capacity to live intracellularly
especially in macrophages (Craig et al 2002). In chronic bronchitis, studies have
shown that large proportions of patients have persistent infection with NTHi and may
show extensive invasion of the lung (Moller et al 1998) NTHi is a heterogeneous
pathogen with many different strains (Bruant et al 2003) and there is considerable
turnover with new strains being acquired periodically (Samuelson et al 1995). In a
study done by King et al, they confirmed that NTHi was the most commonly isolated
H.influenzae in bronchiectasis (King et al 2003).
Studies have demonstrated that serum is bactericidal for NTHi. The bactericidal effect
of serum on NTHi appears to be mediated through a combination of antibody (IgM
and IgG) and complement (King et al 2008, Gnehm et al 1985, Musher et al 1983).
This bactericidal action suggests killing by the terminal attack complex of
complement with insertion of complement components C5-9 to form a pore in the
bacterial membrane. The effect of the membrane-attack complex is well characterized
in NTHi, Neisseria meningitidis (meningococcal), Streptococcus pneumoniae and
Escherichia coli infections (Figueroa and Densen 1991, Joiner et al 1985).
Some strains of NTHi may be more resistant to serum killing, and Williams et al
described an invasive isolate ofNTHi that was able to inhibit C3 deposition (Williams
et al 2001). The role of antibody in respiratory mucosal defence against NTHi is not
well defined, although it is likely to be significant. IgA would prevent the binding of
NTHi to respiratory mucosa and a major pathogenic mechanism of this bacterium is
the production of IgA proteases (Erwin and Smith 2007, Foxwell et al 1998, St. Geme
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1997). However, it is known that inflamed bronchi also produce complement and
IgG/IgM (Peng et al 2005, Reynolds et al 1997), which may enhance bacterial
killing.
There is no widely used effective vaccine for NTHi. There have been problems of
antigenic variability and finding a suitable animal model. Most work has focused
generally upon enhancing humoral immunity. Developing a vaccine to enhance T
lymphocyte responses to NTHi may be important (Williams et al 1998).
Haemophilus influenzae is the most common pathogen isolated from sputum of
bronchiectasis patients. Most bronchiectasis patients with chronic NTHi infection are
able to mount a highly effective humoral immune response that prevents systemic
infection. H influenzae die within 3 hours hence to maximize the chances of isolating
H influenzae, sputum specimens should reach the microbiology laboratory within 3h.
This should be done routinely prior to starting antibiotic therapy for exacerbations.
The choice of antibiotic and the duration of antibiotic therapy for treating
exacerbations with H. influenzae infection are summarized in table 2.
1.3.2. Pseudomonas aeruginosa
Although Pseudomonas aeruginosa has been extensively studied in cystic fibrosis,
there is limited data available in the literature about P. aeruginosa in non cystic
fibrosis bronchiectasis. P.aeruginosa is a gram-negative bacillus (non capsulate and
non sporing) that affects particularly the lower respiratory tract (Banerjee and
Stableforth 2000). Without any treatment, P. aeruginosa infection persists in spite of
the recruitment of the host's defence mechanisms and leads to decreased respiratory
function (Dudley et al 2008). The initial infection is not associated with an immediate
and rapid decline in lung function, and early P. aeruginosa isolates appear non-
resistant to the antibiotic treatment (Geller 2009), giving an opportunity for an early
efficient therapeutic intervention (Rosenfield et al 2003). Aggressive and early
antibiotic treatments of P. aeruginosa infection were shown to increase the life
expectancy of CF patients (Geller 2009, van Westreenen and Tiddens 2010). P.
aeruginosa can form biofilms (Hoiby et al 2010), develop a mucoid phenotype and
lack membrane porins (that are essential for antibiotic diffusion) (Nicas and Hancock
1983) or can develop an active drug efflux mechanism (Nikaido 1994).
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In bronchiectasis, chronic infection with P.aeruginosa is observed in 24-33%
(Pasteur et al 2000) patients. In most cases, mucoid P. aeruginosa infections cannot
be eradicated. However, early aggressive antibiotic treatment is recommended and an
attempt should be made to eradicate it (BTS guidelines 2010). Hence it is of utmost
importance to send sputum promptly for culture and sensitivity, prior to starting
antibiotics. The BTS guidelines recommends that an attempt to eradicate
P.aeruginosa should be made with high dose oral ciprofloxacin 750mg BD, for
2weeks (BTS guidelines 2010). Failing this, it is recommended to administer
intravenous or nebulised anti pseudomonal antibiotic for 2-4weeks (BTS guidelines
2010). However, careful monitoring of renal function and side effects of high doses of
antibiotics should be considered and treatment should be based on a balance of
benefits outweighing risks. The above treatments recommended are recommended are
based on expert opinion only and RCTs are needed to determine whether early
interventions influence outcome.
Chronic P. aeruginosa infection is associated with poorer lung function, decreased
quality of life and frequent hospital admissions (Evans et al 1996, Wilson et al 1997).
Martinez and colleagues (Martinez et al 2008) conducted a study in 67 patients with
stable bronchiectasis and followed them up for 2years, conducting spirometry,
microbiological analysis of sputum and recorded number of exacerbations over the
study period. They detected chronic colonization with P. aeruginosa was a
independent predictor of forced expiratory volume in 1-second (FEVi) decline [odds
ratio (OR), 30.4; 95% CI, 3.8-39.4; p=0.005].
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1.3.2.1. P. aeruginosa and biofilms
One of the important features of P. aeruginosa is its ability to form biofilms. These are
defined as a sessile community characterised by cells that are irreversibly attached to
a surface or interface, or to each other, and embedded in a matrix of extracellular
polymeric substance exhibiting an altered phenotype (Donlan and Costerton 2002).
Biofilms protect the bacterial population against host defence and increase the
tolerance to antimicrobials. It may be difficult for neutrophils to penetrate into mucus
plaques (figure 6). Though being aerobic, P. aeruginosa within biofilm is able to
survive in the hypoxic environment of the mucus plug, which diminishes its
sensitivity to antibiotics (Boucher 2004). This is emphasised by their ability to form
in the lungs of chronically ill patients, on catheters and on prosthetic valves, often
requiring prolonged periods of antibiotic therapy to eradicate the organism. Links
between biofilm formation and quorum sensing have been well established (Popat et
al 2008, deKievit 2009). In environments deplete of iron, flat biofilms are formed
with wild-type P aeruginosa, which had previously grown in the classical mushroom
form in an iron replete medium (Patriqin et al 2008). The primary source of carbon as
a nutrient also influences the structure of the biofilm, which differs from those in
which glucose is the main source rather than citrate. This is thought to be due to
differences in the motility of the bacterial population influenced by the primary
carbon source (Kausen et al 2003). By manipulating the quorum sensing of P
aeruginosa populations and thereby creating mutants, the type and shape of biofilm
formed is also influenced, with mutants forming flat biofilms compared with wild
type (Davies et al 1998).
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Figure 6a. Flat or iron deplete biofilm.
Neutrophil
Figure 6b. Mushroom biofilm.
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1.3.2.2. Quorum sensing and biofilm development
A number of specific bacterial factors enhance the ability of the pathogen to evade
host defences. These include adherence, the ability to impair ciliary clearance and
damage the epithelial surface (which enhances both), and avoidance of phagocytosis
(Nicod 1999). Therefore, the balance between the innate and adaptive immune
response and bacterial factors that avoid this response will result in reduced bacterial
clearance and facilitate proliferation leading to colonization.
An area of increasing interest and research in bacterial behavior is quorum sensing.
This complex cell-to-cell signaling mechanism of bacterial populations modulates
their behavior and ability to survive, colonize and potentially invade the host. Quorum
sensing is defined as the capacity to detect extracellular, small-molecule signals and
to alter gene expression in response to bacterial population densities that reach a
threshold concentration. These signaling pathways modulate various functions of the
bacteria, including their metabolism, expression of virulence factors and biofilm
formation (Bjarnsholt and Givskov 2007).
Many common bacteria contain quorum-sensing genes. Much of the research to date
has specifically examined the quorum-sensing system employed by P aeruginosa. It
is difficult to eradicate and therefore its behaviors mediated by quorum-sensing
systems and potential interactions with the host defence are likely to be of major
importance.
The quorum sensing of Gram-negative bacteria is predominantly via the well
characterised N-acyl homoserine lactone (AHL) signalling system (Popat et al 2008,
Bjarnsholt and Givskov 2007). The AHL-based circuits are encoded by two signalling
systems operating with specific signalling molecules, termed the Las and Rhl system.
The two systems operate with specific signal molecules: 3-oxo C12-HSL for the lasR-
encoded receptor and C4-HSL for the rhlR-encoded receptor (Popat et al 2008,
Bjarnsholt and Givskov 2007). These systems also interact with host defences.
Telford et al (Telford et al 1998) demonstrated that the Pseudomonas quorum-sensing
signal molecule N-(3 oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) had
immunomodulatory activity in addition to its recognised role in regulating virulence.
Ritchie et al (Ritchie et al 2005) showed direct effects on T cells and a role of this
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molecule in the initial stages of T-cell activation and Smith et al (Smith et al 2002)
demonstrated (in mice) that the quorum-sensing systems of Pseudomonas could
induce inflammatory mediators in vivo via T cells, promoting the production of the
inflammatory cytokine y interferon.
In addition, 3-oxo-cl2-HSL induces apoptosis in the neutrophils and macrophages.
Tateda et al (Tateda et al 2003) proposed a mechanism of chronic Pseudomonas
infection in the lungs involving quorum sensing whereby the formation of biofilms
created a favourable environment for Pseudomonas survival. They suggested that 3-
oxo-C12-HSL induced the production of neutrophil chemotactic factors (IL-8 in
humans and macrophage inflammatory protein-2 in mouse models). This sets in
motion a chain of events leading to tissue destruction and accelerated neutrophil
apoptosis, all of which contribute to the persistence of Pseudomonas in the lungs. In
the presence of 3-oxo-C12-HSL neutrophil apoptosis is accelerated, therefore
reducing bacterial killing capacity by these cells. Incubating neutrophils with 3-oxo-
C12-HSL was shown to increase markers of apoptosis. It was proposed that apoptotic
neutrophils also provide nutrients for the bacteria, facilitating their proliferation. This
concept is outlined in Fig 7. It is not known whether these Pseudomonas products are
active in the airways of colonized patients with bronchiectasis and further studies are
clearly needed to establish whether this process is important in establishing and
maintaining colonization ofP aeruginosa in bronchiectasis.
The choice of antibiotic and the duration of antibiotic therapy for treating
exacerbations with P.aeruginosa infection are summarized in table 2.
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P. aeruginosa blofilm
and proliferation molecule + P.aeruginosa
Figure 7. Quorum sensing and biofilm development in P. aeruginosa.
While many investigations into bronchiectasis contain microbiological information,
only a few offer a comprehensive cross-sectional analysis of bacterial isolation.
Difference in methodology and population that is being studied makes it difficult to
compare the studies. However, it can be concluded that P. aeruginosa colonization is
common in bronchiecatic adults and that chronic colonization is associated with more
severe bronchiectasis and worse disease prognosis.
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1.3.3. Other potential pathogenic microorganisms (PPM)
The other PPMs of significance in bronchiectasis are S.pneumoniae, M.catarrhalis,
enteric gram-negative organisms like E.Coli and Klebsiella and S.aureus (both
methicillin sensitive and methicillin resistant).
1.3.3.1. Streptococcus pneumoniae
In bronchiectasis, S. pneumoniae is detected in about 1-22% of patients (Angrill et
al 2002). It is grown on blood agar and to maximise the chances of isolating S.
pneumoniae, specimens should reach the microbiology laboratory within 3 hours.
Exacerbations are treated with oral antibiotics (Amoxicillin 500mg TDS or
Clarithromycin 500mg BD) for 14 days (BTS guidelines 2010). The BTS guidelines
recommend long term antibiotic therapy for S. pneumoniae colonisation with
Amoxicillin 500mg BD as first line and Clarithromycin 250mg BD as second line
of treatment (BTS guidelines 2010). Combination antibiotics are not recommended
for treating exacerbations with S.pneumoniae (BTS guidelines 2010).
S. pneumoniae are lancet-shaped, gram-positive, facultative anaerobic bacteria with
over 90 known serotypes, of which 23 are included in the pneumococcal vaccine
Pneumovax ®. Most S. pneumoniae serotypes have been shown to cause disease,
but only a minority of serotypes produce the majority of pneumococcal infections.
Each serotype is characterized by an individual polysaccharide capsule, which
functions as a key virulence factor (Hyams et al 2010). Antibody to cell wall
constituents of the pneumococcus becomes attached to the surface of the organism,
and in turn binds complement. The presence of the capsule prevents iC3b and the
Fc of immunoglobulins on the bacterial cell surface from interacting with their
receptors on the surface of phagocytic cells, with the result that the organisms
remain extracellular (Musher 1992). The capsule is also crucial for colonization,
prevents mechanical removal by mucus (Nelson et al 2007), and can also restrict
autolysis and reduce exposure to antibiotics (Van der Poll et al 2009).
Another important pneumococcal virulence factor is the exotoxin pneumolysin
(PLY). PLY of most pneumococcal strains is cytotoxic to mammalian cells by
forming large pores into membranes (Mitchell and Mitchell 2010). Pneumococci
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are common inhabitants of the respiratory tract and may be isolated from the
nasopharynx of 5-70% of adults, depending on the population and setting.
S.pneumoniae is the most common cause of community acquired pneumonia and
bacterial meningitis. In bronchiectasis, S.pneumoniae is frequently isolated in
sputum cultures, varying between 1-22%.
S. pneumoniae remains a common pathogen and a major cause of morbidity and
mortality. S. pneumoniae infections are estimated to cause 500,000 cases of
pneumonia, 55,000 cases of bacteremia, and 6,000 cases of meningitis annually in the
United States (Williams et al 1998). The clinical course of S. pneumoniae infections is
affected by a number of factors including the site and severity of infection, the
underlying health of the patient, and the adequacy of antimicrobial therapy.
Therefore, it is not surprising that estimates of mortality are reported to range from
<1% to >50%.
Initially, all S. pneumoniae isolates were exquisitely susceptible to penicillin (MIC,
<;0.06 mg/mL), and this antibiotic served as the drug of choice. Beginning in the
1960s, however, clinical resistance to penicillin and other agents began to be reported.
The clinical significance of penicillin resistance in S. pneumoniae was not appreciated
until 1967, when Hansman and Bullen (Hansman and Bullen 1997) recovered a
penicillin-resistant S. pneumoniae isolate (MIC, 0.6 mg/mL) from a patient with
hypogammaglobulinemia and bronchiectasis.
The choice of antibiotic and the duration of antibiotic therapy for treating
exacerbations with S.pneumoniae infection are summarized in table 2.
34
1.3.3.2. Moraxella catarrhalis
It is a gram-negative, aerobic, oxidase-positive diplococcus. The endotoxin of M
catarrhalis, a lipopolysaccharide may play a role in the disease process. Some
strains ofM catarrhalis have pili or fimbriae, which may facilitate adherence to the
respiratory epithelium. Some strains produce a protein that confers resistance to
complement by interfering with the formation of the membrane attack complex. An
important feature of M. catarrhalis is that at least 90% of isolates produce a p-
lactamase with activity against P-lactams such as penicillin and the amino
penicillins (Fung et al 1994).
Studies have demonstrated that M. catarrhalis is isolated in 1-20% of patients with
bronchiectasis. Its persistence within the respiratory tract is most likely aided by its
capacity to invade respiratory epithelial cells, inactivate complement and form
biofilms (Murphy et al 2009). In addition, more than 90% of M. catarrhalis isolates
are P-lactamase producers and resistant to ampicillin.
Other resident bacterial flora, including a-haemolytic streptococci, can inhibit the
growth of M. catarrhalis, H. influenzae and S. Pneumoniae. This competitive
balance is altered by antibiotics and also during an acute viral respiratory infection
where numbers for all three pathogens are increased (Murphy et al 2009). M.
catarrhalis is acquired early in life and is a prominent coloniser of the upper
respiratory tract in infants and children, before decreasing substantially during the
adult years.
Antibiotic recommended for acute exacerbations is summarized in Table 2 and long
term antibiotic treatment for M. catarrhalis is summarized in Table 2.
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1.3.3.3. Staphylococcus aureus
It is a facultative anaerobic gram-positive coccus. Staphylococci are nonmotile,
non-spore-forming, and catalase-positive bacteria. The cell wall contains
peptidoglycan and teichoic acid. Most strains of S. aureus are sensitive to the more
commonly used antibiotics. Those that are sensitive to methicillin are termed
methicillin-sensitive Staphylococcus aureus (MSSA). Methicillin-resistant
Staphylococcus aureus (MRSA) and MSSA only differ in their degree of antibiotic
resistance. Over the last 20 years, community and hospital infections with S. aureus
have risen-in particular with MRSA and more recently vancomycin resistant S.
aureus.
1.3.3.4. Other enteric gram-negative organisms {Klebsiella, Enterobacteriaceae)
Angrill and colleagues they showed that bronchial colonisation by PPMs are common
in patients with bronchiectasis in a stable clinical situation and in more than 60% of
these patients the distal airways were colonised. They also concluded that sputum
culture is an adequate tool for the evaluation of bronchial colonisation in
bronchiectasis and that early diagnosis of bronchiectasis (before the age of 14),
evidence of varicose-cystic bronchiectasis and a FEVi of <80% predicted are risk
factors for the presence of PPMs in the airways (Angrill et al 2001). Additionally, in a
further study done by the same group, they performed bronchoalveolar lavage (BAL)
in 49 patients with bronchietasis and 9 controls and found that in patients with
clinically stable bronchiectasis: (7) there is an active neutrophilic inflammatory
response in the airways that is present in patients with sterile bronchi but is
exaggerated in patients with PPMs colonizing the airways; (2) colonizing bacteria act
as an inflammatory stimulus with greater bacterial load producing greater
inflammatory response; (3) the bronchial inflammatory response was
compartmentalized and could not be accurately evaluated in blood samples (Angrill et
al 2002). Recently, Chamlers et al, investigated this further in interventional and
observational studies in bronchiectasis and concluded that high airway bacterial loads
were associated with airway and systemic inflammation and a greater risk of
exacerbations. They concluded that short and long-term antibiotic therapies reduce
markers of airways and systemic inflammation (Chalmers et al 2013).
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Organism Recommended Recommended second line Length of
first line treatment treatment
treatment
Streptococcus Amoxicillin Clarithromycin 500mg bd 7-14 days
pneumoniae 500mg tds (po) (po)*
Haemophilus Amoxicillin Doxycycline 1 OOmg bd (po) 7-14 days
influenzae, 500mg tds (po) Or




500 mg* bd (po)
Or
Ceftriaxone 2G od* (IV) or
1 g bd if administering as iv
bolus.
Haemophilus Co-amoxiclav Doxycycline 1 OOmg bd (po) 7-14 days
influenzae, 625mg TDS (po) Or






Ceftriaxone 2G od* (IV) or
1 g bd if administering as iv
bolus.
Moraxella Co-amoxiclav Doxycycline lOOmg bd (po) 7-14 days








Ceftriaxone 2G od* (IV) or
1 g bd if administering as iv
bolus.
Staphylococcus Flucloxacillin Clarithromycin 7-14 days
aureus (MSSA) 500mg QDS (po) 500mg BD (po)*
Doxycycline lOOmg BD or
Coamoxiclav 625mg TDS
Staphylococcus Rifampicin Rifampicin 14 days
aureus (MRSA) 300mg bd (po) 300mg bd (po)+
Oral + Trimethoprim Doxycycline
preparations 200mg bd (po) 200mg od (po)
Third line 14 days
Linezolid
600mg bd (po)
Staphylococcus Vancomycin* Linezolid 14 days
aureus (MRSA) 600mg bd (po)
Intravenous or Teicoplanin*
preparations 400mg od (iv)
Coliforms e.g. Oral Intravenous 7-14 days
Klebsiella, Ciprofloxacin Ceftriaxone
Enterobacter 500mg bd* (po) 2G od or lg bd if
administering as iv bolus.
Pseudomonas Oral Monotherapy Intravenous 14 days
aeruginosa Ciprofloxacin Ceftazidime
500mg bd* (po) 2G tds*
Or
(750mg bd in Tazobactam/Piperacillin







The above can be combined
with gentamicin* (refer to
BNF) or colistin 1-2 MU
tds* (under 60 kg, 50 000-
75 000 units/kg daily
separated into 3 divided
doses) OR oral ciprofloxacin
500mg BD*.
Table 2. Choice of antibiotic and duration of treatment.
*dose needs adjusted in renal impairment
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1.4. DO LONG-TERM ORAL ANTIBIOTICS INFLUENCE OUTCOME?
The BTS guidelines 2010 recommend long term antibiotics in:
1. Patients having > 3 exacerbations per year requiring antibiotic therapy or
patients with fewer exacerbations causing significant morbidity should be
considered for long-term antibiotics.
2. In the first instance, high doses should not be used, to minimise side effects.
3. The antibiotic regimen should be determined by sputum microbiology when
clinically stable
4. Long-term quinolones should not be used until further studies are available.
5. Macrolides may have disease-modifying activity and preliminary data suggest
the need for a large randomised controlled trial. There have been subsequently
3 RCTs that have been conducted with macrolides in bronchiectasis and all
three have shown that long term macrolide treatment leads to decrease in
exacerbation frequency (Wong et al 2012, Serisier et al 2013, Altenburg et al

































1.5.1.1. Chest X ray
The chest X-ray is usually normal unless patients have severe bronchiectasis.
However, a normal chest x ray does not rule out bronchiectasis. Digital acquisition
devices are capable of producing x-rays with improved visualisation of, for example,
bronchiectatic airways behind the heart, with the added potential of radiation dose
reduction (Young et al 1991). However, unless disease is severe, the radiographic
signs of bronchiectasis are usually inconspicuous. Characteristic chest X-ray
appearances include crowding of bronchi, parallel line opacities (tram lines) caused
by thickened dilated bronchi, ring opacities or cystic spaces as large as 2 cm in
diameter resulting from cystic bronchiectasis, sometimes with air-fluid levels, and
oligaemia as a result of a reduction in pulmonary artery perfusion (figure 8). In terms
of specificity, the chest x-ray of a patient with COPD showing bronchial wall
thickening (tramline and ring shadows) and large volume lungs may be erroneously
interpreted as indicating bronchiectasis. In summary, although a baseline chest x ray
is recommended in all patients with bronchiectasis, they are not routinely indicated
for follow up of patients with no change in symptoms (BTS guidelines 2010).
Additionally, there is very little correlation during an exacerbation of bronchiectasis
and chest x ray changes.
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Figure 8. Cystic bronchiectasis- as indicated by arrows.
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1.5.2.High Resolution CT Scan
The current gold standard for diagnosing bronchiectasis is HRCT of the chest. The
appropriate high resolution CT study is a non contrast study with the use of 1.0-
1.5mm window every 1cm with acquisition times of one second, reconstructed with
the use of a high spatial frequency algorithm during full inspiration (Munro et el
1990). Bronchiectasis is diagnosed when there is bronchial wall dilatation, defined as
the internal lumen of the bronchus being greater than that of the accompanying
pulmonary artery, described as the 'signet' ring sign (figure 9). Characteristic features
include, lack of tapering toward the periphery producing cylindrical bronchiectasis
(figure 10), varicose constrictions along the airway (figure 11) and ballooned cysts at
the end of a bronchus (figure 12). Cylindrical bronchiectasis is by far the most
common bronchiectasis identified on CT. The usefulness of categorising
bronchiectasis into cylindrical, varicose or cystic subtypes is limited, but cystic
bronchiectasis usually denotes longstanding and more severe disease.
Bronchial wall thickening is a usual but inconsistent feature of bronchiectasis.
Problems with this variable feature have been widely debated and the definition of
what constitutes abnormal bronchial wall thickening remains unresolved (BTS
guidelines 2010).
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Figure 9. Signet ring (as indicated by arrows).
Non specific findings include consolidation or infiltration of a lobe with dilatation of
the airways, thickening of bronchial walls, mucus plugs and enlarged lymph nodes
(Thomas and Blaquiere 1993). Mucus secretions within bronchiectatic airways are
generally easily recognisable as such. The larger plugged bronchi are visible as
lobulated or branching opacities. Such airways are usually seen in the presence of
non-fluid filled obviously bronchiectatic airways. Mucus plugging of the smaller
peripheral and centrilobular airways produces V- and Y-shaped opacities, the so-
called 'tree-in-bud' pattern (Gruden and Webb 1995, Collins et al 1998, Franquet and
Fern 1999).
In patients with ABPA there is fleeting infiltrates and ultimately patients can develop
proximal bronchiectasis. The characteristic distribution with M. avium complex
infection often involves the middle lobe or lingula (Cartier et al 1999) and typically
shows bronchiectasis, nodes and 'tree in bud' appearences. With the use of high-
resolution CT, dilated airways may be seen in other diseases, adding to the confusion
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regarding the diagnosis of bronchiectasis. Airway dilatation is associated with asthma,
chronic bronchitis, and pulmonary fibrosis (so-called traction bronchiectasis). This
thesis however deals with clinically significant bronchiecatsis, which is radiological
diagnosis and clinical features in keeping with bronchiectasis.
In summary, HRCT is the radiological investigation of choice in bronchiectasis, with
bronchial wall dilation being most characteristic of bronchiectasis.
Figure 10. Tubular bronchiectasis (as indicated by arrows).
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Figure 11. Varicose bronchiectasis (as indicated by arrows).
Figure 12. Cystic bronchiectasis (as indicated by arrows).
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1.5.2 CLINICAL FEATURES OF BRONCHIECTASIS
1.5.2.1. Cough and sputum
Cough is the commonest symptom of bronchiectasis and occurs in >90% patients
(BTS guidelines 2010). The cough is productive of sputum daily in 75-100%,
intermittent in 12-20% and non-productive in 5-8% (Stockley et al 2001). In
bronchiectasis, cough occurs due to overproduction of secretions and impaired
mucociliary clearance of secretions. Mucus hypersecretory states in bronchiectasis
results usually from either hypersecretion of stored mucin or hypertrophy and
hyperplasia of goblet cells.
24 hour sputum volume measurement is perhaps a more accurate assessment of
volume produced, but is entirely dependant on patient compliance. Sputum purulence
is dependant on the release of myeloperoxidase and is classified as mucoid (clear or
grey), mucopurulent (pale yellow) and purulent (dark yellow or green) (Stockley et al
2001). Sputum purulence is related to radiological appearances on CT scan and
purulent sputum is associated with cystic bronchiectasis on HRCT (O'Brien et al
2000) and correlates well with the presence of potential pathogenic microorganisms
(Murray et al 2009).
1.5.2.2. Dyspnoea, hemoptysis, pain and fever
Dyspnoea is present in about 70% of patients and correlates inversely to FEVi.
Haemoptysis can occur with exacerbations but major haemoptysis an infrequently
occur and usually arises from an aberrant blood vessel from the bronchial arteries and
can sometimes require interventions such as bronchial embolisation or lobar resection.
Patients can present with pleuritic chest pain and fever with exacerbations.
1.5.2.3. Infective exacerbations
As previously mentioned, the BTS guidelines recommended antibiotics for
exacerbations that present with an acute deterioration (usually over several days) with
worsening local symptoms (cough, increased sputum volume or change of viscosity,
increased sputum purulence with or without increasing wheeze, breathlessness,
haemoptysis) and/or systemic upset (BTS guidelines 2010). Number of exacerbations
can vary but from the national BTS audit the number of exacerbations in a secondary
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care cohort is 2 per year (Hill et al 2012). Studies have shown that recurrent
exacerbations lead to poor quality of life (Wilson et al 1998).
1.5.2.4.Clinical signs on bronchiectasis
The most characteristic physical finding of bronchiectasis is coarse crackles on
auscultation of the lung bases, and is found in about 70% of patients (BTS guidelines
2010). Some patients may also have airflow obstruction and or clubbing.
1.5.2.5. Impact on quality of life
Assessment of psychological symptoms and quality of life has shown that patients
with bronchiectasis have increased anxiety and depression scores, increased fatigue
and lower quality of life. The St George's Respiratory Questionnaire has been
validated for use in bronchiectasis (Wilson et al 1997). Levels of depression are
related to dyspnoea score, and patients colonised with Pseudomonas have lower
quality of life than those colonised with other microorganisms. Symptoms,
particularly cough, may also impact on family members. The Leicester Cough
questionnaire has been validated for use in bronchiectasis and a lower score indicates
worse cough severity and poorer quality of life (Murray et a 2009).
Diagnosis is based on a combination of clinical, radiological and sputum
microbiology results. Patients are put in severity categories of mild, moderate or
severe bronchiectasis based on a combination of signs and symptoms as outlined in
the table 4 below. This serves more as a guide to stratify patients into severity rather




Sputum microbiology HRCT features


























Table 4. Guide to assessing severity of bronchiectasis.
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1.6. IMMUNE SYSTEM OF THE LUNG AND BRONCHIECTASIS
The innate immune system is the immediate, non-specific and first line of defense
against invading organisms. Key cells of the innate immune response include
neutrophils, macrophages, eosinophils, basophils, dendritic cells and y6 T cells. The
mucociliary escalator is lined by ciliated and mucus-producing cells. Particles >2-3
pm impact on the mucus covering epithelial cells in the upper airways and bronchi
and are removed by a combination of normal mucociliary clearance and cough (Nicod
1999, Loebinger et al 2009). Airway secretions also contain several anti-infective
proteins and polypeptides, including the bacteriostatic proteins lysozyme and
lactoferrin. Secretory leucoprotease inhibitor (SLPI), produced by the mucous glands,
macrophages and epithelial cells, has antifungal, antiviral and antibacterial properties
(Rogan et al 2009). Lactoferrrin, SLPI, lysozyme and defensins are (among others),
derived from recruited neutrophils in addition to submucosal glands (for lactoferrin)
(Rogan et al 2009). Secretary IgA is the main antibody isotype in mucosal secretions
in the respiratory tract that contributes to the initial defence mechanisms, while IgG
predominates in the plasma (Hill et al 2000).
If these primary clearance mechanisms are overwhelmed by a high bacterial load, a
secondary defense system is activated. Animal experiments clearly demonstrate this
relationship between bacterial load and activation of the secondary host response in
that a low bacterial load leads to bacterial clearance, but when the bacterial load is
greater than 106 colony-forming units/ml (cfu/ml) there is a neutrophilic host
inflammatory response (Hiemstra 2007). Our recent paper in bronchiectasis shows
that this response occurs at slO5 cfu/ml (Chalmers et al 2012).
Failure of the local host defenses results in microbial colonization, establishing the
'vicious cycle' described by Cole and colleagues. Airway epithelium responds by
releasing antimicrobial peptides and inflammatory cytokines into the airways. In
human airway epithelial cells the main classes of antimicrobial peptides produced are
the p-defensins and the cathelicidins (LL-37 in humans). Chemokines and cytokines
such as interleukin (IL)-8 are released into the submucosa (Bals and Hiemstra 2004)
and initiate the inflammatory reaction, leading to recruitment of phagocytes
(neutrophils, monocytes and macrophages), dendritic cells and lymphocytes (which
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contribute to the adaptive response) (Weng et al 2010). The airways become inflamed
leading to leakage of serum proteins including circulating antibodies and complement,
therefore increasing local antibacterial potential.
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1.7. KEY INFLAMMATORY CELLS IN BRONCHIECTASIS
1.7.1. NEUTROPHILS
Excessive neutrophilic airways inflammation is the central feature of bronchiectasis.
This paradoxically both promotes bacterial colonization and perpetuates damage to
the airways creating a vicious cycle of bacterial colonization and inflammation (Cole
1984). The lung is a unique vascular and externally exposed organ that is subject both
to PMN-mediated inflammation and PMN-opposed infection.
Granule proteins from activated neutrophils, such as azurocidin and a-defensins, alter
directly permeability changes (Serhan 2007, Houck 1979). Moreover, proteases of
neutrophilic origin such as neutrophil elastase have been regarded to be important in
degradation of surfactant proteins, epithelial cell apoptosis, and coagulation. In
addition, neutrophils produce vast quantities of reactive oxygen (ROS) and nitrogen
(RNS) species like O2 and NO through their oxidant-generating systems such as the
phagocyte NADPH oxidase and nitric oxide synthase (NOS), respectively. Besides
their important antimicrobial effector function, neutrophil-derived oxidants promote
deleterious pro-inflammatory effects thus being a major cause of neutrophil-
dependent tissue injury (Morel et al 1991).
1.7.1.1. Key functions of neutrophils relevant to bronchiectasis
1.7.1.1.1. Recruitment and migration
Recruitment is driven by chemoattractants, with IL8, leukotriene (LT) B4, interleukin-
1 beta, C5a and tumour necrosis factor (TNF) alpha believed to be of significance
(Mikami et al 1998). Elevated levels of these pro-inflammatory cytokines have been
demonstrated in bronchiectasis airway secretions (Stockley and Bayley 2000).
Neutrophil detection of chemotactic stimuli leads to a co-ordinated process of cell
signalling, cytoskeletal rearrangement and changes in surface receptor expression to
facilitate migration. Key to the process of transendothelial migration is the expression
of the integrins CD11/CD18 on neutrophils and the expression of adhesion molecules
on endothelial cells, principally intercellular adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule-1 (VCAM-1) and the selectins (Downey et al 2009, Cowburn
et al 2008).
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Neutrophil migration occurs predominately at the border of endothelial cells where
modifications of cell junctions allow this. The cell adhesion molecules, platelet
endothelial cell adhesion molecule 1 (PECAM-1 or CD31) and junctional adhesion
molecule (Martin-Padura et al 1998, Muller et al 1993, Vaprociyan et al 1993) are
involved in neutrophil transmigration. Migration occurs via PECAM-1/PECAM-1
interaction while maintaining the permeability barrier of the endothelial cell
monolayer (Muller et al 1993) The endothelial surface density of ICAM-1 is
important in regulating this migration (Yang et al 2005).
Neutrophil adhesion to pulmonary endothelial cells and migration into the lung may
occur by CD11/CD18 dependent or CD11/CD18 independent mechanisms
(Doerschuk et al 2000). Different stimuli within the lung can determine whether
CD 18 is required for neutrophil migration into the lung. It is felt that stimuli from
gram negative bacteria require CD 18, as 75-80% of neutrophil migration is inhibited
by CD 18 antibodies (Doerschuk et al 2000, Ramamoorthy et al 1997).
Once neutrophils migrate to the site of infection, neutrophils perform three key
actions: phagocytosis of the bacteria, release of products of pre formed granules and
release of reactive oxygen species-all three actions are directed towards killing of
bacteria.
1.7.1.1.2. Neutrophil phagocytosis
The internalization of bacteria by neutrophil and formation of a phagosome is
facilitated by opsonization. Opsonization is a process where the Fab portion of the
IgG antibody binds to the bacteria and the Fc (receptors are FcyRIIa and FcyRIIIB)
portion then binds to the phagocyte by specific receptors. Fey receptor ligation leads
to extension of the pseudopod around the bacteria, which finally engulfs it
completely. Both intracellular and extracellular enviroment is important to regulate
neutrophil function (Whitters and Stockley 2012). What is known in bronchiectasis, is
that peripheral blood neutrophils function normally in bronchiectasis (Watt et al
2004). Our group demonstrated (unpublished data) that the airway neutrophils do not
function normally in bronchiectasis- however we do not know the mechanism for this
but hypothesize that the complex airway environment with the overwhelming
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bacterial load, inflammatory cytokines and chemokines could all in part contribute to
the impaired neutrophil function. This needs to be explored further.
1.7.1.1.3. Release of products of degranulation
Granule proteins formed during neutrophil development and released upon activation
is one of the key functions of neutrophils. Changes in the cytosolic calcium are
required for granule secretion (Lew et al 1996) and for fusion of the granule to the
neutrophilic phagosome (Jaconi et al 1990). The granules contain enzymes, host
defense proteins with receptors, signaling proteins and adhesion molecules that are
expressed on the cell surface upon activation. Azurophilic granules or primary
granules release MPO, defensins, neutrophil elastase, proteinase 3 and cathepsin G,
among others. Secondary granules release lactoferrin, cathelicidin and tertiary
granules release gelatinase acetyltransferase and lysozyme. Excessive degranulation
and release ofMPO and neutrophil elastase leads to host tissue damage (Mitchell et al
2008).
1.7.1.1.4. Release of superoxide anion
During phagocytosis, neutrophils increase the oxygen consumption by using up
NADPH oxidase and releasing superoxide anion (02"). The 02" then dismutates to
form H2O2, releasing MPO from primary neutrophilic granules (Morel et al 1991).
This oxidative burst is critical for bacterial killing but simultaneously MPO causes
oxidative damage to the epithelial cells mainly through formation of the cytotoxic
oxidant HOC1 (Cantin et al 1987, Cantin et al 1993, Worlitzesh et al 2009). Elevated
MPO levels have been found to correlate to disease severity in bronchiecatsis (Hill et
al 2000). The respiratory burst results in the release of ROS to facilitate bacterial
killing. The release of uncontrolled ROS by neutrophils may however also lead to
damage to surrounding tissues, amplifying the lung disease process (Tung et al 2009).
It had previously been thought that ROS exert a direct toxic effect on ingested
pathogens. However Reeves et al (Reeves et al 2002) suggested that the respiratory
burst sets in motion events, which result in creating a favorable environment for
proteases such as elastase to digest the contents within the phagocytic vacuole (figure
13). By optimising conditions via ion flux and pH change, the enzymes released from
the cytoplasmic granules become more active, facilitating the destruction of ingested
pathogens.
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As NADPH oxidase is key for respiratory burst, patients with chronic granulomatous
disease (defect in one of the subunits of NADPH oxidase genes) are unable to
produce ROS and thereby lead to life threatening bacterial infections (Goody et al
2008). In 2006, King et al demonstrated that in bronchiectasis, neutrophils have
normal phagocytic capacity but impaired oxidative burst as compared to controls
(King et al 2006). However, in contrast, Pasteur et al failed to detect any difference in
oxidative burst between bronchiectatic patients and controls (Pasteur et al 2000). It
remains therefore an important abnormality that needs to be explored further in
bronchiectasis.
STATINS
Figure 13. Schematic representation of NADPH oxidase enzyme, reactive oxygen
species generation and the proposed role of statins. The integral membrane of the
phagocyte consists of 2 subunits: p22 and gp91 which respectively produce the
smaller and larger chain of the cytochrome-bssg. Two cytosolic subunits: p67 and p47;
a p40 accessory protein and a Rac-GTP binding protein then translocate to the cell
membrane upon activation to form the NADPH oxidase complex which generates a
respiratory burst. Superoxide can react to form hydrogen peroxide and hypochlorous
acid, which together participate in bacterial killing (Adaptedfrom Assari 2006).
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1.7.1.1.5. Apoptosis
It has been well established that there is a key role for apoptosis, or programmed cell
death, in the regulation of inflammation and the host immune response. The process
of apoptosis, which is distinct from necrosis (toxic cell death), involves a series of
coordinated morphologic changes in the affected cell, causing its demise and
subsequent recognition and removal by scavenger phagocytes (Wylie et al 1980).
Characteristically, apoptosis initially induces cytoplasmic shrinkage associated with
membrane blebbing (zeiosis), followed by chromatin condensation and DNA
fragmentation. Although cells usually manifest these changes sequentially when
undergoing apoptosis, it is now clear that these events may occur independently under
the control of separate and distinct metabolic pathways (Duffin et al 2010).
Among the leukocytes, mature human neutrophils have the shortest life span and die
rapidly via apoptosis in vivo and in vitro, resulting in the demise of the entire
population within 72h (5-10). As neutrophils proceed through apoptosis, functional
activity declines. Apoptotic neutrophils lose CD16 (FcyRIII) expression (I 1, 12) and
demonstrate a reduced ability to degranulate, generate a respiratory burst, or undergo
shape changes in response to external stimuli such as the chemotactic bacterial
peptide formyl-methyl-leucyl-phenalalanine or fMLF (Sasmono 2007). Although
neutrophils appear to be committed to death via apoptosis, it is now clear that the life
span and functional activity of mature neutrophils can be extended significantly by
proinflammatory cytokines, including granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-y, TNF-a and IL-
2 (Burdon 2008).
Although elevation of cytosolic-free Ca2+ has been associated with apoptosis in a
• 2"F
variety of cell types (Whyte et al 1993), transient elevations of cytosolic free Ca
induced by low doses of calcium ionophores have been reported to inhibit apoptosis
in neutrophils in vitro (Whyte et al 1993). Other experiments employing inhibitors of
tyrosine kinases and phosphatases suggest a possible role for tyrosine phosphorylation
events in the signal transduction pathway mediating neutrophil apoptosis (Erttmann et
al 2014). Furthermore, it has been shown that intracellular acidification precedes, and
56
may be causally related to, the development of morphologic features characteristic of
apoptosis in neutrophils maintained in short term culture (Erttmann et al 2014).
It is also known that the Fas (APO-I; CD95)/ Fas-ligand (FasL) system represents an
important cellular pathway responsible for the induction of apoptosis in diverse
tissues. Fas is a widely expressed 45-kDa type I membrane protein member of the
TNF/nerve growth factor family, which mediates apoptosis following interaction with
agonistic anti-Fas IgM Ab or FasL (Wajant et al 2002). FasL is a 40-kDa type II
protein member of the TNF family, which includes TNF-a, TNF-(3 (lymphotoxin),
CD40 ligand, and CD30 ligand (Wajant et al 2002). In contrast to Fas, the expression
of FasL is relatively restricted in its tissue distribution (Wajant et al 2002) but can be
induced in mature T cells following stimulation with para-Methoxyamphetamine or
PMA, ionomycin, anti-CD3, or bacterial antigen (Wajant et al 2005). Furthermore, it
has been shown that activated T cells can secrete a functionally active soluble form of
FasL that is capable of inducing apoptosis in other cells susceptible to Fas-induced
apoptosis (Wajant et al 2005). The relative contributions of the proapoptotic and pro
inflammatory functions of Fas/FasL sytem to the pathogenesis of lung disease and the
effects of inhibiting this pathway, remains poorly understood.
Binding of Fas to its natural ligand FasL, can trigger apoptosis via activation of
caspase 8. FasL exists in a membrane bound form and a soluble form, both of which
can activate Fas. In addition to triggering apoptotic pathways, the activation of Fas
can also lead to NF-kB translocation and cytokine production (Kreuz et al 2004).
FasL expression is detected on the surface of mature human neutrophils, but not on
monocytes or eosinophils suggesting that neutrophils are susceptible to Fas induced
cell death.
There is limited data available from two studies in the literature on apoptosis of
airway neutrophils in bronchiectasis. Vandivier et al (Vandivier et al 2002) concluded
that sputum of bronchiectatic patients have more apoptotic neutrophils in comparison
to sputum obtained from patients with chronic bronchitis. However, Watt et al
demonstrated that there were low levels of apoptotic neutrophils in induced sputum as
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compared to the findings by Vandivier and colleagues (Watt et al 2004). They found
no significant differences in the levels of apoptotic neutrophils at the beginning and
end of an exacerbation treated with antibiotics. There was however a reduction in the
total number of sputum neutrophils and serum levels of IL-8, TNF-a, neutrophil
elastase (NE) and CRP. In summary, few studies have investigated neutrophil
apoptosis in bronchiecatsis and of the two key studies described to date, the opinion
remains divided.
1.7.2. MACROPHAGES IN BRONCHIECTASIS
Little is known about the role of macrophages in bronchiectasis. One of the key
functions of macrophages is efferocytosis or "burying" the dead (apoptotic)
neutrophils (Serhan 2012). It is well recognized that activated neutrophils must firstly
'switch off by undergoing apoptosis to limit the inflammatory process and then be
cleared by macrophages to prevent secondary necrosis and release of granular
products, and thereby promote resolution of inflammation (Koedel et al 2009).
In bronchiectatic patients, Vandivier et al demonstrated that neutrophil elastase
cleaves phosphatidylserine on the surface of apoptotic cells, preventing efferocytosis




1.7.3.1. Airway host defense and damage
The airway mucociliary clearance system is a key component of primary host defence
in the lungs, responsible for maintaining airway sterility and health. The system
comprises of a mucus gel layer that lines the airway lumen trapping pathogens,
inhaled toxins and cellular debris as it is swept by beating cilia from the distal airways
to the proximal airways for expectoration and clearance.
In health, the respiratory tract is lined by equal numbers of ciliated columnar
epithelial cells and secretory cells. The epithelial cells each have 200 cilia,
approximately 7pm length that rest in a thin layer of periciliary fluid. The cilia beat in
a 2 stage process, an effective beat where their tips engage with the airway mucus
sweeping it through the airways and a recovery beat in the opposite direction where
their tips disengage and recover (Purkinje 1835, Lucas 1934). Alveoli produce
surfactant to maintain bronchial patency. Bronchioles are lined with ciliated
epithelium and secretory cells that produce a thin mucus layer for the airway lumen.
The airway mucus is composed predominantly of water (97%) and mucins (3%) and
accumulates as it is transported through the larger airways, trachea and pharynx for
expectoration.
Dilated, damaged bronchial wall function impairs clearance of mucus and excessive
mucus accumulation causes the airways to be persistently exposed to toxic insults and
pathogens. In bronchiectasis, the airways are permanently damaged and the normal
mucociliary mechanism is believed to be impaired.
1.7.3.2. Abnormal ciliary function
In order to ensure effective mucus transport, the cilia must beat at a normal rate, in a
consistent direction and in a coordinated fashion (Eliezer et al 1970). Studies have
used ciliated nasal epithelium as a non-invasive means of assessing ciliary function in
the respiratory tract. Ciliary beat frequency is significantly slower in bronchiectasis
(Rutland and Cole 1981). This finding has been confirmed in a more recent study of
152 patients with idiopathic bronchiectasis which found ciliary beat frequency to be
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significantly slower than healthy controls (Tsang et al 2005b). The purulent sputum in
bronchiectasis contains excessive quantities of elastase due to the persistent
neutrophilic airways inflammation. Such purulent sputum from patients with
bronchiectasis has been shown to slow ciliary beat frequency on normal ciliated nasal
epithelium in healthy controls. The addition to the sputum of an elastase inhibitor (al-
antitrypsin) resulted in no significant change in ciliary beat frequency over the same
time period, suggesting that elastase activity is an independent factor affecting ciliary
function (Smallman et al 1984). The effect of elastase on ciliary function and ciliated
epithelium has been shown in vitro to increase with increasing concentrations of
elastase in the sputum with progressive disruption of the epithelium and slowing of
ciliary beat frequency at higher levels (Amitani et al 1991). The effect of other
inflammatory molecules on ciliary function in bronchiectasis is unknown and needs
further study. The effect of bacterial products on ciliary function has been
investigated in vitro. Exposure of ciliated nasal epithelium to the supernatants of
Pseudomonas aeruginosa and Haemophilus influenzae over a 4 hour period was
associated with significant slowing of ciliary beat frequency and a disorganised
beating pattern. A dose related effect was also observed and it may be that the release
of a factor or factors by these organisms complements the effect of human neutrophil
elastase on ciliary inhibition (Wilson et al 1985).
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1.8. MANAGEMENT
In mild bronchiectasis, the mainstay of treatment is regular chest clearance with
physiotherapy, annual influenza and prompt treatment of exacerbations. In more
advanced bronchiectasis, in addition, there should be consideration of long term
antibiotic therapy and or anti inflammatory therapy.
1.8.1. Current controversies in the management of bronchiectasis
To achieve the main treatment goals in bronchiectasis, it is important to break the
'vicious circle' of infection and inflammation. Long term antibiotics and chest
physiotherapy are the mainstay of long-term treatment in severe bronchiectasis.
However, there are certain caveats that we have to bear in mind. We are faced with
the burden of Clostridium difficile and Methicillin resistant Staphylococcus aureus
(MRSA) in addition to antibiotic resistance, with the prolonged use of antibiotics.
Consensus on several therapeutic strategies that have been evaluated in cystic fibrosis
(CF) and COPD is lacking in bronchiectasis, and a number of controversies need
further elucidation. Over the last few years, there has been an international drive to
reduce antibiotic usage. There is an urgent need for novel non-antibiotic treatments.
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1.9. ROLE OF ANTI-INFLAMMATORY AGENTS IN BRONCHIECTASIS
Bronchiectasis is characterized by permanently damaged airways, excess neutrophilic
airways inflammation and despite this, there is persistent bacterial colonization. The
kinetics of the establishment of infection and their relationship with the subsequent
inflammatory response is poorly understood (Chimel et al 2002). Severity of
inflammatory response depends on the interplay between pro-inflammatory cytokines,
which are upregulated, and anti-inflammatory cytokines and various cytokine
inhibitors, which are released to limit its extent and duration (Wouters 2005). The
drivers for persistent neutrophilic airway inflammation in bronchiectasis is unknown.
We hypothesize that bacteria are a major driver but there maybe other factors as well,
which needs to be explored.
1.9.1 Macrolides in bronchiectasis
In bronchiectasis, several studies have been conducted with macrolides, but only three
RCTs (randomized control trials) have been conducted to date, assessing the role of
macrolide as an anti-inflammatory agent with immunomodulatory properties in
bronchiectasis. Key studies are summarized below.
In an open label study Davies et al (Davies et al 2004) investigated the effects of
regular azithromycin in patients with recurrent exacerbations, starting at 500mg once
daily for 6 days reducing to 250mg once daily for 6 days before regularly taking
250mg three times a week. After 4 months of treatment they recorded a reduction in
the number of exacerbations requiring antibiotics and an improvement in symptoms
and carbon monoxide gas transfer. Similarly, Cymbala et al in their open label study
also noted a reduction in exacerbation frequency with azithromycin 500mg twice
weekly (Cymbala et al 2005).
Wong (Wong et al 2012) confirmed these findings in the Effectiveness of Macrolides
in patients with Bronchiectasis using Azithromycin to control Exacerbations
(EMBRACE) trial. This was a randomised double-blind placebo controlled trial of
141 patients randomised to either taking azithromycin 500mg three times a week or
placebo for 6 months. They showed a significant reduction in the rate of event-based
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exacerbation from 1.57 in the placebo group to 0.59 with the azithromycin group.
There was no statistically significant difference in lung function or quality of life.
More recently the Bronchiectasis and long term Azithromycin Treatment (BAT) study
in 83 bronchiectasis patients with 3 or more exacerbations in the past year were
randomised to either 250mg azithromycin once daily or placebo for 1 year (Altenburg
et al 2013). Results showed a significant decrease in exacerbation frequency in the
azithromycin group with a longer time to first exacerbation during treatment. FEV)
and FVC improved with azithromycin as did quality of life as assessed by SGRQ.
Sputum microbiology was similar at baseline and at 1 year but significant macrolide
resistance was recorded in 88% compared with 26% in the placebo group.
Haemophilus influenzae, Staphylococcus aureus and Moraxella catarrhalis were
resistant to macrolides at the end of treatment. Adverse reactions were reported,
mainly gastrointestinal symptoms, but not severe enough to discontinue treatment.
The Bronchiectasis and Low dose Erythromycin Study (BLESS) investigated the
effect on exacerbations rates and resistance rates post 1-year therapy with low dose
erythromycin (Serisier et al 2013). Patients were randomised to low dose
erythromycin or placebo for 48 weeks. Results showed a significant reduction in
exacerbation frequency, reduced FEVi decline but an increase in macrolide
resistance. Erythromycin was well tolerated without any evidence of significant
adverse effects. However, there was a significant rise in the proportion of
erythromycin resistant oropharygeal Streptococci.















































QTc Not recorded. Not recorded No change in either
group.
Table 5. Comparison of key findings in the macrolide trials.
1.9.2 Limitations of long term macrolide use in bronchiectasis
It is indeed very encouraging to see the results from the above three trials using
macrolides as an anti inflammatory agent in bronchiectasis in reducing exacerbations.
However, the inherent limitation with the use of long-term use of antibiotics
(including macrolides), in respiratory diseases is the emergence of new pathogens and
increased antimicrobial resistance against the airway microbiota, which limits the
enthusiasm for widespread use of antibiotics such as macrolides in bronchiectasis.
About 2-10% of patients with bronchiectasis develop non-tuberculous mycobacteria
(NTM) disease. The 1st line of treatment for NTM is macrolides and hence there is a
concern of macrolide resistance in this group of patients. It seems pragmatic that
macrolide maintenance therapy should be considered in patients that have been
carefully selected, experience at least 3 exacerbations annually and have had
mycobacterial disease excluded.
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1.10. STATINS AS AN ANTI INFLAMMATORY
1.10.1. Mechanism of action: Inhibition ofHMG CoA reductase
Statins target hepatocytes and inhibit HMG-CoA reductase, the enzyme that converts
HMG-CoA into mevalonic acid, a cholesterol precursor. Statins do more than just
compete with the normal substrate in the enzymes active site. They alter the
conformation of the enzyme when they bind to its active site. This prevents HMG-
CoA reductase from attaining a functional structure. The change in conformation at
the active site makes these drugs very effective and specific. Binding of statins to
HMG- CoA reductase is reversible, and their affinity for the enzyme is in the
nanomolar range, as compared to the natural substrate, which has micromolar affinity
(Corsini et al 1999). The inhibition of HMG-CoA reductase determines the reduction
of intracellular cholesterol, inducing the activation of a protease that slices the sterol
regulatory element binding proteins (SREBPs) from the endoplasmic reticulum.
SREBPs are translocated at the level of the nucleus, where they increase the gene
expression for LDL receptor. The reduction of cholesterol in hepatocytes leads to the
increase of hepatic LDL receptors, that determines the reduction of circulating LDL
and of its precursors (intermediate density-IDL and very low density-VLDL
lipoproteins) (Sehayak et al 1994). All statins reduce LDL cholesterol non-linearly,
dose-dependent, and after administration of a single daily dose (Blum 1994). Efficacy
on triglyceride reduction parallels LDL cholesterol reduction (Stein et al 1998).
By inhibiting mevalonic acid synthesis, statins also prevent the synthesis of other
important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as
farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) (figure 14)
(Sharpe and Brown 2013). These isoprenoids are necessary for the posttranslational
modification and subsequent trafficking of intracellular signaling molecules. In
addition, they serve as important lipid attachments for the posttranslational
modification of a variety of proteins, including the y subunit of heterotrimeric G-
proteins; Heme-a; nuclear lamins; and small guanosine triphosphate (GTP)-binding
protein Ras; and Ras-like proteins, such as Rho, Rab, Rac, Ral, or Rap (Buhaescu
2007). Both Ras and Rho are small GTP-binding proteins, which cycle between the
inactive GDP-bound state and active GTP-bound state. In endothelial cells, Ras
translocation from the cytoplasm to the plasma membrane is dependent on
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farnesylation, whereas Rho translocation is dependent on geranylgeranylation (Patel
et al 2003). Statins inhibit both Ras and Rho isoprenylation, leading to the
accumulation of inactive Ras and Rho in the cytoplasm. Because Rho is major target
of geranylgeranylation, inhibition of Rho and its downstream target, Rho-kinase, is a
likely mechanism mediating some of the pleiotropic effects of statins on the vascular
wall (Buhaescu 2007). Of significnce is that RhoA-dependent cytoskeleton is a
negative regulator of eNOS mRNA stability, and statins up regulate eNOS expression
by inhibition of RhoA geranylgeranylation (Buhaescu 2007). Hence, it is now
possible to explain some important downstream effects of HMG CoA reduction at a
cellular level and how they modify cellular phenotype through non-lipid-dependent
mechanisms. In addition, many of these effects can be experimentally reproduced in
much shorter time course than would be expected by effects mediated by lipid
lowering alone. However, the question remains, do these effects occur in humans -
and are they quantitatively relevant?




* HMG CoA Mevalonate
Cholesterol Squalene
Figure 14. The mevalonic acid pathway.
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1.11. STATINS AND THE INFLAMMATORY PROCESS
1.11.1. Statins and sterile inflammation
Statins can reduce the expression and function ofmolecules on the leukocytes surface
(Weber et al 1997). Atorvastatin reduces the number of intimal macrophages,
monocyte-chemoattractant protein-1 (MCP-1) and the activation of nuclear factor
NFkB in hypercholesterolemic rabbits (Bustos et al 1998). Cytokines receptors are
coupled to GTP-bound proteins, and the binding of leukocytes to the endothelium is
regulated by G protein. Statins can effect small GTP-ases or trimeric G proteins, by
preventing their prenylation and thus reducing the inflammatory response. Statins
diminish leukocytes recruitment in postcapillary venules, stimulated by a lipid
mediator (platelets activation factor-PAF or leukotriene B4) in hypercholesterolemic
rats (Kimura et al 1997). In addition, statins are capable to inhibit transendothelial
migration and chemotaxis of neutrophils, which can explain the anti inflammatory
effect of these compounds. Another anti-inflammatory effect of statins on monocytes
and macrophages was the decrease of the expression of intercellular adhesion
molecule -1 and the secretion of interleukine-6 (IL-6), induced by lipopolysacharides
(LPS) (Bellosta 2000).
Statins are being explored as adjunctive therapy for acute lung injury. They have
immunomodulatory, antioxidative and anticoagulant properties both in vivo and in
vitro. These effects may be contributed to reduce the markers of systemic
inflammation (TNF-a, IL-8, IL-6, MMPs, CRP), decrease mortality, and improve
outcomes of in patients with sepsis Viasus et al 2010).
High sensitivity C-reactive protein (hs-CRP) is a non-specific marker of inflammatory
disease, which has been shown to be associated with vascular risk independent of
cholesterol levels. Treatment with statins lowers hs-CRP levels, and, interestingly,
this effect does not correlate with the lowering of LDL-C (Thomas and Mann 1998,
Ridker et al 2003, Ridker et al 2001). For example, retrospective analysis of the
CARE (Cholesterol and Recurrent Events) trial suggests that elevated CRP predicted
risk independent of the lipid profile and patients with high CRP benefited the most
from pravastatin treatment, supporting an anti-inflammatory and cholesterol-
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independent effect of statins in humans (Ridker et al 2001) (table 6). However, the
relation between CRP and atherogenesis needs to be further investigated. In addition
to these findings, statins have been shown to reduce graft vessel disease after heart
and renal transplantations and to inhibit pro-inflammatory cytokine release (Ridker et
al 1999, Southworth and Mauro 1997, Goldberg and Roth 1996).
Statins have a well established in the prevention of cardiovascular disease and have
been shown to exert numerous effects in addition to their lipid-lowering properties.
These pleiotropic properties include anti-inflammatory and immunomodulatory
effects resulting in improved endothelial function, reduced thrombogenicity and
plaque stabilization (Gao et al 2008, Faglas et al 2008, Terblanche et al 2006). Of
interest to us is the anti inflammatory property of statins.
68
Cells Effect
Endothelial cells feNOS expression and activity
t Tissue type plasminogen activator (t-PA) expression
iROS
fPPAR-a expression
i Pro inflammatory cytokine expression
JMHC class II antigen expression




Platelets | Platelet reactivity
[ Thromboxane A2 reactivity
Macrophages j Macrophage growth
| MMP expression and secretion
jiNOS expression
J, Pro inflammatory cytokine expression
jMCP 1 secretion
1 IL-8 secretion
Vascular inflammation 1 High sensitivity c reactive protein level
| Leucocyte endothelial cell adhesion
| ICAM-1 expression
i P selectin expression
Other effects i Tumor growth
| Intracellular Ca2+mobilization
t Bone formation
Table. 6. Effects of statins unrelated to lipid lowering.
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Hydroxymethyl-glutaryl (HMG) coenzyme A (CoA) reductase inhibitors or statins
exert pleiotropic effects on cellular signalling and cellular functions involved in
inflammation (figure 15). Statin-sensitive signalling molecules include Rho guanosine
triphosphatases (GTPases), mitogen-activated protein kinases, and Akt (Okuchi et al
2003, Patel and Corbett 2004, Patel and Corbett 2003); statin sensitive cellular
functions include adhesion, chemotaxis, and release of superoxide anion (O2") and
cytokines (Chello et al 2003, Ando et al 2000, Kanno et al 1999). Although recent
reports indicate that some statins may inhibit leukocyte function antigen-1 through
direct binding (Weitz-Schmidt et al 2001), it is generally believed that the majority of
the observed anti inflammatory effects of statins stem from their inhibiting the
prenylation of signalling proteins (e.g., Rho GTPases) (Laufs and Liao 2003). In
support of the fact that statins inhibit protein prenylation by depleting the cellular pool
of isoprenoids (e.g., geranylgeranyl-pyrophosphate) downstream of mevalonic acid
(the product of HMG CoA reductase), reports document that various effects of statins
on cellular signalling and functions are blocked by co incubation of cells with
mevalonic acid or isoprenoids (Stalker et al 2001, Wong et al 2001, Dunzendorfer et
al 2007).
Fessler and colleagues studied the effects of statins in a murine model of LPS induced
lung inflammation (Fessler et al 2005). They found that LPS and KC (keratinocyte
derived chemokine) induced airway neutrophils were reduced by statins likely arising
from an inhibition of the Rho GTPase Rac and actin cytoskeletal remodelling. Statins
were also associated with reduced parenchymal MPO and microvascular
permeability, and altered airway and serum cytokines after LPS. They concluded that
statins attenuate pulmonary inflammation induced by aerosolized LPS and this was
















Figure 15. Pleiotropic effects of statins.
1.11.2. STATINS- ROLE IN BACTERIAL INFECTION AND
INFLAMMATION
Several studies have reported on the beneficial effect of statins in community
acquired pneumonia. In 2004, a prospective observational cohort study of individuals
admitted with bacterial infection on statins, had reduced incidence of sepsis and
admission to intensive care units (Almog et al 2004). Mortensen et al conducted a
retrospective study and concluded that prior statin use was associated with reduced 30
day mortality in patients admitted with CAP and sepsis (Mortensen et al 2005,
Mortensen et al 2007). Till date, more than 20 studies have reported the effect of
statins in CAP and sepsis with a recent meta analysis by Janda et al, reporting a strong
beneficial effect against pneumonia and sepsis related mortality (Janda et ai 2010).
However, as there are no RCTs to date that have studied the effects of statins in
community acquired pneumonia, the direct evidence of whether statins confer
protection in community acquired pneumonia remains to be established.
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Several animal studies have been done assessing the effect of statins on bacterial
infections. In an animal model ofStaphylococcus aureus, high dose statin therapy was
shown to enhance the formation of extracellular DNA traps by phagocytes in the mice
lung and protect against dissemination of infection (Chow et al 2010, Janda et al
2010). Boyd et al (Boyd et al 2012), found that mice treated with prolonged high dose
statin, (in a model of lung infection with a gram-positive microorganism- S.
pneumoniae, which produces the cholesterol dependant cytolysin-pneumolysin), had a
strong dose dependent effect on protection against S.pneumoniae as evidenced by
reduced neutrophil infiltration, maintenance of vascular integrity and less chemokine
protection. However, mortality was not affected by statin pre-treatment. Antibiotic
treatment with ampicillin was initiated 48hours after the microbial challenge and it
would be interesting to see if mortality would have been affected if antibiotics were
commenced earlier. Another definite caveat to the data on mortality in this study is
that rodents metabolize statins at different rates than humans so the beneficial effects
in humans could occur in lower doses. While these studies may not directly translate
to complex patients settings, it does provide us with extremely important data that
might help form the basis for large RCTs in the clinical settings of acute and chronic
infection and inflammation.
1.11.3. STATINS IN NORMOCHOLESTERLOEMIC PATIENTS
In a study by Laufs et al, normocholesterolaemic men with normal vascular function
were treated with high-dose atorvastatin (80 mg). This increased forearm blood flow
within 24 h, whereas serum cholesterol and high-sensitivity C reactive protein (hs-
CRP) were not decreased until 2 days of treatment. Cessation of statin treatment after
30 days, resulted in a rebound of forearm blood flow within 24 h of withdrawal,
whereas cholesterol and hs-CRP slowly and steadily returned to baseline (Laufs et al
2001). This is supported by other studies, involving withdrawal of treatment (e.g.,
PRISM), where the benefits of statin treatment have been lost sooner than any
changes in lipid levels (Heeschen et al 2002, Thomas and Mann 1998). Therefore, the
potential importance of cholesterol-independent effects of statins in humans may also







First synthesized in 1985 by Bruce Roth, it is a completely synthetic compound.
Figure 16. Atorvastatin
Several large clinical trials had identified low-density lipoprotein cholesterol (LDL-C)
as one of the major predictors of coronary heart disease (CHD). HMG CoA reductase
inhibitors, also known as statins, are considered first-line drugs to prevent CHD
because of their potent LDL-C lowering effect (Cannon et al 2004).
1.11.4.1. Comparison of lipid lowering effect
Currently there are six statins commonly used for this indication, including lovastatin,
simvastatin, pravastatin, fluvastatin, atorvastatin, and rosuvastatin. All have a similar
therapeutic effect. However, the differences in their chemical structures,




therapeutic equivalence. In a meta analysis conducted by Weng et al, where they
analysed 75 comparative statin studies, the LDL lowering effect of the different
statins. It was determined that atorvastatin lOmg, fluvastatin 80mg, lovastatin 40-
80mg, and simvastatin 20mg could decrease LDL-C by 30^10%, and fluvastatin
40mg, lovastatin 10-20mg, pravastatin 20-40mg, and simvastatin 1 Omg could reduce
LDL-C by 20-30%. Rosuvastatin at lOmg or higher dose and atorvastatin at 20mg or
higher dose could reduce LDL-C by more than 40% (Weng et al 2010).
1.11.4.2. Comparisons for prevention of coronary heart disease
Till date, there has been two RCTs comparing statins in CHD prevention. Both trials
found that atorvastatin 80 mg provided greater protection against unstable angina, in
reducing the risk of non-fatal myocardial infarction, peripheral arterial disease and
coronary revascularization than pravastatin 40mg or simvastatin 20mg (Cannon et al
2004, Pedersen et al 2005).
1.11.4.3. Comparison of adverse events
The incidence of muscle toxicity was rare in all the included trials. Even when all the
muscle related symptoms were considered, the rate was still <10%. However, the
studies involving rosuvastatin generally reported a higher adverse event rate than the
other comparison arms. When these studies were excluded, the muscle-related
adverse events of statins decreased to around 5%. The incidence of elevated ALT /
AST level (i.e. three times the upper limit of normal) was <1% in most trials (Weng et
al 2010).
In summary atorvastatin is a potent lipid lowering statin, providing greater protection
against coronary heart disease, hence ideal for secondary prevention and has a
comparatively lower side effect profile. Hence, atorvastatin was the statin of choice in
our study.
1.11.4.4. Pharmacokinetics
The systemic bioavailability for HMG CoA reductase activity of atorvastatin is 30%.
The primary proposed mechanism of atorvastatin metabolism is through cytochrome
P450 3A4 hydroxylation to form active ortho- and parahydroxylated metabolites, as
well as various beta-oxidation metabolites. The ortho- and parahydroxylated
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metabolites are responsible for 70% of systemic HMG-CoA reductase activity. The
ortho-hydroxy metabolite undergoes further metabolism via glucuronidation. As a
substrate for the CYP3A4 isozyme, it has shown susceptibility to inhibitors and
inducers of CYP3A4 to produce increased or decreased plasma concentrations,
respectively. This interaction was tested in vitro with concurrent administration of
erythromycin, a known CYP3A4 isozyme inhibitor, which resulted in increased
plasma concentrations of atorvastatin. It is also an inhibitor of cytochrome 3A4.
Atorvastatin is primarily eliminated via hepatic biliary excretion, with less than 2%
recovered in the urine. Atorvastatin has an approximate elimination half-life of 14 h.
Noteworthy, the HMG-CoA reductase inhibitory activity appears to have a half-life of
20-30 h, which is thought to be due to the active metabolites.
1.11.4.5. Mechanism of action
As with other statins, atorvastatin is a competitive inhibitor of HMG-CoA reductase.
HMG-CoA reductase catalyzes the reduction of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) to mevalonate, which is the rate-limiting step in hepatic
cholesterol biosynthesis. Inhibition of the enzyme decreases de novo cholesterol
synthesis, increasing expression of low-density lipoprotein receptors (LDL receptors)
on hepatocytes. This increases TDL uptake by the hepatocytes, decreasing the amount
of LDL-cholesterol in the blood. Like other statins, atorvastatin also reduces blood
levels of triglycerides and slightly increases levels of HDL-cholesterol.
1.11.4.6. Formulations
Atorvastatin calcium tablets are marketed by Pfizer under the trade name of Lipitor,
for oral administration. Tablets are available as lOmg, 20mg, 40mg and 80mg and are
taken after food at night, to minimize the side effects of leg pain.
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1.12. STUDY HYPOTHESIS
Our study hypothesize is that long-term atorvastatin treatment will reduce the
persistent neutrophilic airway inflammation in bronchiectasis. This will lead to
reduction of patients' symptoms and thereby improve cough, reduce sputum volume
and bacterial load, improve airway function and exercise tolerance, reduce
exacerbation frequency and consequently improve health related quality of life.
Atorvastatin could be a potential novel non antibiotic therapeutic target in
bronchiectasis.
This hypothesis then led us to design and conduct a randomized control trial of
atorvastatin in bronchiectasis.
1.13. AIMS
The main aims of this randomized double blind control study are:
1. To evaluate the efficacy of a 6 months treatment with atorvastatin versus placebo in
patients with clinically significant bronchiectasis.
2. To establish that statin therapy leads to clinical improvements (cough, sputum
volume, bacterial load, airway function, exercise tolerance and health related quality
of life).






2.1.1. RANDOMIZED CONTROL TRIAL- STUDY DESIGN AND SETTING
Patients were recruited from South East of Scotland Bronchiectasis Clinic in the
Royal Infirmary of Edinburgh, UK from November 2010 to January 2013. Patients
were invited to a group meeting and the study was proposed and discussed with them
by the research group. Patients were given an opportunity to ask relevant questions
regarding the study. They were given up to 7 days for consenting to take part in the
study.
Both investigators and participants were blinded to treatment allocation and patients
were randomized in equal numbers to receive either atorvastatin 80mg or placebo
orally, once daily for 6months.
Sequence generation was done by block randomization of 4 by NHS Tayside, of a list
of 60 patients provided by the researchers. The placebo (lactose) was not matched to
the atorvastatin in appearance. However the researchers had no access to the study
medications as this was provided to the patients directly by pharmacy. We chose
atorvastatin as it is a potent statin for reducing cholesterol and we used it at maximum
dosage, as this is a proof of concept study.
2.1.2 PARTICIPANTS
Inclusion criteria:
(i) Patients aged 18-79 with an established radiological diagnosis of
bronchiectasis (HRCT of the chest) and
(ii) Clinically significant bronchiectasis expectorating mucopurulent or purulent
sputum when clinically stable with at least 2 chest infections per year.
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Exclusion criteria:
(i) Current smokers or ex-smokers of less than 1 year or those with a greater than
fifteen pack year history.
(ii) Patients with cystic fibrosis, active allergic bronchopulmonary aspergillosis,
active tuberculosis, poorly controlled asthma, pregnancy or breast feeding,
(iii) known allergy to statins,
(iv) active malignancy,
(v) chronic liver disease,
(vi) statin use in the last year,
(vii) patients on long term oral macrolides due to the interaction with statin
therapy,
(viii) patients chronically colonized with Pseudomonas aeruginosa (defined as two
or more isolates of Pseudomonas aeruginosa whilst clinically stable in 6
months prior to the study).
2.1.2.1 Pseudomonas aeruginosa colonization
Patients chronically colonized with Pseudomonas aeruginosa were excluded, as they
are patients with more severe disease (Davies et al 2006, Martinez-Garcia et al 2007)
and the objective of this study was to investigate atorvastatin in clinically significant
bronchiectasis. Further studies are needed for patients colonized with P. aeruginosa.
2.1.3. PRIMARY OUTCOME
The primary outcome of this study was whether there is a difference in the proportion
of patients with a clinical improvement in cough [as defined by a 1.3 unit increase in
the Leicester Cough Questionnaire14 score] in those treated with atorvastatin versus
placebo. The LCQ has 19 items divided into 3 domains: physical (8 items),
psychological (7 items) and social (4 items). The total severity score ranges from 3-
21, where a lower score indicating a greater impairment of health status due to cough.
We have validated use of this scoring system in bronchiectasis (Murray et al 2009).




Secondary outcomes included: forced expired volume in one second (FEVi), forced
vital capacity (FVC) and its ratio; incremental shuttle walk test; qualitative and
quantitative sputum bacteriology; exacerbation frequency; health related quality of
life assessed by the St George's Respiratory Questionnaire; assessment of sputum
neutrophil numbers and apoptosis; neutrophil activation in the airway by measuring
sputum myeloperoxidase and free elastase activity; neutrophil chemottractant in
sputum interleukin (IL)-8; systemic inflammation- measuring white cell count, C-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR), additional systemic
inflammatory markers [IL-ip, IL-6, IL-8, IL-10, IL-12p70 and tumor necrosis factor
(TNF)-a] -and safety of statin therapy.
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2.1.5. ASSESSMENTS










Sputum colour Sputum colour






FBC, U+E, LFT, CK, ESR,CRP,
cholesterol, cytokines
Bloods
FBC, U+E, LFT, CK, ESR, CRP,
cholesterol, cytokines
FEV, + FVC FEVj+ FVC
FEVj/FVC FEV/FVC
Incremental exercise test Incremental exercise test







Assess side effects and compliance
Table 1. Assessments done at baseline and at end of study.
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2.1.5.1. Cough
Assessed using the Leicester Cough Questionnaire (LCQ). It is a 19 item self-
completed quality of life measure of chronic cough. It has 3 domains: physical (8
items), psychological (7 items) and social (4 items). The total severity score ranges
from 3-21, a lower score indicating greater impairment of health status due to cough.
It assesses the impact of symptoms over the preceding 2 weeks and has been used in
COPD and asthma. It has been validated for use in bronchiectasis (Murray et al 2009).
The LCQ offers a pertinent, timely and useful clinical tool for bronchiectasis. It
focuses purely on the impact of cough severity on HRQoL, unlike other
questionnaires that encompass multiple respiratory symptoms. Cough is the dominant
symptom of bronchiectasis, present in up to 98% of patients and measuring its impact
on HRQoL is critical for both disease assessment and targeted management.
Additionally, the LCQ is concise, consisting of only 19 items, offering greater patient
acceptance than lengthier questionnaires. The minimum clinically important
difference for change (MCID) is 1.3 units (Birring et al 2003).
2.1.5.2. Spirometry
Forced expiratory volume in 1 second (FEVi) and Forced Vital Capacity (FVC) were
measured according to standardized guidelines (Miller et al 2005) using a
MicroMedical Microloop ML3535 (Viasys Healthcare).
FEVi is the maximal volume of air exhaled in the first second of forced expiration
following a forced expiration from a position of full inspiration and is expressed in
litres. FVC is the maximal volume of air exhaled with maximally forced effort from a
maximal inspiration and is expressed in litres. The highest of three technically
satisfactory measurements (within 10%) was recorded for each and the ratio was
calculated. Actual values were recorded and were also expressed as % predicted for
the patients age, sex, and height.
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2.1.5.3. Incremental shuttle walk test
The incremental shuttle walk test (ISWT) was used to assess functional exercise
capacity. It has been proven in patients with COPD to provide an objective measure
of disability and can be used for direct comparison of patients performances (Singh et
al 1992).
The ISWT comprises a 10-metre shuttle course with the walking speed externally
paced or controlled using pre-recorded audio signals from a computerised disc. It
consists of twelve incremental levels, with each level lasting one minute. It is a
symptom-limited test with the endpoint of the test determined when the patient
becomes too breathless to continue or when the patient becomes unable to complete
the shuttle in the paced time (defined as being 0.5metres or further from the marker).
All patients were instructed to walk at a steady pace walk aiming to turn around at
each end of the course at the sound of the audio signal. All were advised to continue
to walk until they felt unable to maintain the required speed without becoming unduly
breathless. The level achieved was recorded and total distance covered calculated. At
the start and end of the ISWT all patients had their heart rate, oxygen saturations and
dysnoea score according to the modified BORG dyspnoea scale (Borg G 1982) in
accordance with standardised guidelines.
Modified Borg Score
0 Nothing at all











10 Very very severe (almost maximal)
Table 2. Borg score.
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Prior to starting the study, all patients attended the physiotherapy gym and or the
laboratory to familiarize them with the equipment and to minimize the effects of test
habituation. This was done on two separate days to assess reproducibility of tests and
this was achieved for all patients.
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2.1.5.4. Sputum gram staining
A lOpl sterile loop was used to transfer sputum to a clean, dry, frosted glass slide.
lOpl of sterile saline was gently pipetted onto the sputum and the sample smeared
uniformly and thinly across the slide. The sample was air-dried and subsequently heat
fixed by passing the slide through a low flame several times until all moisture had
evaporated. The slide was then flooded with the primary staining reagent methyl
violet for one minute followed by gentle rinsing in deionized water. The mordant
iodine was then used to flood the slide for one minute followed by further gentle
rinsing in deionized water. Following draining, acetone was used as a decolourising
agent, flooding the slide until the fluid appeared colourless (approximately ten
seconds). The slide was immediately rinsed in deionized water. The counterstain basic
fuschin was then used to flood the slide for one minute before further rinsing in
deionized water. The slide was gentle blotted using paper towel and allowed to air
dry. The results of the staining procedure were observed under oil immersion
microscopy. At low (xlOO) magnification, the number of squamous cells and
polymorphonuclear leukocytes per field were counted. At high (xlOOO) magnification,
bacterial cell colour was described as purple (gram positive) or pink (gram negative)
and morphology was noted (rods or cocci).
All sputum samples were considered to be valid if there were >25 polymorphonuclear
leukocytes and <10squamous cells on gram stain per low-power (xlOO magnification)
field (Gleckman et al 1988).
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2.1.5.5. Cytospins
Induced sputum was washed with 8 times volume of phosphate buffered saline (PBS).
This was then centrifuged at 2000g for lOminutes. The supernatant was discarded
and then washed with 4 times volume of PBS at 1500g for 10 mins. Supernatant was
discarded and then 4 times volume of sputolysin was added and left on roller for
lOminutes. Following this, the sputum was filtered through sterile gauze swab and
viability was ascertained by exclusion of trypan blue. Viable cells were counted by a
hematocytometer. Final centrifuge was done at 2000rpm for 10 minutes at 4°C. After
discarding the supernatant, sputum cells were re suspended in PBS. Cytospins were
prepared in a Shandon cytospin 4 (Shandon, Pittsburgh, PA, USA) and stained with
Diff-Quick stain (Merz Dade, Switzerland). Cell differential counts were determined
by counting 400 cells per sample.
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2.1.5.6. Quantitative and qualitative sputum microbiology
24 hour sputum volume: Collected the day before each clinic visit. Patients were
advised to store sputum samples at 4°C (in the fridge) during collection.
Induced sputum:
Sputum was induced in all study patients at both study visits. Any upper respiratory
secretions were cleared before the procedure was commenced. Patient was positioned
in a chair to achieve maximum deposition. 30mls hypertonic saline (3%) was used to
induce sputum. Most patients were already practicing active cycle breathing
techniques (ACBT) or if patients were physiotherapy na'ive, the researcher taught
ACBT, before commencing procedure. Once commencing the induced sputum
procedure, the aerosol was run for 5 minutes and then stopped. At this point the
patient was asked to perform ACBT and try to provide a sample. If this is
unsuccessful, the whole procedure was repeated again at 5-minute intervals (up to 20
minutes).
Our senior chest physiotherapist advised us that the procedure was to be discontinued
if patient started to spontaneously cough or if the patient became distressed, was
coughing excessively or saturations dropped below 90%. Sputum induction was
successfully carried out in all patients in the study.
Each sample was confirmed to be a valid sample suitable for processing if there are
>25 polymorphonuclear leukocytes and <10 squamous cells present on Gram stain on
low power magnification. 1 ml of the sample was used for qualitative and quantitative
microbiology.







Figure 1. Sputum colour chart (Murray et al 2009)
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2.1.5.7. Sputum processing
Sputum was homogenized and liquefied using an equal volume of dithiothreitol and
serially diluted using sterile 0.85% saline to achieve dilutional factors of 10"' to 10~4.
Pseudomonas isolation agar (Difco), chocolate blood agar containing bacitracin
(Oxoid) and horse blood agar (Oxoid) plates were inoculated with 100 pi of dilution.
These were incubated at 37°C for 48 hrs. Colonies of the pathogens were then
counted to determine the sputum bacterial density, expressed as logio colony forming
units/ml (cfu.mf'). The rest of the sample was divided equally into portions; the first
was ultracentrifuged at 30000g for 90 min at 4°C (Hill et al 1999).The sol phase was
stored at -70°C until needed for analyzing.
2.1.5.8. Qualitative sputum bacteriology
Bacterial Count was calculated: Number of bacteria x 2 x 10 x dilution factor to give
the number of cfu/ml.
Viable pathogens were identified following incubation based on colonial morphology,
Gram stain and further, specific standardised identification tests. The identification
methods used for the most common organisms cultured is described.
2.1.5.9. Haemophilus influenzae
The primary isolation media used for Haemophilus influenzae was chocolate with
bacitracin agar incubated at 37°C at 5%CO. Colonies are small, round and convex
and typically appear after 24hrs incubation. The species appear negative on Gram
staining as spherical, oval or rod shaped cells of less than 1 pm diameter. Colonies
suspected to be Haemophilus species from morphology and Gram stain appearance
were further identified based on their requirement for X and V factors. One or more
colonies were selected using a sterile straight wire loop and emulsified in distilled
water to produce a light suspension. 1 OOpl of suspension was inoculated onto nutrient
agar and spread evenly using a sterile hockey stick spreader. Three filter paper discs
incorporating X factor (comprising protoporphyrin IX and haemin), V factor
(comprising nicotinamide adenine dinucleotide) and XV factors together respectively,
were positioned on the inoculated agar surface in the configuration of an equilateral
triangle with a minimum of 3.5cm distance between the discs. Following overnight
incubation at 37°C, the agar plate was examined for growth around the discs.
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Haemophilus influenzae was distinguished from Haemophilus parainfluenzae as
detailed in Table 3.
Factor Haemophilus influenzae Haemophilus
parainfluenzae




V Negative for growth
around disc
Positive for growth around
disc
Xand V Positive for growth around
disc
Positive for growth around
disc
Table 3. X, V and XV test results for Haemophilus influenzae and Haemophilus
parainfluenzae.
Figure 2. Haemophilus influenzae isolated from sputum in our laboratory (upper
panel) and the XV tests (lower panel).
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2.1.5.10. Streptococcus pneumoniae
The primary isolation media used for Streptococcus species was horse blood agar.
Colonies appear white, l-2mm in diameter and may have a classic draughtsman
appearance due to autolysis after incubation. Streptococcus species are positive on
Gram staining, appear round and are in pairs, chains or clusters. Colonies suspected
from morphology and Gram stain appearance to be Streptococcus pneumoniae was
further identified by assessing their sensitivity to ethylhydrocupreine hydrochloride
(optochin test). Ethylhydrocupreine hydrochloride causes changes in surface tension
of the cell membrane causing Streptococcus pneumoniae to lyse. Fresh suspicious
colonies were selected using a sterile straight wire loop and streaked across a horse
blood agar plate. An optochin disc (filter paper disc impregnated with 5pg of
ethylhydrocupreine hydrochloride) was placed in the centre of the inoculated agar and
incubated at 37°C at 5% CO for 24hours. Following incubation, the inoculated agar
was examined for zones of inhibition. A positive result was defined as a radial zone of
inhibition measuring 5mm or more from the edge of the disc. A negative result was
defined as either no zone of inhibition or a zone of inhibition less than 5mm radius
from the edge of the disc.
Figure 3a. S. pneumoniae, b. Optochin disc test confirming Spneumoniae.
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2.1.5.11. Staphylococcus aureus
The primary isolation media used for Staphylococcus aureus was horse blood agar.
Colonies are opaque with either a creamy white colour or a yellow-orange colour.
Gram staining shows gram positive cocci occurring either singly, in pairs or in
irregular clusters. Colonies suspected to be Staphylococcus aureus were confirmed
using the commercial test kit Dryspot Staphytect Plus, a latex slide agglutination test
according to the manufacturer's instructions (Oxoid Limited, Basingstoke,
Hampshire).
Figure 4. Staphylococcus aureus isolated in our laboratory.
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2.1.5.12. Pseudomonas aeruginosa
Cetrimide (Difco) Pseudomonas isolation agar was used as the primary selective
media for Pseudomonas aeruginosa. Morphological identification of colonies may
have included several characteristics. The most common type of colony is a large, low
oval convex shape with a rough appearance. There may be a characteristic smell of
aminoacetophenone and colonies may have a blue-green appearance due to the
production of pyocyanin (blue) and pyoverdin (yellow). The production of this
pigment is indicative of Pseudomonas aeruginosa, although some strains particularly
mucoid strains may not produce pyocyanin. Further identification of colonies was
confirmed using the commercially available API20NE kit (bioMerieux UK Linited,
Basingstoke, Hampshire) according to the manufacturers' instructions. Briefly,
approximately one to four colonies were selected using a sterile straight wire loop and
emulsified with 2ml of 0.85% sterile saline to produce a suspension approximating a
0.5McFarland standard. The API20NE test strip consists of twenty microtubes
containing dehydrated substances. These microtubes were inoculated with the
bacterial suspension and incubated for 24 or 48 hours at 30°C with the addition of
reagants and interpretation of reactions done according to the manufacturer's
directions. The biochemical reactions were converted accordingly into an octal profile
number and decoded using the Analytical Profile Index (API Database Vn6.0,
APILAB Software Vn3.3.3, Apilab Plus; bioMerieux).
Figure 5. Mucoid P. aeruginosa isolated in our laboratory.
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2.1.5.13. Moraxella catarrhalis
The primary isolation media used for Moraxella species was horse blood agar.
Colonies are white or buff and convex in shape. The species appear as negative cocci
on Gram stain, are approximately 0.6-1.Opm diameter, and occur either singly or in
pairs. Colonies suspected to be Moraxella species from morphology and Gram stain
appearance were tested for a positive oxidase reaction. Filter paper was soaked in the
test reagent N, N, N', N'-tetra-methyl-p-phenylenediamine dihydrochloride. A sterile
wooden stick was used to select at least one suspicious colony and rub it onto the pre-
soaked filter paper. A reaction was looked for within ten seconds. A positive result
was confirmed with the development of a blue colour, indicating oxidase production.
A negative result was indicated by an absence of colour.
Figure 6. M. catarrhalis isolated in our laboratory.
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2.1.5.14. Enterobacteriaceae
Enterobacteriaceae were selected from horse blood agar. The colonies are 2-3mm in
diameter, are low, convex, grey and maybe smooth or mucoid. The cells appear as
Gram negative rods. Further identification of suspicious colonies was initially with a
negative oxidase test as described previously and then the commercial kit API20E
was used (bioMerieux UK Linited, Basingstoke, Elampshire). The principle and
preparation of the API20E strip is similar to the API20NE strip described above, with
incubation for only 24 hours at 30°C.
Figure 7. Gram negative microorganism isolated from sputum of bronchiectasis
patient in our laboratory.
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2.1.5.15. Sputum inflammation markers
For measurement of markers of airway inflammation, sputum, not treated with DTT,
was ultracentrifuged (Sorvall™ Ultracentrifuge, UK) at 30000g for 90 minutes at
4°C. The sol phase was removed, immediately frozen in aliquots at -80°C. We
measured sputum Myeloperoxidase, free neutrophil elastase and IL-8.
2.1.5.15.1. Myeloperoxidase (MPO): MPO activity was measured by a chromogenic
substrate assay.
Myeloperoxidase (Calbiochem ®) and samples were diluted as necessary in
phosphate buffered solution. All reagents were brought to room temperature first.
25pL of standard or sample was added to the wells of a 96 well microtitre plate
(Costar®). 25pL of tetramethylbenzidine (Sigma) was added to each well. The plate
was then incubated for 5minutes at 25°C. Reaction was stopped by adding 50uL of
sulphuric acid solution to each well. Absorbance was measured using a dual
wavelength of 450 and 560nm and MPO concentration interpolated from the standard
curve and expressed as pg/ml. The MPO concentration was determined in duplicate
for each sample or standard and the mean determined for each.
2.1.5.15.2. Free Elastase activity (NE):
NE activity present in the samples was measured spectrophotometrically using the
synthetic substrate methoxysuccinyl-ala-ala-pro-valparanitroanilide
[MeOSAAPVpNa 4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid] (Sigma) as
described below (Hill et al 1999, Stockley et al 2000).
Standards (NE from Sigma Aldrich) and samples were diluted as necessary in buffer.
40pL of standard or sample were added to each well of a 96 well microtitre plate
(Costar®). 40pl of MeoSAAPvn was added to each well and samples read
immediately at 37°C for a minimum of thirty minutes with readings every two
minutes.
The rate of change in optical density is converted into elastase activity and expressed
in units per milligram. The elastase concentration for each sample is determined in
duplicate and the mean determined for each.
95
2.1.5.15.3. Measurement of IL-8:
IL-8 is a key neutrophil chemoatttractant in bronchiectasis (Milkami et al 1998).
Untreated sputum sol phase was assayed using commercially available specific
enzyme linked immunosorbant assay (ELISA, R+D systems, Abingdon, UK) using
kits previously validated for sputum use according to established methodology
(Stockley and Bayley 2000).
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2.1.5.16. Validation of sputum ELISA's
All assays for sputum were validated as described (Stockley and Bayley 2000).
Standard curves for each assay were obtained using pure mediator provided by the
manufacturer following the assay protocol. Three pools of sputum sol were prepared
from 4 patients each with mucoid (grade 1), muco-purulent (grade 2) and purulent
sputum (grade 3 or 4) based on a previously published sputum colour chart (Murray et
al 2009). Three parameters were assessed in validating assays: Reliability, recovery of
spiked mediators and the effect of sample dilution.
Reliability: The quantity of mediator in each sputum pool was determined by
interpolation against the standard curve. Individual samples were assayed 5 times on a
single plate to obtain the intraassay co-efficient of variation. Each sample was also
assayed 5 times on different plates to obtain the inter-assay co-efficient of variation.
Spike and recovery: a known quantity of each mediator was spiked into the 3 pools of
sputum. These "spiked" samples were then assayed and compared to the values
obtained for the original pool. The obtained value was divided by the predicted value
to calculate the % recovery.
Dilution effect: The 3 sputum pools were assayed at dilutions ranging from 1 in 1000,
to 1 in 5.
An assay was deemed to be valid if it had a reliable standard curve, an intra-assay and
inter- assay coefficient of variation <10%, recovery of spiked samples in the range
80-120% of predicted and a linear dilution effect (Stockley and Bayley 2000). The
results of Interleukin-8 assay is shown below, figure 8. This assay passed each
validation step and was used in the study. Table 4 shows the validation data for all
sputum assays tested.
The figure below shows the validation data for IL-8. Figure 9 shows the linearity of
dilution effect. In view of these results, dilution of 1 in 20 was used for each assay
with re-assay at higher or lower dilution in cases where results were outside the


















Figure 8. Validation of assays for sputum cytokine measurements: linearity of
dilution effects for sputum measurement of interleukin-8. * indicates outside the
dynamic range of the assay.
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Figure 9. Validation of sputum assays for inflammatory mediators: representative
standard curve for sputum measurement of interleukin-8.
Finally, spike a recovery experiments demonstrated a majority of values between 80%
and 120% of expected recovery with a median recovery and range within acceptable











Myeloperoxidase 102% (94-105) 4.2% 3.7% Yes
Free neutrophil
elastase
102% (83-115) 7.1% 7.7% Yes
Interleukin-8 93% (86-118) 8.5% 8.1% Yes
Table 4. Validation of assays used in sputum
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2.1.5.17. Health related quality of life- St. George's Respiratory Questionnaire
Health related quality of life was measured using the St George's Respiratory
Questionnaire (Wilson et al 1997). It is a 50 item self administered health related
quality of life questionnaire divided into 3 main domains, symptoms, activities and
impacts. The total score ranges from 0-100; a higher score indicates a poorer health
related quality of life. The MCID for SGRQ is 4 units (Wilson et al 1997).
2.1.5.18. Systemic markers of inflammation
30 ml of venous blood was collected for full blood count, ESR, CRP, urea,
electrolytes, creatinine kinase, liver function tests and chloesterol.
5 ml of blood was centrifuged at 750g for 10 min and the supernatant collected and
stored at -70C, for measuring pro and anti inflammatory cytokines and
chemoattractants by cytometric bead array (BD™ Cytometric Bead Array kits).
Cytometric bead array was done as per manufacturer' instructions (preconfigured kits
for consistent results and an intra-assay and inter- assay coefficient of variation <10%,
recovery of spiked samples in the range 86-110% of predicted and a linear dilution
effect) and we measured IL1 (3, IL6, IL-8, IL10, IL12p70 and TNFa.
2.1.6. SIDE EFFECTS
The presence or absence of side effects was assessed at all study visits. If the alanine
aminotransaminase was greater than five times normal or the creatinine kinase greater
than three times normal, the study medication was stopped. All side effects were
recorded in a patient diary card (Appendix 1).
2.1.7. INFECTIVE EXACERBATIONS DURING THE STUDY
Exacerbations were defined as per the BTS guidelines (BTS guidelines 2010).
Exacerbations were treated according to their baseline sputum bacteriology and
received 14 days oral antibiotic treatment. Macrolides were not used because of the
interaction with statin therapy.
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2.1.8. SAMPLE SIZE
Using a two-sided, two-sample test with a 5% level of significance, 90% power, a
sample size per group of 27 was needed to detect a change of 1.3 Units in the
Leicester Cough Questionnaire. 30 patients were recruited in each group to allow for
dropouts,
2.1.9. STATISTICAL ANALYSIS
All data was analyzed on SAS Version 9.2. We used an intention to treat analysis for
the primary endpoint and a modified intention to treat analysis for the secondary
endpoints. For demographic and clinical variables, data are presented as median
(interquartile range) for continuous variables and n (%) for categorical variables
unless otherwise stated. Baseline to 6 month change of LCQ was calculated by an
unpaired t-test between those receiving atorvastatin versus placebo, as the data was
normally distributed. To compare the proportion of patients with clinical
improvement as measured by the LCQ or quality of life as measured by the SGRQ a
binomial test for the comparison of proportions has been used and differences
presented as percentages with accompanying 95% confidence intervals [CI].
Categorical data have been compared between groups using Chi-squared test. A P-
value of <0.05 was considered statistically significant for each analysis.
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2.2. NEUTROPHIL ISOLATION
Ethical approval was obtained from the Lothian Research Ethics Committee
(Approval #08/Sl 103/38).
Requirements:
• Sodium citrate 3.8 % (3.8 g Sodium citrate tribasic dihydrate (SIGMA 25116)
in 100 ml bottled water (BAXTER UKF7114)) (solution is sterile filtered
using a 0.22 pm filter unit)
6% Dextran [6.0g Dextran 500 (GE Healthcare 17-0320-02*) in 100ml 0.9%
NaCl (BAXTER UKF7124)]. Dissolve in 0.9% NaCl Saline warmed to 37°C
(solution is sterile filtered using a 0.22 pm filter unit)
Percoll (GE healthcare 17-0891-02)
2+ 2+
PBS (phosphate buffered saline) - without Ca /Mg (PAA HI5-002)
• PBS (xlO) - without Ca /Mg (Sigma D1408)
Iscove's modified Dulbecco's modified Eagle's medium (IMDM) (PAA El 5-
018)
Method:
All procedures carried out at room temperature unless otherwise stated.
Freshly drawn blood was collected from healthy volunteers, into sodium citrate; (4ml
of citrate per 40 ml of blood in a 50 ml falcon tube) and mixed by gentle inversion of
tube, parafilm cap before centrifugation. This was centrifuged at 350g for 20 minutes
(Accl/ Brake 0 Hettich centrifuge, AccO/Brake 0 Mistral centrifuge).
Platelet-rich plasma (PRP) was aspirated without disturbing the pelleted cells.
Autologous recalcified plasma (serum) was prepared by adding 220 pi of 1M CaCl
/10 ml plasma in glass tubes at 37°C for 1 hour. "Serum" was separated from platelet
plug and transferred to a Falcon tube for later use/storage (4°C for short term or
frozen for longer term storage). Leukocytes were separated from erythrocytes by
dextran sedimentation: 6 ml of dextran (see above) was added to each tube (adjust
volume of dextran added if necessary - 2.5ml / 10ml cell pellet) and then made to
50ml with saline pre-warmed to 37°C. This was then mixed carefully to ensure cells
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were fully resuspended then allowed to sediment for between 20 and 30 mins (not
more than 30 minutes) at room temperature.
Percoll gradients were prepared at this point-at room temp. Stock Percoll solution was
2+ 2+
made isotonic with lOx PBS (WITHOUT Ca /Mg ) (yields a 90% solution that
represents "stock")(enough for 3 grads- i.e. 6 tubes of blood: 27 ml Percoll + 3ml
lOxPBS)
81% Percoll made in PBS WITHOUT Ca2+/Mg2+ (8.1ml Percoll "stock" +1.9 ml
PBS)
70% Percoll made in PBS WITHOUT Ca2+/Mg2+(7ml Percoll "stock" + 3 ml PBS)
55% Percoll made in PBS WITHOUT Ca2+/Mg2+(5.5ml Percoll "stock" + 4.5ml
PBS).
Following dextran sedimentation, each leukocyte-rich upper layer was removed and
transferred to a fresh 50 ml tube and topped up to 50ml with saline and then
centrifuged at 350g for 6 min (Acc5/ Brake 5 for both Hettich and Mistral
centrifuges).
The pellets from 2 tubes of cells were resuspended in 3ml of the 55% Percoll (upper
layer).
3ml of 81% Percoll (bottom layer) was carefully placed in the bottom of a 15ml
Falcon tube.
3ml of 70% Percoll (middle layer) was carefully overlayered onto the bottom layer
(slowly to avoid mixing of the gradients).
3ml of cells resuspended in the 55% Percoll layer was carefully overlayered onto the
middle layer.
Gradients were centrifuged at 720g for 20 min, (Accl/ Brake 0 Hettich centrifuge,
AccO/Brake 0 Mistral centrifuge).
Granulocytes were harvested (70/81 interface) and residual erythrocytes pelleted at
the bottom of the tube.
2+ 2+
Leukocytes were then washed twice in PBS without Ca /Mg centrifuged at 230g
for 6 min, (Acc5/ Brake5 Hettich and Mistral centrifuges). Cells were resuspended at
desired concentrations in media and counted using a haemocytometer. lOql of the
granulocyte suspension was placed on the haemocytometer slide and visualised under
a light microscope, the number of neutrophils present in 25 squares were counted. The
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number obtained was equal to the number of neutrophils per 0.1 pi of suspension, to
calculate the number of neutrophils in lml, this was multiplied by 10,000.
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Freshly isolated peripheral blood neutrophils (at least 97% purity - performed
cytocentrifuge preparation as described above) was suspended at lOxlO6 cells/ml in
IMDM supplemented with 10% autologous serum and penicillin/streptomycin (lx).
Then 75 pi of neutrophil suspension was added to wells of a 96 well flat-bottom plate.
A row of wells was left clear from the periphery of the plate- to allow for addition of
reaction media to minimise evaporation. To each well 15pl of treatment (10 times
concentration) or 20pM of roscovitine or buffer control was added. Following this,
60ml IMDM with 10% serum was added to each well. If two agents were used in
combination only 45ml of IMDM was required. Each treatment was done in
duplicates or triplicates. Plates were then covered with a lid, and incubated at 37°C in
a 5% CO2 incubator for the desired length of time (12 or 20 hours).
Dose and time response experiments were done.
Following incubation for the desired length of time, the plates were taken out of the
incubator. Each well was then vigorously pipetted to dislodge adherent cells and
transfer 20pl of cells into a flow tube containing 200pl of Annexin V buffer [Annexin
buffer= annexin V (Roche, West Sussex, UK)+ FIBBS with Ca and Mg in the ratio of
1:500], The flow tubes were then incubated for 5 min on ice. Immediately prior to
running each sample on a flow cytometer propidium iodide (Sigma- Aldrich) (PI; lpl
of lmg/ml stock solution) was added. Samples were analysed by flow cytometry
using FL-l/FL-2 channel analysis following appropriate compensation. Cytospins




3.1. Completion/ Timing of visit
A total of 62 patients were recruited into this study, 2 were lost prior to randomization
so were replaced to give a total sample size of 60 patients. Through the course of the
study 7 patients withdrew and the remaining 53 (83%) patients completed the study.
24 (80%) patients completed in the statin group and 29 (97%) in the placebo group
(see consort diagram).








Atorvastatin 24 176.0 180.5 183.5 191.0 211.0
Placebo 29 175.0 182.0 184.0 191.0 206.0
Table 1. Timing of 6month visit in patients completing the study.
3.2. Baseline Characteristics
60 patients were randomized to receive treatment; 30 received active treatment with
atorvastatin 80 mg and 30 received placebo. Baseline characteristics of the study
population were not statistically significant different between the two groups (see
table 2) with the exception of smoking. The smoking differences were not clinically
relevant as we excluded current smokers, smokers >15 pack year history and those
with COPD. 2 patients in the statin group isolated Pseudomonas aeruginosa at
baseline only and were not chronically infected with Pseudomonas aeruginosa as per




Assessed for eligibility (n=82)
Excluded (n= 22)
♦ Not meeting inclusion criteria (n= 14)





llocated to atorvastatin 80mg OD (n=30)
Received allocated intervention (n=30)
Did not receive allocated intervention (n= 0)
Follow-Up
Allocated to placebo intervention (n=30)
♦ Received allocated intervention (n=30)











Age 60.2(10.7) 59.1 (11.4) 0.719
Gender
(% female)













11 (37%) 10(33%) 0.787
IHD 2 (7%) 1 (3%) 1.00*
Asthma 19(63%) 17(57%) 0.598
Previous
malignancy
1 (3%) 1 (3%) 1.00*
Diabetes
mellitus




2.1 (0.8) 2.2 (0.9) 0.457
FEVi
(% predicted)






94.8% (4.2%) 86.4% (25.6%) 0.190
FEV, /FVC 69% (0.13%) 69.6% (0.12%)
Inflammatory markers in serum





4.3 (1.9) 3.9(1.1) 0.280
ESR (mm/hr) 15.1 (11.7) 14.8 (10.7) 0.926




1246(173) 1577 (158) 0.509
Myeloperoxidase
(pg/ml)












8 (27%) 6 (20%)
Streptococcus
pneumoniae
4 (13%) 1 (3%)
Staphylococcus
aureus


















Pre treatment exercise capacity




22 (73%) 18(60%) 0.07









Units 13.1 (4.0) 15.1 (4.4) -
Table 2. Baseline characteristics of study population. P value indicates the differences
between the groups at baseline; BMI = body mass index; CRP= C-reactive protein;
FEVi= Forced expiratory volume in 1 second; FVC= Forced vital capacity;
ICS=inhaled corticosteroid; IgG2= Immunoglobulin G2; IFlD=ischaemic heart
disease; ISWT= incremental shuttle walk test.
* About a third of the patients were asthmatics in both groups- subanalysis of this
group not done in this thesis.
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3.3. AETIOLOGY
Most common etiology in both groups was idiopathic with post infectious and
autoimmune cause being the next most common aetiologies. The aetiologies are






Idiopathic 21 (70%) 21 (70%) 1.00
Post infectious 4(13%) 4(13%) 1.00
Auto immune disease 4 (13%) 4(13%) 1.00
Inflammatory bowel disease 1 (3%) 0 1.00
IgG2 deficiency 0 1 (3%) 1.00
Table 3. Etiology of bronchiectasis in study patients
80% 1
Figure 1. Aetiology of bronchiectasis in study patiemts.
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3.4. PRIMARY OUTCOME
The change from baseline to 6 months in LCQ score differed between groups, with a
mean change of 1.5 units in patients allocated atorvastatin versus -0.7 units in those
assigned placebo (mean diff erence 2.2, 95% CI 0.5-3.9; p=0.01). 12 (40%) of
30 patients in the atorvastatin group improved by 1.3 units or more on the LCQ
compared with five (17%) of 30 in theplacebo group (diff erence 23%, 95% CI 1-45;
p=0.04) (Figure 2&3).
At 3 months
There was evidence of a difference in baseline to 3-month change in LCQ between
the treatment groups, with a significant improvement in the statin treated group, with







/ ✓ / oN
O Statin group
□ Placebo group
Figure 2: Reduction of cough in the statin group, as measured by LCQ; *p=0.01 for
comparison of reduction in cough between both groups, at the end of 6months.
*p=0.01
2:1.3 Units improvement




























3.5.1. Sputum differential count
In the statin group, there was a decrease in the total number of sputum neutrophils and
increase in number of apoptotic neutrophils/ 400 cells counted for each sample, with a
median (IQR) difference of 5.5 (0.0, 15.0) in the number of apoptotic neutrophils/
400 cells counted; p value 0.04 and -32.5 difference in the total number of
neutrophils/ 400 cells; p=0.09; figure 5. At the end of 6-months of statin treatment the
% change of viable neutrophils in the sputum was -19.5% and apoptotic neutrophils
was 15.14%, compared to baseline, p=0.0001. In the placebo group, at 6-months %
change of viable neutrophils was -1.4% and apoptotic neutrophils 1.4% compared to
baseline, p=0.7; figure 5.
There was no significant difference in the number of eosinophils, basophils or
monocytes, between active and placebo groups.






Sputum differential count (per 400 cells counted)










(% difference of viable
neutrophils)





















































Figure. 6. Cytospin (x400 magnification) at baseline from patient on statin therapy.
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Figure 7. Cytsospin (x400 magnification) from same patient at the end of treatment
with statins with lower number of viable neutrophils and an increase in the number of








Figure 8. Increased levels of sputum neutrophil apoptosis following atorvastatin.
Figure shows neutrophils (xlOOO) from sputum (per 400 cells counted) in a patient on
6-months statin therapy. Apoptotic neutrophils indicated by arrows.
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Figure 10. Cytsospin (x400 magnification) from same patient at the end of treatment
with placebo. No evidence of apoptotic neutrophils or reduction in total number of
viable neutrophils.
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3.5.2. Sputum inflammatory markers
There is no significant difference in the baseline to 6month change in IL-8, MPO or
free NE between those treated with statin compared to placebo, p value= 0.6, 0.6 and
0.9 respectively (table 4).







































Table 4. Median change (IQR) of sputum inflammatory markers, from baseline to
end of treatment at 6months.
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3.5.3. Systemic Inflammation
There was a significant reduction in IL-8 in the atorvastatin group at 6 months;
p=0.03 (figure 11, table 5), compared to baseline. However, there was no affect on the
IL-1 (3,1L-6,1L-10, lL12p70 or TNF-alpha levels.
There was no statistically significant difference in the baseline to 6-month change in
leucocyte count, total neutrophil count or ESR in the atorvastatin treated group
compared to the placebo group. However, CRP levels decreased in the atorvastatin












Figure 11. Serum IL8 measured at baseline and at 6 months; *p=0.03.
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Table 5. Median change (IQR) of sputum inflammatory markers, from baseline to
end of treatment at 6months.
* unpaired t test done for IL8.
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3.5.4. Spirometry
There was no difference in the baseline to 6-month change by treatment for FEVi,
FVC or FEV,:FVC ratio (table 6).
3.5.5. Exercise Capacity
There was a trend towards improvement in the baseline to 6-month change by
treatment, p=0.07 (table 6).































Table 6. Median change (IQR) of spirometry and incremental shuttle walk test, from
baseline to end of treatment at 6months.
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3.5.6. Exacerbation Frequency
8/24 (33%) of patients on statin had 2 or more exacerbations compared to 16/29
(55%) in the placebo group, with a relative risk ratio of 0.6 (95% CI 0.3-1.2).
5/24 (21%) of patients on statin had 3 or more exacerbations compared to 10/29
(34%) in the placebo group, with a relative risk ratio of 0.6 (0.2-1.5) (table 7).
Exacerbations Statin group Placebo
N (%) N (%)
0 6 (25%) 9(31%)
1 10(42%) 4 (14%)
2 3 (13%) 6(21%)
*3 5 (21%) 10(34%)
Table 7. Exacerbations in both groups while on treatment.
3.5.7. Comparison of exacerbations while on therapy to 6months before start of
trial
At baseline median number of exacerbations in the statin group were 3 (1-5.5) and in
the placebo were 2 (0-3); pvalue 0.04.
While on treatment for 6months, number of exacerbations in the statin group were 1
(0.5-2) and in the placebo were 2 (1-4). Comparison of exacerbations were done in
both groups and is demonstrated graphically in figure 13. Wilcoxon signed rank test
was done on the difference in exacerbation frequencies recorded, in either group. In
the statin treated group, there was a significant reduction in exacerbation frequency at
the end of statin therapy compared to 6months before, p=0.001.
There was no significant change in the placebo group at the end of treatment
compared to 6months before, p=0.67. However, given the difference in baseline












Figure 12. Exacerbations 6months before and during the 6months on the study- statin
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Figure 13. Exacerbations 6months before and during the 6months on the study-
placebo group (days along y- axis and individual patients along x-axis).
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3.5.8. Sputum Microbiology
Haemophilus influenzae was the most common colonizing organism in both groups at
baseline. At the end of treatment, 63% were colonized with microorganisms in the
statin group (57% at baseline), compared to 41% in the placebo group (43% at
baseline); p=0.1 for end of treatment proportion. There was no difference in bacterial
load when comparing the baseline to 6-month change on the basis of treatment. Mean
change in bacterial load was -2.7x107cfu/ml after 6-months of statin therapy p=0.1. In
the placebo group, mean change in bacterial load at the end of treatment
1.9xl07cfu/ml; p=0.1, table 8.
3.5.9. Quality of life- St. George's Respiratory Questionnaire
There was no evidence of improved quality of life in the atorvastatin treatment group,
difference in proportion -13%, 95% CI for difference (-29%, 3%) p=0.2 (table 8).
























■ v " <s ,■ . ■ -
BHHBBMHBHhHBHBIHHM!
24(83%) Hill
Yes (as 4 unit
improvement)
1(4%) 5(17%) 0.2
Table 8. Median change (IQR) of sputum microbiology and quality of life
questionnaire, from baseline to end of treatment at 6months.
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3.5.10. Routine blood tests
There was no statistically significant difference in the baseline to 6-month change in
urea, creatinine, alanine aminotransferase (ALT), or creatinine kinase levels in those
treated with statin compared to placebo. However, there was a difference in the
baseline to 6-month change in cholesterol in the statin group exhibiting a greater drop,
difference in means -1.40, 95% CI (-1.77, -1.02); pO.OOOl (table 9).






































Table 9. Mean change (SD) with 95% CI of routine blood tests, from baseline to end
of treatment at 6months.
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3.5.11. Comparison of variables where compliant
Using the baseline to 6-month change in cholesterol levels as an indicator of
compliance, a stratified analysis was conducted.
In the placebo group, 27/29 did not have a reduction of lmmol/L point or more in
cholesterol and in the atorvastatin group, 15/24 had a reduction of lmmol/L or more.
Within these patients, there is evidence of a difference in baseline to 6-month change
in LCQ between the treatment groups, difference 2.2, 95% CI for difference (0.4, 3.9)
p=0.016. This sub analysis shows an improvement in LCQin the statin treated group,
compared to the placebo group.
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3.6. Adverse Events and Safety
Ten of 30 (33%) patients had an adverse event in the statin group compared to three
of 30 (10%) in the placebo, difference in proportion 23% (95% CI for difference 3%,
43%), p=0.02. There were however no serious adverse events.
2/30 (7%) patients in the statin group developed leg pain in the first week of starting
the treatment, but this subsided in the second week for both patients. 1/30 (3%) in the
statin group and 2/30 (7%) in the placebo group had raised creatinine kinase (CK)
while on treatment (<three times upper limit of normal). This was detected at 3
months after starting treatment. These patients had repeat CK levels measured after 1
week and there was either a reduction in the levels or the levels had normalized. No
patients had to withdraw from the study due to high CK levels. In the statin group,
1/30 (3%) developed headache, while on treatment and had to withdraw from the
study due to it. Diarrhoea was reported in 1/30 (3%) patient within 1 week of starting
statin treatment and had to discontinue due to persisting diarrhea. 2/30 (7%) patients
developed both diarrhoea and headache whilst on statin treatment and both had to
withdraw from the study, due to persisting symptoms. 1/30 (3%) of the patients in
both groups developed abdominal discomfort one week after starting treatment, but
this improved spontaneously and did not need to stop the trial therapy. At 3 months,
1/30 (3%) patient in the statin group had an ALT of 325 U/L and, as this was >5times
normal, the patient was withdrawn from the study. Checking ALT, three days after
stopping treatment with statin, showed that it had normalized. 1/30 (3%) patient in the
statin group developed haematuria during the first week of starting the treatment.
However, he was known to have renal calculi, surgeons reviewed him to confirm this,
and he underwent lithotripsy for the renal calculi and continued the study treatment.
All patients had normal renal function throughout the study, when measured at
baseline and 6-months; table 2.
Adverse events of the study are summarized in table 10.
134





Leg pain 2 (7%) 0
Raised CK 1 (3%) 2 (7%)
Headache 3 (10%) 0
Diarrhea 3 (10%) 0
Abdominal discomfort 1 (3%) 1 (3%)
Deranged LFTs 1 (3%) 0
Haematutria 1(3%) o




4.1. KEY STUDY FINDINGS
In summary, atorvastatin 80mg orally, daily for 6months in patients with moderately
severe bronchiectasis, led to reduced cough (as measured by the Leicester Cough
Questionnaire); increased number of apoptotic sputum neutrophils at the end of
treatment and a significant reduction in serum IL8. Although the mechanism for
reduction in cough is not clear, we hypothesize that statin enhance apoptosis of
sputum neutrophils, thereby promoting resolution of inflammation, which is
beneficial in bronchiectasis.
There is limited data available in the literature on apoptosis of airway neutrophils in
bronchiectasis. Two important studies have discussed airway neutrophil apoptosis in
bronchiectasis. Vandivier et al concluded that sputum of bronchiectatic patients have
more apoptotic neutrophils in comparison to sputum obtained from patients with
chronic bronchitis. Although they attribute that presence of increased apoptotic cells
could be secondary to several key mechanism, they showed through in vitro studies
that failure of clearance of apoptotic neutrophils by macrophages was perhaps one of
the key contributors to persistence of apoptotic cells. They were able to demonstrate
that free neutrophil elastase (NE), which is present in abundance in bronchiectatic
airways, cleaves the phosphotidylserine receptor on macrophages, rendering poor
efferocytosis. Hence persistence of inflammatory cells in the airways promotes further
inflammation leading to failure of resolution.
In comparison, a study by Watt et al showed that in bronchiectasis, there were low
levels of apoptotic neutrophils in induced sputum, as compared to the findings by
Vandivier. They found no significant differences in the levels of apoptotic or necrotic
neutrophils at the beginning and end of an exacerbation treated with antibiotics. There
was however a reduction in the total number of sputum neutrophils and serum levels
of IL-8, TNF-a, NE and CRP were reduced.
136
In summary, few studies have investigated neutrophil apoptosis in bronchiectasis. Of
the two key studies described to date, the opinion remains divided. In view of our
study findings of increase in sputum neutrophil apoptosis after 6 months of statin
treatment and the paucity of data on neutrophil apoptosis in bronchiectasis, we
investigated the role of statins on neutrophil apoptosis and possible mechanisms by
which statins induce apoptosis.
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4.2. APOPTOSIS AND EFFEROCYTOSIS
It is known that in bronchiectasis, there is excessive neutrophilic airways
inflammation. However, despite this, over two thirds of patients are chronically
colonized with microorganisms. This apparent paradox in bronchiectasis needs to be
explored further. Granulocyte apoptosis and their removal by phagocytes, particularly
macrophages, are essential for resolution of inflammation (Greening and Simon
2011). The neutrophil, which although short-lived in the circulation, is granted an
extended life span by survival signals at inflammatory sites (Lee et al 1993).
Apoptosis renders these potentially histotoxic cells functionally redundant and
ensures their recognition and clearance by macrophages (Savill et al 1989). It is
known that phagocytosis of apoptotic cells (efferocytosis) is integrally involved with
the regulation of the inflammatory response and maintenance of lung homeostasis by
1) removing dead cells before the onset of necrosis (Henson et al 2001), by 2)
inducing release of anti-inflammatory mediators (Henson et al 2001) and
antiproteases (Odaka et al 2003), and by 3) increasing production of growth factors
(Morimoto et al 2001, Golpon et al 2004). Hence impaired efferocytosis is involved in
the pathogenesis of a variety of chronic inflammatory lung diseases such as cystic
fibrosis, bronchiectasis, asthma and COPD (Vandivier et al 2002, Hodge et al 2003,
Bratton and Henson 2005). It is essential for activated neutrophils to be turned off, for
resolution of inflammation to take place. Neutrophils that are over-activated or
undergo necrosis release their toxic granule contents, causing unwanted tissue
damage. By inducing neutrophil apoptosis together with efficient macrophage




Figure 1. Diagram showing resolution and failure of resolution of neutrophil mediated
inflammatory process. Neutrophilia is resolved by apoptosis and clearance by
macrophages. Failure of resolution after apoptosis, where neutrophils are in excess or
are not cleared leads to secondary necrosis. ROS= Reactive oxygen species.
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4.3. ATORVASTATIN
Mechanism of action: Inhibition of HMG CoA reductase
Statins target hepatocytes and inhibit HMG-CoA reductase, the enzyme that converts
HMG-CoA into mevalonic acid, a cholesterol precursor. Statins do more than just
compete with the normal substrate in the enzymes active site. They alter the
conformation of the enzyme when they bind to its active site. This prevents HMG-
CoA reductase from attaining a functional structure. The change in conformation at
the active site makes these drugs very effective and specific. Binding of statins to
HMG- CoA reductase is reversible, and their affinity for the enzyme is in the
nanomolar range, as compared to the natural substrate, which has micromolar affinity
(Corsini et al 1999). The inhibition of HMG-CoA reductase determines the reduction
of intracellular cholesterol, inducing the activation of a protease that slices the sterol
regulatory element binding proteins (SREBPs) from the endoplasmic reticulum.
SREBPs are translocated at the level of the nucleus, where they increase the gene
expression for LDL receptor. The reduction of cholesterol in hepatocytes leads to the
increase of hepatic LDL receptors, that determines the reduction of circulating LDL
and of its precursors (intermediate density-IDL and very low density-VLDL
lipoproteins) (Sehayak et al 1994). All statins reduce LDL cholesterol non-linearly,
dose-dependent, and after administration of a single daily dose (Blum 1994). Efficacy
on triglyceride reduction parallels LDL cholesterol reduction (Stein et al 1994). By
inhibiting mevalonic acid synthesis, statins also prevent the synthesis of other
important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as
farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) (Evans and
Rees 2002). These isoprenoids are necessary for the post translational modification
and subsequent trafficking of intracellular signalling molecules.
Inhibition of HMG-CoA reductase, the regulatory enzyme of the pathway, results in
disturbances in practically all vital cellular processes, such as protein glycosylation
and prenylation, cell signaling, functioning of the respiratory chain and integrity of
cellular membranes (Buhaescu and Izzedine 2007). The impairment of these
processes may contribute to the pleiotropic side effects of statins (Evans and Rees
2002, Onfrei et al 2008, Zhou and Liao 2009). The pleiotropic effects of statins have
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now been studied extensively. Of significance to us are the anti inflammatory effects
of statins (figure 2).
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Figure 2. Anti inflammatory effects of statins. NFkB= nuclear factor kB cells: NO-
nitric oxide.
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4.4. STATINS AND LUNG INFLAMMATION
Several studies have documented the beneficial effects of statins in vitro and in vivo
in experimental animal models of pulmonary inflammation. Shyamsundar et al first
reported the effects of statin in vivo on LPS induced lung inflammation in humans.
Briefly, in this RCT, healthy volunteers were given simvastatin for 4 days following
which they were challenged with inhaled LPS. Bronchoalveolar lavage (BAL) was
performed at 6 hours after challenge and serum was collected after 24 hours. Pre
treatment with simvastatin reduced LPS induced BALF neutrophilia, MPO, TNF-a,
matrix metalloproteinases 7, 8 and 9 as well as plasma CRP and had reduced
upregulation of nuclear factor (NF) kB, as compared to control subjects. In addition,
pretreatment with simvastatin significantly increased the number of neutrophils in late
apoptosis, as compared to placebo. This data was obtained from 15 subjects in the
active group and 9 healthy controls.
This was the first study to report the increase in pulmonary neutrophil apoptosis in
vivo in humans when pretreated with statin, following acute lung injury stimulation.
The neutrophil apoptosis findings from this study were similar to our study findings.
After 6 months of treatment with Atorvastatin 80mg, there was an increase in the
number of apoptotic sputum neutrophils as compared to those who were treated with
6months of placebo.
We hypothesize that statins enhance apoptosis by regulating calcium flux. Hence it is
of relevance to discuss key mediators such as roscovitine, fMLF, formyl peptide




Systematic name: (3i?)-3,5-Dihydroxy-3-methylpentanoic acid
Molar mass: 148.16 g/mol
Figure 3. Mevalonic acid
Mevalonic acid (MVA) (derived from dihydroxymethylvalerolactone) is a key
organic compound in the mevalonic acid pathway that leads to the synthesis of sterol
isoprenoids, with the final product cholesterol, and nonsterol isoprenoids, such as
dolichols, the side chain of ubiquinone, farnesyl diphosphate (FPP) and
geranylgeranyl diphosphate (GGPP). Statins inhibit HMG CoA reductase which is
the rate limiting step (see figure below). Hence blocking the production ofmevalonic
acid inhibits the production of the key final products of farnesyl diphosphate and
cholesterol (figure 4). Replacement of mevalonic acid after inhibition by statins
should thereby reverse the effects of statins.
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Molar mass: 354.45 g/mol
Figure 5. Roscovitine
Neutrophils are key to the immune system and are recruited rapidly to the site of
inflammation. Neutrophils then release products of degranulation and activation to
defend and destroy invading microorganisms but these byproducts are detrimental to
the surrounding tissues (Nathan 2002). Activated neutrophils need to 'switch off and
undergo apoptosis for the resolution of inflammation. Once apoptosis has been
engaged, the neutrophil secretory activity is shutdown; the cells remain intact and are
phagocytosed by macrophages using recognition mechanisms (efferocytosis) that fail
to elicit a pro-inflammatory response (Savill et al 1989, Whyte et al 1993).




Neutrophil apoptosis is controlled by a complex network of signalling pathways that
regulate both the turnover of key molecules, including the anti-apoptotic
proteinmyeloid cell leukemia 1 (Mcl-1) and the pro-apoptotic Bcl-2 family member
Bax, and activation of the caspase family of proteases. (Riley et al 2006).
Cell division of eukaryotic cells occurs in four phases (Gl, S, G2, M) and in some
circumstances, where the cell is terminally differentiated, the cell will rest in GO
phase. Neutrophils are terminally differentiated cells. The cyclin dependent kinases
(CDK) are key regulators of the cell cycle, whereby different CDKs become activated
during cell-cycle progression when complexed with their associated cyclin partners
(Vermeulen et al 2003).
Rossi et al have been investigating the role of CDK inhibitors in neutrophil apoptosis,
both in vitro and in vivo (Rossi et al 2006). They have shown that human neutrophils
express functional CDKs and that different CDK inhibitors directly induce caspase-
dependent neutrophil apoptosis and inhibit cell survival induced by several
biologically important powerful anti- apoptotic agents. In addition, the CDK inhibitor
R-roscovitine downregulates Mcl-1 expression induced by survival factors in
neutrophils. Further studies have demonstrated in vivo that roscovitine markedly
enhances resolution of inflammation in mouse models of carrageenan-induced acute
pleurisy, bleomycin-induced lung inflammation and passively induced arthritis. The
roscovitine enhanced resolution of established pleurisy is driven by a caspase-
mediated pro-apoptotic effect (Rossi et al 2006).
Perhaps unsurprisingly, given the terminally differentiated state of these cells, the
most significantly expressed CDKs (McGrath et al 2011, Leuenroth et al 2000) have
no direct role in the cell cycle but are essential for transcription of a key subset of
genes. Mcl-1 (pro survival protein) is down regulated to the level of genes and this is
essential for the initiation of apoptosis. It has been further demonstrated that
roscovitine manipulates the transcriptional machinery of the neutrophils to thereby
promote apoptosis (Leitch et al 2012).
These findings suggest that CDK inhibitors may provide a therapeutic strategy to
promote resolution of inflammatory diseases, through specific induction of
inflammatory cell apoptosis.
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4.7. N- FORMYL- METHYL- LEUCYL- PHENYLALANINE (fMLF)
Neutrophils are first responders in an organism's rapid assault on infectious
pathogens. Through genetically conserved receptors, neutrophils recognize
chemoattractants, lipid products, and the molecular patterns present on the surface of
bacteria, viruses, and fungi (Medzhitoov and Janeway 2000). fMLF is recognized by
neutrophils and is a potent neutrophil chemoattractant. fMLF, upon binding to its
heterotrimeric G protein-coupled receptor, initiates signaling cascades that activate
multiple pathways (Haribabu et al 2000). These pathways include the mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI-3K) cascades,
which are important for the development of the functional responses of neutrophils in
inflammation (e.g., the respiratory burst, transmigration, and phagocytosis) (Mocsai et
al 2000, Rane et al 1997, Delia Bianca et al 1993, Coffer et al 1998).
4.8. FORMYL PEPTIDE RECEPTOR (FPR) 1
The FPR receptor family was extensively characterised throughout the 1980s as seven
membrane spanning, G-protein coupled receptors (GPCR) via pertussis toxin
sensitivity; specifically attributed to G-protein coupling (Lavigne et al 2002). The
human family was cloned in 1990 (Boulay et al 1990) with three genes encoding
FPR1, FPR2/ALX and FPR3 clustered on chromosome 19q 13.3.
FPR1, the first chemotactic receptor to have its primary structure delineated by
molecular cloning (Boulay et al 1990), has been extensively studied for its high
affinity binding to fMLF. Following agonist ligation, FPR1 undergoes rapid
phosphorylation in a concentration and time dependent manner (Ali et al., 1993)
leading to conformation changes. (Migeotte et al 2006). Downstream of G-protein
2+
interaction there are a number of signalling pathways including calcium (Ca ) flux,
phospholipase (PL) A, C and D, phosphoinositide-3-kinase (PI3K) and MAP kinase
pathways (Selvatici et al 2006).
PLC is an essential upstream mediator of both PI3K and mitogen- activated protein
kinase pathways via protein kinase C (PKC). PLA is well characterised for mediating
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PLC activation central to the biosynthesis of eicosanoids. In neutrophils, activation of
PI3K following fMLF has been shown to selectively regulate oxidative burst and
actin relocalisation, essential for cell polarisation. The MAP kinase pathway, in
particular ERK-1/2, selectively regulates chemokinesis as well as signal transducers
and activators of transcription proteins and adaptor proteins (Wenzel-Seifert et al
1998).
Signalling via FPR1 is regulated by two processes, receptor desensitisation and
agonist-induced internalisation. Desensitisation is the result of uncoupling of G-
protein from the receptor, and can occur either by direct ligation or following
activation of similar GPCRs. It has been shown that receptor desensitisation and
internalisation is reliant on PKC following both homologous activation of FPR1 or
heterologous activation of other GPCRs (Le et al 2001b). After initial activation of
FPR1 with fMLF, the receptor rapidly reduces its responses to secondary stimulation
with the same agonist; this is termed homologous desensitisation. FPR1 is also
susceptible to heterologous desensitisation via ligation of a GPCR receptor, C5aR
(complement receptor) or CXCL2 (interleukin-8 receptor), in a concentration-
dependent manner (Ali et al 1999). These processes complement the classical idea of
concentration-gradient dependent migration by peripheral cells to a site of
inflammation.
Apart from the ability of FPR1 to mediate chemotaxis it was also noted that fMLF
2+
^ 2+
induced a rapid Ca mobilisation (Andersson et al 1986). Although Ca has been a
2+
robust functional response to fMLF, its biological relevance is still unclear. Ca is
required for cytoskeleton reorganisation, but phagocytosis and chemotaxis can occur
2+
in Ca depleted cells (Fu et al 2006).
Functionally, FPR1 is mostly associated with host defence; fMLF has been associated
with eliciting shape change, adhesion, phagocytosis, cytokine production, superoxide
production and degranulation in phagocytic cells (Selvatici et al 2006).
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Figure 6. Simplified representation of leukocyte migration cascade via the FPR family
(Adapted from Dufton and Peretti 2010). Increasing gradient of formyl peptide leads
to a well-characterised sequential response activating circulating and resident
leukocytes. FPR1 is activated at low concentration of formyl peptide. FPR activation
of leukocytes, results in integrin expression and activation inducing firm adhesion to
the endothelial cells. High concentration or repeated stimulation by formyl peptide
can lead to receptor desensitisation, which may be a prominent regulatory mechanism.
FPRs play a role in macrophage phagocytosis and as yet uncharacterised roles in
innate-adaptive cell interactions.
FPR1= Formyl peptide receptor 1; ICAM= intracellular adhesion molecule; PSGL-1=
P-selectin glycoprotein 1; VCAM= vascular cellular adhesion molecule.
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4.9. FPR1 AND DISEASE
Besides receptor mutations, the degree of FPR1 expression can be modulated in
disease. For instance, increased fMLF binding sites are reported on circulating PMN
taken from patients suffering from emphysema (Stockley et al 1994), indicative
perhaps of an unabated systemic response to bacteria in the lungs that lead to the
chronic pathology. Fligher binding for the tri-peptide was also shown in patients
suffering from Crohn's disease, and this was associated with augmented responses to
fMLF (Anton et al 1989). It is plausible that FPR1 expression on the surface of
circulating leukocytes could change as result of cell activation, and thus serve as a




Alternate name: 5-(N-Methyl-D-valine)-cyclosporin A
Molecular wt.: 1202.6
Figure 7. Cyclosporin H
Cyclosporin is an immunosuppressive compound that acts by lowering the activity of
T-cells and their immune response. Cyclosporin A (CsA) binds with high affinity to
the cytosolic protein cyclophilin of T-cells, a critical step in the molecular mechanism
of action of cyclosporins, whereas cyclosporin H, an undecapeptide, (CsH) has
extremely low affinity for cyclophilin. CsH differs from CsA by the substitution of
the L-methyl valine at position 11 with its D-isomer. CsH is a potent and competitive
inhibitor of the formyl peptide receptor. In contrast to CsA, which suppresses early
events in the activation of T and B lymphocytes, CsH has no effect (Von Wartburg
and Traber 1986, Sigal and Dumont 1992). Studies have shown that CsH is a potent
inhibitor of fMLF induced release of 02"from neutrophils (Wenzel-Seifert et al 1991).
Interestingly, CsH has no effect on neutrophil chemoattractants C5a, platelet
activating factor and LTB4 (Wenzel-Seifert et al 1991), suggesting that CsH is a
selective FPR. receptor antagonist. CsH may be a valuable drug to elucidate further
the role of endogenous and bacterial formyl peptides in the pathogenesis of
inflammatory processes in vivo (de Paulis et al 1996). Finally, studies are needed for




Fura-2-acetoxymethyl ester or Fura-2AM, is a membrane-permeable derivative of the
ratiometric calcium indicator Fura-2 used to measure cellular calcium concentrations
by fluorescence. When added to cells, Fura-2AM then crosses cell membranes and
once inside the cell, the acetoxymethyl groups are removed by cellular esterases.
Removal of the acetoxymethyl esters regenerates "Fura-2", the pentacarboxylate
9+
calcium indicator (figure 8). Measurement of Ca -induced fluorescence at both 340
nm and 380 nm allows for calculation of calcium concentrations based 340/380 ratios.
The use of the ratio automatically cancels out certain variables such as local
differences in fura-2 concentration or cell thickness that would otherwise lead to
artifacts when attempting to image calcium concentrations in cells.
CO,R CO,R CO:,R C02R CO,H r.O.H CO,H CO:H
Fura 2-Ca co-np ex
COjR Fura 2-AM CO-H F'jra 2
Figure 8. Mechanism by which Fura 2am detects calcium flux.
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4.12. RESULTS FROM APOPTOSIS ASSAYS
Dextran sedimentation and discontinuous Percoll gradient, as a means to isolate
neutrophils from peripheral venous blood, result in cell purity of >95%, with between
1% and 5% eosinophils and 1-2% contaminating mononuclear cells. In individuals
with atopic conditions, such as hay fever and asthma, eosinophils can represent >5-
10% of the granulocyte population.
Once isolated by Percoll Gradient, peripheral human neutrophils were exposed to the
following conditions:
1. Atorvastatin (Sigma Aldrich) at final concentrations of InM, lOnM, lOOnM,
lpM, lOpM (standard doses that have been used in the literature, Wassmann
et al 2002).
2. Atorvastatin lOpM + lOOpM Mevalonic acid (standard dose that has been
used in the literature, Wassmann et al 2002) (Sigma Aldrich).
3. Mevalonic acid at final concentrations of lOnM, lOOnM, lOpM, lOOpM.
Flow Inference
Annexin V negative and PI negative Live cells
Annexin V positive and PI negative Apoptotic cells
Annexin V and PI positive Necrotic cells
Table 1. Interpretation of Annexin V and propidium iodide staining
Apoptosis was assessed by blinded morphological assessment of May-Griindwald-
Giemsa stained cytospins, confirmed by quantification of annexin-V-fluorescein
isothiocyanate binding and propidium iodide staining.
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4.13. CELL COUNTS
At 12 and 20hours, cytocentrifuge preparations from treated and control neutrophil
suspensions were fixed and stained. Cells were examined under oil immersion light
microscopy and apoptotic cells were defined as cells containing darkly stained
pyknotic nuclei (Savill et al 1989). For each time point at least 400 cells were counted
from at least 4 different fields.
4.14. STATISTICAL ANALYSIS
Flow cytometry analysis was performed using FlowJo vl0.0.4 (Tree Star, Ashland,
OR, USA). Results are presented as mean ± standard deviation (SD). Data were
analyzed by one-way ANOVA with a Newman-Keuls multiple comparison post hoc
test (GraphPad Prism v6; GraphPad Software, La Jolla, CA, USA); significance was
accepted with P values: *P < 0.05.
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4.15. TIME COURSE FOR APOPTOSIS- 12 and 20 hours (N=5)
When cultured under physiological conditions, neutrophils showed a time dependent
increase in the number of cells exhibiting the classical morphological features of
apoptosis (N% &SD). Apoptosis was confirmed by flow cytometry and by cell counts
of cytospins.
When neutrophils were co cultured with atorvastatin, there was a dose and time
dependent increase in the number of neutrophils undergoing apoptosis. Atorvastatin
failed to induce apoptosis at an earlier time point of 12 hours even at a dose of lOpM.
Doses higher than lOpM led to necrosis of cells even at 12 hours, hence maximum
dose used waslOpM.
At 20 hours, maximum apoptosis was achieved at a dose of lOpM atorvastatin;
p=0.0002 (see table 2).
Apoptosis facilitated by atorvastatin at 20 hours, was reversed by co culturing cells
with mevalonic acid lOOpM.
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Negative control 67.3(2.1) 29.6(1.8) 1.2 (0.2)
lOOnM
Atorvastatin
69.6 (0.8) 30.3 (1) 0.6 (0.8)




70.0(1.6) 28.8 (5.6) 1.9(1.2)
Roscovitine 6.5 (2.7) 83.7 (3.2) 9.9 (0.4)
Table 2. Table showing cumulative flow data of the treatments.
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APOPTOSIS FLOW PLOTS AT 20-HOURS
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Figure 9. Flow plots obtained at 20 hours. 9a= negative control; 9b= lOOnM
atorvastatin; 9c=10pM atorvastatin; 9d= lOpM atorvastatin+ lOOpM mevalonoc acid;
9e= 20pM mevalonic acid
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Figure 10. Negative control; red arrows indicate apoptotic neutrophils with pyknotic,
darker stained nuclei with intact cell membrane; blue arrows indicate apoptotic cells
undergoing secondary necrosis. Note other neutrophils in the field which are viable,
have multi lobulated nuclei, intact cell membrane and uniformly stained nuclei.
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Figure 11. 10|aM atorvastatin
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• HBSS (Hanks balanced salt solution) without divalent cations-no phenol red
• fura-2/AM
• HBSS without phenol red but with divalent cations.
• 250 mM EGTA ethylene glycol tetraacetic acid (pH 8.0 (diluted in ddHiO)
• Triton-100(1%)
After isolation of neutrophils as described above, neutrophils were resuspended
(10^/ml) in HBSS without divalent cations-no phenol red. Cells were then incubated
with with fura-2/AM (acetoxymethyl ester) (final concentration 2 pM) for 30 mins at
37 °C (1:1000 dilution). Cells were then washed twice to remove fura-2/AM and
leave in HBSS without divalent cations for 10 mins for optimal de-esterification.
6
Neutrophils were then resuspended at 2 x 10 /ml in HBSS without phenol red but
with divalent cations.
The changes in fluorescence were determined upon agonist fMLF stimulation;
addition using a fluorimeter, with dual wavelength excitation (340 and 380 nm),
emission at 510 nm, fitted with a thermostated cuvette compartment and stirring
attachment, to ensure complete mixing of reagents. 2000ml of cells were used in a
3ml cuvette or 500ml cells in 1ml cuvette. Fluorescence was calibrated at start and
end of experiment. Maximal fluorescence (Rmax) and the minimum fluorescence
2+
(Rmin) was obtained. Rmax is the ratio obtained in the presence of saturating [Ca ]i
[after treatment with 200ml (50ml if small cuvette) Triton-100 (1%). Rmin is the
2+
ratio obtained in the absence of Ca (addition of 200ml of 250 mM EGTA (50ml if
small cuvette)].
Atorvastatin (at final concentrations of InM, lOnM, lOOnM, 1 iiM, lOpM) and
lOOpM) was added to neutrophils in 1:100 volume.
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Cyclosporin H (FPR1 receptor antagonist) was used as a positive control and was
added at a final concentration of lpM.
2+ 2+
[Ca ]i was calculated from the relationship [Ca ]i = Kd.(R-Rmin)/(Rmax-R)b:
2+
where [Ca ]i is the cytosolic calcium concentration, R is the ratio of fluorescence
obtained at 340 and 380 nm in the cuvette before calibration, Rmax is the
2+
fluorescence ratio under saturating [Ca ]j, Rmin is the fluorescence ratio in the
2+
absence of Ca , Kd is the dissociation constant for fura-2/AM, taken as 224 nm at




4.16.1. STATINS AND Ca2+ FLUX
(i) fMLF induced Ca2 flux
fMLF (lOnM) induced a significant rise in calcium flux and this was inhibited when
FPR1 receptor blocker cyclosporin H- lqM was added simultaneously (positive
control). fMLF induced increase in cytoplasmic Ca2+ was reduced by addition of
atorvastatin (figure 14).
OH 1 1 1 1
0 25 50 75 100
Time (sees)
2+
Figure 15. fMLF induced increase in [Ca ]i flux; inhibited by Cyclosoprine Ft and
reduced by Atorvastatin.
— fMLF10nM
— CsH 1 jiM
— 10pM Atorvastatin
(ii) Pre incubation with statins
Pre incubation for at least 15 minutes (shown below) was required for statins to
2+
reduce fMLF induced increase in [Ca ]i flux. There was no effect of statins on
2+
[Ca ]i flux when added concurrently with fMLF.
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9
Figure 16. Pre incubation with statins for 900 sees before addition of fLMF.
2+
(iii) Dose response curve with stains
The minimum dose at which statins were able to reduce fMLF induced [Ca ]i flux
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Figure 17 a&b. Atorvastatin dose response curves in fMLP induced [Ca ]i flux.
Maximum inhibition is obtained at lOpM; AUC= 16888 (fMLF lOnM); 16181 (lpM
atorvastatin) and 16134 (lOpM atorvastatin); p=0.05 for comparisons.
Hence further studies are needed to establish if statins regulate Ca2+ flux by altering
the extracellular or intracellular pathways. If statins are regulating extracellular
Ca2+mobilization, is this occurring specifically by activation of store operated calcium
influx receptors? Alternatively, if statins are mobilizing Ca2+ by release from
intracellular stores, are statins mediating this response by the G-protein coupled
receptors or are the tyrosine kinase receptors? Exploring the role of statins in PAF
mediated Ca2+ flux, would help assess if statins cause cross receptor desensitization or




5.1. SUMMARY OF BRONCHIECTASIS
Bronchiectasis is a chronic disabling respiratory condition characterized by chronic
cough, chronic sputum production and recurrent chest infections. It is regarded as an
orphan disease not because of its rarity but because of the paucity of randomized
controlled trials. In a recent PubMed search, only 133 trials have been conducted in
bronchiectasis, compared with 3253 for chronic obstructive pulmonary disease, 5405
for lung cancer, and 8748 for asthma (Mandal P and Hill A). The true incidence of
bronchiectasis in the modern era of using computed tomography of the chest is not
known. We have over 750 patients in Edinburgh, UK monitored in secondary care
from a population of about 483,000. Patients frequently utilize primary and secondary
care resources through consultations, A&E attendances and inpatient admissions.
The pathogenesis is poorly understood but pulmonary pathology shows excess
neutrophilic airways inflammation, but despite this over two thirds of patients are
chronically infected with potential pathogenic organisms (Angrill et al 2001).
Described by PJ Cole in 1984, there is a vicious cycle of airways inflammation and
bacterial infection (Cole 1984). The excessive neutrophilic airways inflammation
leads to damage of the bronchial wall and paradoxically promotes more airways
inflammation and bacterial infection creating a vicious cycle. Bronchiectasis is a
common respiratory condition with a lack of long-term evidence based therapies
available. Treatment to date has focused on chest physiotherapy and long-term
antibiotics. There are concerns about the use of long term antibiotics in view of
antibiotic resistance, side effects and healthcare associated infections. Limitations
with the long term use of antibiotics and the exaggerated inflammatory response in
the airways, has led to a drive to investigate the efficacy of anti-inflammatory
therapies in bronchiectasis.
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5.2. CURRENT TREATMENT MODALITIES
To achieve the main treatment goals in bronchiectasis, it is important to break the
'vicious circle' of infection and inflammation. Long term antibiotics and chest
physiotherapy is the mainstay of long-term treatment in bronchiectasis. However,
there are certain caveats that we have to bear in mind. We are faced the burden of
Clostridium difficile and Methicillin resistant Staphylococcus aureus (MRSA) in
addition to antibiotic resistance, with the prolonged use of antibiotics. Consensus on
several therapeutic strategies that have been evaluated in cystic fibrosis (CF) and
COPD is lacking in bronchiectasis, and a number of controversies need further
elucidation. Over the last few years, there has been an international drive to reduce
antibiotic usage. There is an urgent need for novel non-antibiotic treatments.
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5.3. STATINS IN LUNG INFLAMMATION AND INFECTION MODELS
Cardiologists have used stains for more than two decades for primary prevention of
cardiovascular disease. Over the last few years, studies have established that statins
have pleiotropic effects, which include modulation of the innate and adaptive immune
system and anti-inflammatory properties (Dinarello 2010, Kwak et al 2000). Studies
have investigated the role of statins in both animal and human models of sterile and
infective inflammation. For example, during sterile inflammation statins attenuate
neutrophil recruitment in animal and human experimental systems (Shyamsundar et al
2009, Fessler et al 2005). In an animal model of pulmonary infection with
Staphylococcus aureus, high dose statin therapy was shown to enhance the formation
of extracellular DNA traps by phagocytes within the lung and protect against
dissemination of infection (Chow et al 2010, McDowell et al 2011). Boyd et al, found
that mice treated with prolonged high dose statin, in a model of lung infection with S.
pneumoniae, had a strong dose dependent effect on protection against S. pneumoniae
as evidenced by less neutrophil infiltration, maintenance of vascular integrity and less
chemokine production (Boyd et al 2012) Additionally, observational studies in
community-acquired pneumonia have shown a reduction in 30-day mortality in
patients who were on prior statins (Chalmers et al 2008).
We hypothesized that long term statin treatment would improve patients' symptoms
through its anti-inflammatory effect consequent on reduced neutrophilic airways
inflammation. The aim of our proof of concept study was to establish if atorvastatin
could reduce cough, a key feature with clinically significant bronchiectasis.
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5.4. STUDY FINDINGS
Six months treatment with high dose atorvastatin led to an improvement in cough
from baseline. Cough is one of the cardinal features of bronchiectasis and high dose
atorvastatin for 6-months in patients with moderately severe bronchiectasis led to
significant reduction of cough, in 40% of patients, the primary end point of this study.
In comparison, only 17% had a reduction in cough in the placebo group. There were
also significantly reduced IL-8 levels in serum and a significantly increased number
of apoptotic airway neutrophils and a trend towards a decreased total number of
neutrophils in the sputum in the atorvastatin treated subjects. There was a trend to
improvement in exercise tolerance, improvement of 39m more in the statin treated
group compared to the group on placebo, but this just failed to reach conventional
statistical significance. There was also a trend towards reduction in systemic
inflammation (CRP) in the statin treated group, but this did not reach conventional
statistical significance. There was no effect on spirometry, airways inflammation,
bacterial colonisation or load, quality of life or exacerbations during the study. The
study was however not powered for these endpoints. Subanalysis of the data based on
compliance to therapy, showed the same results as analysis of the study as a whole.
The primary end point was still achieved confirming that although the study was
small, the study findings are robust.
The other key study finding was a significant increase in number and proportion of
apoptotic neutrophils, decrease in the proportion of viable neutrophils and a trend
towards a reduction in the total number of neutrophils, obtained from sputum of
patients at the end of 6 months of atorvastatin treatment. We therefore hypothesize
that this decrease in the overall number of neutrophils may be related to the altered
lifespan of the neutrophils in response to statin treatment.
Surprisingly, there was no reduction in sputum MPO or neutrophil elastase as might
be expected. It is expected apoptotic neutrophils would maintain membrane integrity
until clearance and have reduced ability to degranulate, generate a respiratory burst,
or undergo shape changes in response to external stimuli (Houck 1979). However,
release of these granule contents could occur before the induction of apoptosis or
169
could indicate that there is occurrence of secondary necrosis. This needs to be
explored further.
These results are however similar to a study by Llewellyn-Jones et al, where
indomethacin 75 mg per day was given to 9 patients with clinically stable
bronchiectasis (Llewellyn-Jones et al 1995). Pre-treatment with indomethacin, led to a
reduction in neutrophil chemotaxis but had no effect on sputum MPO or free elastase
activity, suggesting that these measurements in sputum may not accurately reflect
airway neutrophil numbers. Further mechanistic studies are needed to assess the
immunomodulatory effects of statins on neutrophils.
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5.5. ADVERSE EVENTS
There were more dropouts in the statin group compared to the group on placebo (20%
compared to 3% in the placebo). The most common cause for dropout was headache
and diarrhea (67% of the dropouts), with deranged liver function tests due to statins
necessitating withdrawal in one patient. The only dropout from the placebo group was
due to personal reasons. However, 80% in the statin group were able to tolerate the
high dose statins and complete the full 6-month treatment.
5.6. MECHANISTIC STUDIES
As the key study findings were cough reduction and increase in the number of
apoptotic neutrophils and a general trend towards reduction in the number of total and
viable neutrophils, our discussion will be focusing mainly on in vitro studies done to




Neutrophils are the predominant leucocytes and play a central role in the pathogenesis
of bronchiectasis. They amplify the inflammatory process by releasing oxidants and
proteases that damage the airways tissues, as well as inflammatory products that leads
to recruitment and activation of greater numbers of neutrophils, thereby extending the
severity of tissue damage (Kawahito et al 2000).
Neutrophils have the shortest half-life among leukocytes and normally survive for less
than a day in the circulation (Liles and Klebanoff 1995) before undergoing
morphologic and functional changes characteristic of apoptosis. During culture, 50%
to 70% of neutrophils undergo constitutive apoptosis by 20 hours (Ward et al 1999).
Apoptosis is a process of regulated cellular death (Akgul 2001) that is mediated by a
family of intracellular cysteine proteases or caspases (Hankart 1996) and represents
the predominant process responsible for the resolution of the neutrophil-mediated
inflammatory response. As neutrophils undergo apoptosis, they lose surface adhesion
molecules and the ability to secrete granular contents (Whyte et al 1993) and are
subsequently ingested rapidly by macrophages and removed from the area of
inflammation with minimal damage to the surrounding tissue. A delayed neutrophil
apoptosis could therefore potentially prolong the airway inflammatory response.
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5.8. SECONDARY NECROSIS
Morphologically, necrosis is characterized by a disruption of the cellular membrane
and a swelling of the cytoplasm and mitochondria, culminating in the complete
disintegration of organelles. This is known as primary necrosis (type 1 necrosis). The
presence of necrotic cells does not however imply that they did not die by apoptosis.
The term secondary necrosis (type 2 necrosis) refers to a process in which late stage
apoptotic cells that failed to be engulfed by phagocytes or neighboring cells undergo
necrosis. Secondary necrosis is therefore a post-apoptotic event. This process is seen
in cultured cells that are undergoing cell death by apoptosis in vitro, induced by the
absence of survival factor signals or activation of death receptors. These cells, in the
absence of phagocytic cells that could engulf them, ultimately cease to be
metabolically active, lose membrane integrity, and release their cytoplasmic contents
into the culture medium. Secondary necrosis can also occur in vivo, in autoimmune
disorders associated with impaired clearance of apoptotic cells. In addition, secondary
necrosis is seen during massive local apoptosis when macrophages may be unable to
cope with the load of apoptotic cells. Therefore, secondary necrosis plays a critical




Ca2+ ions also serve as important second messengers in signal transduction in many
cell types, including neutrophils, leading to the activation of downstream molecules
(Lewis 2001). Cytoplasmic levels of Ca2+ can increase either from release from
internal calcium stores [such as the endoplasmic reticulum (ER) by ionisitol] or by
entry from outside the cell via calcium channels, leading to the rapid activation of
molecules that promote cell proliferation and cell death (McConkey et al 2001). In
neutrophils, stimulation by agonists that bind to the G protein coupled seven
transmembrane type receptors such as the fMLF receptor, trigger increases in
intracellular Ca2+. Elevation of intracellular free Ca2+ levels or mobilization of
intracellular Ca2+ stores promotes neutrophil longevity (Cousin et al 1997). However,
the overall role of calcium in apoptosis is complex and cell specific. Studies have
demonstrated that elevation of [Ca2+]i in neutrophils by calcium ionophores inhibits
apoptosis (Whyte et al 1993).
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5.10. REGULATION OF THE INFLAMMATORY RESPONSE
5.10.1. Reduction in cough
The primary end point of the study was a reduction in cough and at the end of
6months, 40% of patients in the statin group had a reduction of cough by 1.3 units or
more as measured by the Leicester Cough Questionnaire. This compared to a
reduction of cough in only 17% of those on placebo for 6 months.
Cough is reported in 90-98% of patients with bronchiectasis (Nicotra et al 1995, King
et al 2006). Cough in bronchiectasis is consequent to hypersecretion of mucus and
impaired clearance of secretions. The mucus stasis is compounded by the impaired
mucociliary clearance, which reflects damaged epithelium. Torrego et al
demonstrated that bronchiectasis patients have a sensitive cough reflex (to increasing
doses of capsaicin). They hypothesized that chronic neutrophilic inflammation and
subsequent damage could lead to cough sensitization (Toreggo et al 2006). Studies
have shown raised levels of products of neutrophil activation and degranulation such
as neutrophil elastase and myeloperoxidase, in bronchoalveolar lavage from
bronchiectasis patients (Angrill et al 2001). In addition, high levels of the pro
inflammatory cytokines TNF-a, IL-6, IL-8 and LTB4 have been detected in BAL
fluids in bronchiectasis (Wilson 2001, Mikami et al 1998). The presence of bacterial
infection is usually associated with more severe inflammation.
As cough is the dominant symptom of bronchiectasis, reduction of cough and
measuring its impact on health related quality of life is critical for both disease
assessment and targeted management. LCQ is a symptom specific questionnaire and
we have validated it for assessing cough severity in bronchiectasis. The mechanism
for reduction of cough in our study was not clear, hence we explored this further
through in vitro studies conducted, based on the other study findings.
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5.10.2. Statins and apoptosis
In bronchiectasis, there is prolonged neutrophil persistence that promotes excess
airways inflammation (Watt et al 2004). It has been well established that there is a
key role for apoptosis, or programmed cell death, in the regulation of inflammation
and the host immune response (Rossi et al 2006). In vivo models of pneumococcal
infection, have demonstrated that inducing apoptosis of neutrophils improved
resolution of inflammation and accelerated recovery (Koedel et al 2010).
Although neutrophils appear to be committed to death via apoptosis, it is now clear
that the life span and functional activity of mature neutrophils can be extended
significantly by pro inflammatory cytokines, including granulocyte colony-
stimulating factor, granulocyte-macrophage colony-stimulating factor, interferon
gamma, TNF-a and IL-2 (Rossi et al 2006). Increased levels of IL8 and TNF-a have
been consistently detected in bronchial secretions in bronchiectasis (Eller et al 1994,
Tsang et al 1998). It is therefore likely that high levels of these inflammatory
mediators inhibit apoptosis (Dunican et al 2000, Taggart et al 2000), thereby
promoting further ongoing inflammation. Hence, it is speculated that in
bronchiectasis, the airways tend to enter a positive-feedback loop between prolonged
survival and release of pro inflammatory cytokines, leading to further airway
inflammation and damage.
Our in vitro mechanistic studies showed that statins significantly enhance neutrophil
apoptosis at 20 hours and this is dose dependent. We were able to demonstrate this by
both flow cytometry and sputum cytospin counts. Rossi et al have previously shown
that neutrophil apoptosis can be induced by treatment with agents such as CDK
inhibitor drugs, with consequent pro-resolution effects (Rossi et al 2006, Leitch et al
2012). Statin induced apoptosis was reversible when neutrophils were co-incubated
with mevalonic acid (mevalonic acid is a precursor in the biosynthetic pathway of
cholesterol synthesis). However at 12 hours, statins were unable to enhance apoptosis
even at a maximum dose of lOpM atorvastatin.
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We hypothesize that statin treatment in part regulates neutrophil apoptosis thereby
playing an important role in inflammation and resolution.
In a study by Shyamsundar et al, they showed that simvastatin has anti inflammatory
effects in the pulmonary and systemic compartment in humans exposed to inhaled
LPS. They were able to demonstrate that pretreatment with simvastatin for 4days led
to an increase in pulmonary neutrophil apoptosis in humans. It is known that during
apoptosis, neutrophil secretory processes are shut down and the intact senescent
neutrophil is removed by macrophages (Shyamsundar et al 2009). The increase in
neutrophil apoptosis was attributed to reduced pulmonary CRP levels. CRP is known
to inhibit neutrophil apoptosis (Khreiss et al 2002) and plasma CRP is suggested to
have a role in the delayed neutrophil apoptosis seen in cystic fibrosis (McKeon et al
2008). In our study, there was a reduction in CRP although this just failed to reach
conventional statistical significance. This needs to be explored further.
Several reports have found that statins reduce the levels of the anti-apoptotic protein
Bcl-2 and increased apoptosis and cell death, in human cancer cell lines and murine
non-cancer cells (Wood et al 2013). Till date there have been no studies assessing the
role of statins on neutrophil apoptosis in a model of chronic airways infection and
inflammation. There is also evidence demonstrating that statins enhance efferocytosis
in vitro and in vivo, and that they may play an important therapeutic role in diseases
where efferocytosis, a key regulator of inflammation is impaired (Merx et al 2005).
Based on the available data in the literature, we corroborated our study findings and
summarized that there was an increase in neutrophil apoptosis, a significant reduction
in peripheral IL-8 levels and a reduction in peripheral CRP levels, after 6 months of
statin treatment, although this just failed to reach statistical significance. Reduced
levels of the pro survival mediator IL-8 in peripheral blood with 6 months statin
treatment, could contribute to regulate neutrophil apoptosis, but this needs to be
interpreted with caution, as sputum IL8 levels were not reduced. However, we were
still unable to explain the mechanism by which statins enhance neutrophil apoptosis
in bronchiectasis, but what was clear was that "switching off of the activated
neutrophils and inducing apoptosis has therapeutic potential in bronchiectasis by
promoting the resolution of inflammation.
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To investigate the mechanism by which statins enhance neutrophil apoptosis, we
assessed the role of statins on calcium flux during neutrophil apoptosis. Upon
pretreatment with statins for 15 mins, a dose dependent reduction was observed in
cytoplasmic calcium levels, measured by spectrofluorimetry of Fura-2-loaded
neutrophils, and calcium flux, following stimulation with fMLF.
5.10.3. Apoptosis and Ca2+ flux
fMLF increases [Ca2+]i but the role of fMLF in neutrophil apoptosis is not clear.
Colotta et al reported that fMLF has no appreciable influence on the in vitro life span
of neutrophils. Studies have reported fMLF stimulated a considerably greater amount
of respiratory burst superoxide release than TNF-a but did not cause significant
apoptosis. Lee and colleagues however demonstrated through in vitro experiments
that the inflammatory mediators fMLF, prolong the functional life span of neutrophils
through modulation of apoptosis.
While neutrophils undergo apoptosis constitutively, the rate of apoptosis itself can be
modulated. For example, neutrophil apoptosis is delayed by bacterial products and
inflammatory mediators, such as fMLF and C5a (Liles and Klebanoff 1995), as well
as other receptor-mediated stimuli associated with calcium mobilization and elevation
of [Ca2+]i during neutrophil activation (Ward et al 1999, Whyte et al 1993, Jimenez et
al 1997). These data raise an interesting paradox, that apoptosis in the neutrophilis
inhibited by stimuli increasing [Ca2+]j whilst this event has been shown to trigger
apoptosis in other cells. McConkey et al reported that there was rapid increase in the
rate of apoptosis in lymphoid cells with ionophores and the subsequent elevations in
[Ca2+]j, were sustained. Neutrophils response to [Ca2+]j appears to be different.
2+ . .
Whyte et al demonstrated that increase in [Ca ]; in neutrophils is transient but elicits
signalling events leading to prolonged inhibition of apoptosis. The role of fMLF and
Ca2+ in apoptosis is still not clear.
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In our studies, we were able to demonstrate that statins reduction in [Ca2+]i was
associated with increase in neutrophil apoptosis in vitro. Further studies are needed to
explore this pathway further to determine the mechanisms by which statins regulate
neutrophil apoptosis.
5.10.4. Statins as an anti inflammatory in infection models
Studies using animal sepsis models have also demonstrated that statins reduce
endothelial dysfunction and have anti-thrombotic effects that improve outcome
(Tleyjeh et al 2009). In addition, studies using in vivo models of pneumococcal
infection, have demonstrated that inducing apoptosis of neutrophils improved
resolution of inflammation and accelerated recovery (Koedel et al 2010).
In a prospective observational study, Chalmers et al showed that in patients admitted
to hospital with community acquired pneumonia, prior statin use was associated with
significantly lower c rective protein levels on admission and 30-day mortality
(Chalmers et al 2008). In a recently published RCT of atorvastatin in critically ill
patients admitted to intensive care unit, prior and continued statin use was associated
with a an improved survival (Kruger P et al 2013).
We found no adverse effect on viable bacterial load in the sputum of the statin treated
patients. There was a trend for fewer patients on statin therapy having three or more
exacerbations compared to patients on placebo although this was not statistically
significant. Larger multicentre studies are needed to assess exacerbations as the
primary endpoint. Our study findings, in addition to the studies listed above, it is
perhaps appropriate to conclude that the immunomodulatry effects of statins do not
have any detrimental effects on models of acute and chronic lung infection.
The literature supports long-term anti-infective therapies in bronchiectasis and
possibly anti-inflammatory therapies using macrolides. Three RCTs using macrolides
(2 studies with azithromycin; 1 study with erythromycin) as an anti-inflammatory
agent in bronchiectasis have been recently published (Wong et al 2012, Serisier et al
2013, Altenburg et al 2013). All three studies showed that 6-12 month use of
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macrolides, either in full dose or lower maintenance dose, led to reduced exacerbation
frequencies in bronchiectasis. Here we report the first study exploring the role of
statins as a potential anti-inflammatory therapy in bronchiectasis. With 6months statin
treatment, there was significant improvement in cough reduction, a decreased serum
IL-8 and an increase in airways neutrophil apoptosis. While the mechanism for cough
reduction is not entirely clear, we hypothesize that long term statins will enhance
apoptosis of sputum neutrophils thereby promoting resolution of inflammation.
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5.11. FUTURE PERSPECTIVES
In our 6 months study with atorvastatin in bronchiectasis, we showed that statins
reduce cough, enhance neutrophil apoptosis and leads to reduction in systemic
inflammation. Further mechanistic studies done following the RCT established that
statins enhance neutrophil apoptosis at 20 hours. We were also able to demonstrate
that statins reduce fMLF induced increase in [Ca2+]j and we hypothesize that
reduction in calcium flux regulates neutrophil apoptosis, although the mechanism for
this needs to be established.
Further mechanistic studies are needed to explore the mechanism by which statins
modulate Ca2+ flux in neutrophils. Rise in [Ca2+]j concentrations could be either
intracellular or extracellular. As discussed above, rise in [Ca2+]j comes from release
from endoplasmic reticulum by ionisitol triphosphate or from the sarcoplasmic
reticulum by cyclic ADP ribose; or influx via plasma membrane Ca2+ channels. The
most common signaling pathway that increases cytoplasmic Ca2+ concentrations is the
phospholipase C (PLC) pathway. G protein coupled receptors and the tyrosine kinase
receptors activate the PLC pathway by converting membrane phospholipid PIP2 to
IP3 and diacylglycerol. IP3 then releases Ca2+ from the endoplasmic reticulum.
Platelet activating factor (PAF) is a major inflammatory mediator activating
neutrophils by increasing [Ca2+]i concentration. PAF mobilizes cytosolic-free calcium
[Ca2+]j from inositol 1,4,5 triphosphate (InsPjj-sensitive endoplasmic reticulum (ER)
calcium stores via a G protein-coupled, phospholipase C-InsP3 pathway. Studies have
demonstrated that PAF induced calcium signals are dependent on store operated
calcium influx (SOCI) and hence therapeutic interventions blocking SOCI mediated
calcium mobilization will modulate inflammatory diseases.
Hence further studies are needed to establish if statins regulate Ca2+ flux by altering
the extracellular or intracellular pathways. If statins are regulating extracellular
Ca2+mobilization, is this occurring specifically by activation of store operated calcium
• • 2"Finflux receptors? Alternatively, if statins are mobilizing Ca by release from
intracellular stores, are statins mediating this response by the G-protein coupled
receptors or are the tyrosine kinase receptors? Exploring the role of statins in PAF
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2+mediated Ca flux , would help assess if statins cause cross receptor desensitization
or whether it affects Ca2+ flux further downstream.
Neutrophil apoptosis is significantly enhanced following statin treatment (as
demonstrated in chapter 4). However, it is not known whether the findings of
increasing apoptotic cells in bronchiectatic airways is consequent on uncontrolled
apoptosis or failure of clearance of apoptotic neutrophils by macrophages
(efferocytosis), thereby also leading to secondary necrosis. Statins have been shown
to increase efferocytosis in the murine lung and ex vivo in chronic obstructive
pulmonary disease alveolar macrophages in an HMG-CoA reductase-dependent
manner. However macrophages have not been studied in bronchiectasis and needs to
be explored further.
Arguably, the most important enzymes responsible for the cellular events occurring
during apoptosis are the caspase (cysteinyl aspartate specific protease) family of
enzymes. Of the 14 caspases identified so far, those involved in apoptosis are the
initiator caspases (caspase 8,9,10) and effector caspases (caspase 3,6,7) (Murphy et al
2003). The primary function of the effector caspases is the cleavage of key proteins
that leads to the characteristic features of apoptotic cells (Nicholson 1999). Do statins
regulate apoptosis by modulating the caspase pathway? Further studies assessing the
role of statins in caspase inhibition are needed.
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5.12. CONCLUSION
Pleoitropic effects of statins have now been well established. In our study, we found
that six months of atorvastatin improved cough in clinically significant bronchiectasis
patients. There was an increase in the number of airways apoptotic neutrophils
suggesting a possible reduction of inflammation and promotion of resolution, thereby
impacting on cough.
Multi-centered studies are now needed to assess whether long-term statin therapy can
reduce exacerbations. In addition, further studies are needed to assess statin treatment
in severe bronchiectasis in patients chronically colonized with Pseudomonas
aeruginosa.
Mechanistic studies have established that statins enhance neutrophil apoptosis and
this is perhaps regulated in part by [Ca2+], flux. Further studies are needed to explore
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Bronchiectasis is characterized by chronic cough, sputum production and recurrent chest infections.
The pathogenesis is poorly understood but pulmonary pathology shows excess neutrophilic airways
inflammation. Accumulating evidence suggests that statins have pleiotropic effects, including
modulation of innate and adaptive immune system and anti-inflammatory effects and therefore is a
potential novel anti inflammatory therapy for patients with bronchiectasis.
The aim of our study was to establish if atorvastatin could reduce cough, a key feature in
bronchiectasis.
Methods
In this RCT patients aged 18-79 years were recruited. Patients had clinically significant bronchiectasis,
which is patients with cough and sputum production when clinically stable, with two or more chest
infections in the preceding year and bronchiectasis confirmed on CT scan of the chest.
We excluded: current smokers or ex-smokers of less than 1 year, those with a greater than fifteen pack
year history or those with predominant emphysema on CT scan; cystic fibrosis; active allergic
bronchopulmonary aspergillosis; active tuberculosis; poorly controlled asthma; pregnancy or breast
feeding; known allergy to statins; currently on statins or statin use within 1 year; active malignancy;
chronic liver disease; patients on long term oral macrolides; patients chronically colonized with
Pseudomonas aeruginosa.
Sequence generation was done by block randomization of four, by Tayside pharmaceuticals, NHS
Tayside, for 30 patients to receive either atorvastatin 80mg or 30 to receive placebo orally, once daily
for 6 months. The placebo (lactose) was not matched to the atorvastatin in appearance. Pharmacy
directly dispensed study medications to the patients, hence allocation concealment was maintained at
all times to the study investigators. The primary endpoint of this study was a reduction in cough at 6
months compared to baseline as measured by the Leicester Cough Questionnaire (LCQ) score. It is a
19 item self completed quality of life measure of chronic cough which ranges from 3-21, a lower score
indicating a more severe cough. The minimum clinically important difference (MC1D) is 1.3 Units.
The LCQ score is repeatable over 6 months in stable disease. Analysis done was intention to treat.
Secondary outcomes included: forced expired volume in one second, forced vital capacity; incremental
shuttle walk test; qualitative and quantitative sputum bacteriology; exacerbation frequency; health
related quality of life; sputum neutrophil numbers and apoptosis; sputum myeloperoxidase and free
elastase activity; sputum-interleukin (IL)-8; systemic inflammation- white cell count, C-reactive
protein (CRP) and erythrocyte sedimentation rate, additional systemic inflammatory markers (IL-ip,
IL-6, IL-8, IL-10, IL-12p70 and tumor necrosis factor-a) and safety of therapy.
Trial number: NCT01299181; this trial is now completed.
Findings
There was evidence of a difference in baseline to 6-month change in LCQ between the treatment
groups, with a significant improvement in the statin treated group, with a mean difference 2.2, 95% CI
for difference (0.5, 3.9) p=0.01.
When analyzed as proportion of improvement in LCQ, in the statin treated group 40% patients had a
1.3 Units or more improvement in the LCQ compared with 17% in the placebo group; difference in
proportion 23% (95% CI for difference 1%, 45%), p=0.04.
Ten (33%) patients had an adverse event in the statin group compared to three (10%) in the placebo,
difference in proportion 23% (95% CI for difference 3%, 43%), p=0.02. There were however no
serious adverse events.
Interpretation
In this proof of concept study, six months of atorvastatin improved cough in bronchiectasis. Multi-
centered studies are now needed to assess whether long-term statin therapy can reduce exacerbations.




Bronchiectasis is a chronic disabling respiratory condition characterized by chronic cough, chronic
sputum production and recurrent chest infections. It is regarded as an orphan disease not because of its
rarity but because of the paucity of randomized controlled trials- 133 trials in a recent PubMed search,
compared with 8,748 for asthma.1 The true incidence of bronchiectasis in the modern era of using
computed tomography of the chest is not known. We have over 750 patients with bronchiectasis in
Edinburgh, UK monitored in secondary care from a total Edinburgh population of about 490,000, as
per the National Scottish Register 2011. Patients frequently utilize primary and secondary care
resources through consultations, A&E attendances and inpatient admissions.
The pathogenesis is poorly understood but pulmonary pathology shows excess neutrophilic airways
inflammation, but despite this over two thirds of patients are chronically infected with potential
pathogenic organisms.2 Described by PJ Cole in 1984, there is a vicious circle of airways inflammation
and bacterial infection.' The excessive neutrophilic airways inflammation leads to damage of the
bronchial wall and paradoxically promotes more airways inflammation and bacterial infection creating
a vicious cycle. Studies have shown that markers of systemic inflammation including CRP are elevated
and correlate directly to disease severity and inversely to lung function and quality of life in stable state
bronchiectasis.4 There is a lack of long-term evidence based therapies available and treatment to date
has focused on chest physiotherapy and long-term antibiotics. There are concerns about the use of long
term antibiotics in view of antibiotic resistance, side effects and healthcare associated infections. As a
result of this and the excess inflammatory response in the airways, there has been a drive to investigate
the efficacy of anti-inflammatory therapies.
Statins [3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors] have pleiotropic effects, which
include modulation of the innate and adaptive immune system and anti-inflammatory properties.5 6 For
example, during sterile inflammation statins attenuate neutrophil recruitment in animal and human
experimental systems.7 8 In an animal model of pulmonary infection with Staphylococcus aureus, high
dose statin therapy was shown to enhance the formation of extracellular DNA traps by phagocytes
within the lung and protect against dissemination of infection.9'10 Boyd et al, found that mice treated
with prolonged high dose statin, in a model of lung infection with S. pneumoniae, had a strong dose
dependent effect on protection against S. pneumoniae as evidenced by less neutrophil infiltration,
maintenance of vascular integrity and less chemokine protection." Additionally, observational studies
in community-acquired pneumonia have shown a reduction in 30-day mortality in patients who were
on prior statins.12 We hypothesized that long term statin treatment would improve patients' symptoms
through its anti-inflammatory effect consequent on reduced neutrophilic airways inflammation. The




Study Design and Setting
Patients were recruited from South East of Scotland Bronchiectasis Clinic in the Royal Infirmary of
Edinburgh, UK from November 2010 to January 2013. We chose atorvastatin as it is a potent statin for
reducing cholesterol and we used it at maximum dosage as this is a proof of concept study. Ethical
approval was obtained from South East of Scotland Research Ethics Committee.
Randomization
Sequence generation was done by block randomization of four, by Tayside pharmaceuticals, NHS
Tayside, for patients to receive either atorvastatin 80mg or placebo orally, once daily for 6 months. The
placebo (lactose) was not matched to the atorvastatin in appearance. As pharmacy directly dispensed
study medications to the patients, allocation concealment was maintained at all times to the study
investigators. The allocation sequence was generated by Tayside pharmaceuticals. The patients were
enrolled and assigned to the study by the investigators. The investigators (who also performed the
various interventions and assessment) were blinded as the study medications were directly dispensed
by pharmacy to the patients. The study statistician analyzed the data. Pfizer, an American based
company, manufactures Atorvastatin.
Participants
In this RCT, patients aged 18-79 years were recruited. Patients had clinically significant bronchiectasis,
which is patients with cough and sputum production when clinically stable, with two or more chest
infections in the preceding year and bronchiectasis confirmed on CT scan of the chest. For
bronchiectasis to be diagnosed, the CT scan of the chest was required to show bronchial dilatation, with
a bronchus to arterial ratio >1.
We excluded: current smokers or ex-smokers of less than 1 year, those with a greater than fifteen pack
year history or those with predominant emphysema on CT scan; cystic fibrosis; active allergic
bronchopulmonary aspergillosis; active tuberculosis; poorly controlled asthma; pregnancy or breast
feeding; known allergy to statins; currently on statins or statin use within 1 year; active malignancy;
chronic liver disease; patients on long term oral macrolides due to the interaction with statin therapy
and patients chronically colonized with Pseudomonas aeruginosa (defined as two or more isolates of
Pseudomonas aeruginosa whilst clinically stable in 6 months prior to the study). Patients chronically
colonized with Pseudomonas aeruginosa were excluded, as they are patients with more severe
disease1114 and the objective of this study was to investigate atorvastatin in less severe bronchiectasis.
Procedures and Outcomes
The primary outcome of this study is a reduction in cough at 6 months compared to baseline as
measured by the Leicester Cough Questionnaire15 score. We have validated use of this scoring system
in bronchiectasis.16 Cough is a key feature in bronchiectasis and improving this is of major importance
to patients with bronchiectasis.
Secondary outcomes included: forced expired volume in one second (FEVi), forced vital capacity
(FVC) and its ratio; incremental shuttle walk test; qualitative and quantitative sputum bacteriology;
exacerbation frequency; health related quality of life assessed by the St George's Respiratory
Questionnaire; assessment of sputum neutrophil numbers and apoptosis; neutrophil activation in the
airway by measuring sputum myeloperoxidase and free elastase activity; neutrophil chemottractant in
sputum interleukin (IL)-8; systemic inflammation- measuring white cell count, C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR), additional systemic inflammatory markers [IL-lp,
IL-6, IL-8, IL-10, IL-12p70 and tumor necrosis factor (TNF)-a] -and safety of statin therapy.
Assessments
Assessments below were done at baseline and 6 months. At 3 months, blood tests and compliance was
checked (data not presented).
Cough was assessed using the Leicester Cough Questionnaire (LCQ). It is a 19 item self completed
quality of life measure of chronic cough which ranges from 3-21, a lower score indicating a more
severe cough. The minimum clinically important difference (MCID) is 1.3 Units. The LCQ score is
repeatable over 6 months in stable disease (intraclass correlation coefficient of 0.96 (95%CI 0.93-0.97),
pO.OOOl).16
An induced sputum using hypertonic (3%) saline for 10 minutes was collected.17 Each sample was
confirmed to be a valid sample suitable for processing if there are >25 polymorphonuclear leukocytes
and <10 squamous cells present on Gram stain on low power magnification. 1 ml of the sample was
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used for qualitative and quantitative microbiology. Sputum was homogenized and liquefied using an
equal volume of dithiothreitol and serially diluted using sterile 0.85% saline to achieve dilutional
factors of 10"' to 10"4. Pseudomonas isolation agar (Difco), chocolate blood agar containing bacitracin
(Oxoid) and horse blood agar (Oxoid) plates were inoculated with 100 pi of dilution. These were
incubated at 37°C for 48 hrs. Colonies of the pathogens were then counted to determine the sputum
bacterial density, expressed as log10 colony forming units/ml (cfu.mf1). The rest of the sample was
divided equally into portions; the first was treated with 0.1% dithiothreitol to assess total cell numbers
and cytocentrifuge samples prepared for total and differential cell counts. Briefly, sputum was washed
twice, centrifuged, filtered and cytocentrifuge samples prepared. Cell differential counts determined by
counting 400 cells per sample.18 Apoptosis was confirmed by the colour and shape change of the
neutrophil nuclei on the cytospins of sputum samples, as visualized under the microscope. The rest was
ultracentrifuged at 30000g for 90 min at 4°C.19 The sol phase was stored at -70°C until needed for
analysing the myeloperoxidase, free neutrophil elastase and IL-8. Myeloperoxidase activity was
measured by a chromogenic substrate assay,20 free elastase activity (NE) was measured
spectrophotometrically using the synthetic substrate methoxysuccinyl-ala-ala-pro-valparanitroanilide
(MeOSAAPVpNa) (Sigma),1921 and IL-8, a key neutrophil chemoattractant in bronchiectasis22 was
assayed using commercially available specific ELISAs (R&D Systems).
Pre bronchodilator FEV|, FVC and FEV,/FVC followed by an incremental shuttle walk test were
performed (an externally paced, 10 metre incremental field walking test with assessment of dyspnoea
before and after using the BORG scale recorded).2.
Health related quality of life was measured using the St George's Respiratory Questionnaire.24 It is a
50 item self administered health related quality of life questionnaire with a total score ranges from 0-
100; a higher score indicates a poorer health related quality of life. The minimum clinical important
difference is 4 units.
Thirty ml of venous blood was collected for full blood count, ESR, CRP, urea, electrolytes, creatinine
kinase and liver function tests. 5 ml of blood was centrifuged at 750g for 10 min and the supernatant
collected and stored at -70°C, for measuring pro and anti inflammatory cytokines and chemoattractants
by cytometric bead array (BD™ Cytometric Bead Array kits).
Side Effects
The presence or absence of side effects was assessed at all study visits. If the alanine
aminotransaminase was greater than five times normal or the creatinine kinase greater than three times
normal, the study medication was stopped. All side effects were recorded in a patient diary card.
Infective Exacerbations during the Study
Exacerbations were defined as per the BTS guidelines.25 Exacerbations were treated according to their
baseline sputum bacteriology and received 14 days oral antibiotic treatment. Macrolides were not used
because of the interaction with statin therapy.
Sample Size
Using a two-sided two-sample test with a 5% level of significance, 90% power, a sample size per
group of 27 was needed to detect a change of 1.3 Units in the Leicester Cough Questionnaire. 1.3 Units
was chosen as this is the accepted minimum clinically important difference. 30 patients were recruited
in each group to allow for dropouts.
Statistical Analysis
All data was analyzed on SAS, Version 9.2. We used an intention to treat analysis for the primary
endpoint and a modified intention to treat analysis for the secondary endpoints. For demographic and
clinical variables, data are presented as median (interquartile range) for continuous variables and n (%)
for categorical variables unless otherwise stated. Baseline to 3 and 6 month change of LCQ was
calculated by an unpaired t-test between those receiving atorvastatin versus placebo, as the data was
normally distributed. To compare the proportion of patients with clinical improvement as measured by
the LCQ or quality of life as measured by the SGRQ a binomial test for the comparison of proportions
has been used and differences presented as percentages with accompanying 95% confidence intervals
[CI]. Categorical data have been compared between groups using Chi-squared test. A P-value of <0.05
was considered statistically significant for each analysis.
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Role of funding source
This study is registered with ClinicalTrials.gov, number NCT01299181.
The funding source had no role in the study design, data collection or analysis or in writing the report.




Study enrollment started on 26th June 2011. 60 patients were randomized to receive treatment; 30
received active treatment with atorvastatin 80 mg and 30 received placebo. 24 and 29 completed the
study in the active and placebo group respectively. 2 patients in the statin group isolated Pseudomonas
aeruginosa at baseline only and were not chronically infected with Pseudomonas aeruginosa.
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Consort Diagram
Enrollment Assessed for eligibility (n=82)
Excluded (n= 22)
♦ Not meeting inclusion criteria (n= 14)




Jlocated to atorvastatin 80mg OD (n=30)
Received allocated intervention (n=30)
Did not receive allocated intervention (n= 0)
A
Discontinued intervention (n=6)
1 due to ALT>5 times normal
1 due to diarrhoea
2 due to headache and diarrhoea
1 due to headache





30 analyzed for primary outcome
analysis
24 analyzed for secondary endpoints
• 24 analyzed for
exacerbations
• 24 analyzed for sputum cell
counts
Analysis
Allocated to placebo intervention (n=30)
♦ Received allocated intervention (n=30)
♦ Did not receive allocated intervention (n=0)
Discontinued intervention (n=1)
1 due to other reason
Completed treatment n=29
30 analyzed for primary outcome
analysis
29 analyzed for secondary
endpoints
• 29 analyzed for
exacerbations




There was evidence of a difference in baseline to 6-month change in LCQ between the treatment
groups, with a significant improvement in the statin treated group, with a mean difference 2.2, 95% CI
for difference (0.5, 3.9) p=0.01.
When analyzed as proportion of improvement in LCQ, in the statin treated group 40% (12/30) patients
had a 1.3 Units or more improvement in the LCQ compared with 17% (5/30) in the placebo group;
difference in proportion 23% (95% CI for difference 1%, 45%), p=0.04 (Figure 1).
At 3 months
There was evidence of a difference in baseline to 3-month change in LCQ between the treatment
groups, with a significant improvement in the statin treated group, with a mean difference 3.3, 95% CI
for difference (0.9, 5.6) p=0.006.
Sputum Microbiology
Haemophilus influenzae was the most common colonizing organism in both groups at baseline. At the
end of treatment, 19/30 (63%) were colonized with microorganisms in the statin group [17/30 (57%) at
baseline], compared to 12/30 (40%) in the placebo group [12/30 (40%) at baseline]; for end of
treatment proportion. There was no difference in bacterial load when comparing the baseline to 6-
month change on the basis of treatment. Mean change in bacterial load was -2.9xl07 (1.3X107) cfu/ml
after 6-months of statin therapy. In the placebo group, mean change in bacterial load at the end of
treatment 1.9xl07 (1.2X107) cfu/ml.
Sputum differential count
After 6-months, in the statin treated group, there was an increase in number of apoptotic neutrophils/
400 cells counted for each sample and a reduction in the total number of sputum neutrophils; table 2
and appendix 1. There were less viable neutrophils and more apoptotic neutrophils. In the placebo
group, there was minimal change. There was no evidence of a difference in the number of eosinophils,
basophils or monocytes, between active and placebo groups (see table 2).
Sputum inflammatory markers
There is no difference in the baseline to 6month change in IL-8, MPO or free NE between those treated
with statin compared to placebo (table 2).
Spirometry
There was no difference in the baseline to 6-month change by treatment for FEVt, FVC or FEV,:FVC
ratio (table 2).
Exercise Capacity
There was an improvement in the baseline to 6-month change in the statin treated group (table 2).
Systemic Inflammation
There was a reduction in IL-8 in the atorvastatin group (table 2), compared to baseline. However, there
was no effect on the IL-lp, IL-6, IL-10, IL12p70 or TNF-a levels (data not shown). In the placebo
group, none of the inflammatory markers were significantly reduced.
There was no difference in the baseline to 6-month change in leucocyte count, total neutrophil count or
ESR in the treatment group. However, CRP levels decreased in the statin treated group (table 2).
Exacerbation Frequency
8/24 (33%) of patients on statin had 2 or more exacerbations compared to 16/29 (55%) in the placebo
group, with a relative risk ratio of 0.6 (95% CI 0.3-1.2).
5/24 (21%) of patients on statin had 3 or more exacerbations compared to 10/29 (34%) in the placebo
group, with a relative risk ratio of 0.6 (0.2-1.5).
Quality of life- St. George's Respiratory Questionnaire
There was a mild improvement in the total SGRQ scores in the statin treated group, but not meeting the




There was no difference in the baseline to 6-month change in urea, creatinine, alanine aminotransferase
(ALT), or creatinine kinase levels in those treated with statin compared to placebo. However, there was
a difference in the baseline to 6-month change in cholesterol in the statin group exhibiting a greater
drop, difference in means -1.40, 95% CI (-1.77, -1.02); p<0.0001 (table 2).
Comparison of variables where compliant
Using the baseline to 6-month change in cholesterol levels as an indicator of compliance, a stratified
analysis was conducted.
In the placebo group, 27/29 did not have a reduction of lmmol/L point or more in cholesterol and in
the atorvastatin group, 15/24 had a reduction of lmmol/L or more. Within these patients, there is
evidence of a difference in baseline to 6-month change in LCQ between the treatment groups,
difference 2.2, 95% CI for difference (0.4, 3.9) p=0.016.
Comparison of primary outcome where CRP was reduced or remained stable or worsened
Independent of the CRP response, patients on statins had improved LCQ score, see table 2.
Comparison of primary outcome in never smokers
Subanalyses of the data in never smokers in both groups, detected a LCQ improvement in 10 out of 26
patients in the statin group, compared to 2 out of 18 in placebo; 34% difference in proportion (95% CI
13%, 57%);p=0.04.
There were 26 never smokers in the statin treated group and 4 ex smokers. All 4 ex smokers dropped
out of the study and hence no analysis was done on ex-smokers due to lack of comparative baseline to
6month data.
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Adverse Events and Safety
Ten of 30 (33%) patients had an adverse event in the statin group compared to three of 30 (10%) in the
placebo, difference in proportion 23% (95% CI for difference 3%, 43%), p=0.02. There were however
no serious adverse events.
2/30 (7%) patients in the statin group developed leg pain in the first week of starting the treatment, but
this subsided in the second week for both patients. 1/30 (3%) in the statin group and 2/30 (7%) in the
placebo group had raised creatinine kinase (CK) while on treatment (<three times upper limit of
normal). This was detected at 3 months after starting treatment. These patients had repeat CK levels
measured after 1 week and there was either a reduction in the levels or the levels had normalized. No
patients had to withdraw from the study due to high CK levels. In the statin group, 1/30 (3%)
developed headache, while on treatment and had to withdraw from the study due to it. Diarrhoea was
reported in 1/30 (3%) patient within 1 week of starting statin treatment and had to discontinue due to
persisting diarrhea. 2/30 (7%) patients developed both diarrhoea and headache whilst on statin
treatment and both had to withdraw from the study, due to persisting symptoms. 1/30 (3%) of the
patients in both groups developed abdominal discomfort one week after starting treatment, but this
improved spontaneously and did not need to stop the trial therapy. At 3 months, 1/30 (3%) patient in
the statin group had an ALT of 325 U/L and, as this was >5times normal, the patient was withdrawn
from the study. Checking ALT, three days after stopping treatment with statin, showed that it had
normalized. 1/30 (3%) patient in the statin group developed haematuria during the first week of starting
the treatment. However, he was known to have renal calculi, surgeons reviewed him to confirm this,
and he underwent lithotripsy for the renal calculi and continued the study treatment. All patients had
normal renal function throughout the study, when measured at baseline and 6-months; table 2.
Adverse events of the study are summarized in table 3.
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DISCUSSION
Six months treatment with high dose atorvastatin led to an improvement in cough from baseline. Cough
is one of the cardinal features of bronchiectasis and high dose atorvastatin for 6-months in patients with
clinically significant bronchiectasis led to significant reduction of cough, in 40% of patients, the
primary end point of this study. In comparison, only 17% had a reduction in cough in the placebo
group. There were also reduced IL-8 levels in serum and an increased number of apoptotic airway
neutrophils and a reduction total number of neutrophils in the sputum in the atorvastatin treated
subjects. There was an improvement in exercise tolerance and a reduction in systemic inflammation
(CRP) in the statin treated group. There was an association with CRP reduction and LCQ improvement
in the statin treated group. In addition, there was an association between statin therapy and
exacerbation frequencies with a relative risk reduction in patients with 2 or more exacerbations or 3 or
more exacerbations. This exacerbation reduction however did not reach statistical significance but the
study was not powered for this end point. There was no effect on spirometry, airways inflammation,
bacterial colonisation or load and quality of life during the study. The study was however not powered
for these endpoints. Subanalysis of the data based on compliance to therapy, showed the same results
as analysis of the study as a whole. The primary end point was still achieved confirming that although
the study was small, the study findings are robust.
There was a reduction in systemic IL-8 levels after 6months of atorvastatin. It is known that IL-8 and
leukotriene-EL (LTB4) are responsible for the majority to the chemotactic activity of bronchiectatic
lung secretions.25 There was no reduction however in sputum IL-8 levels and hence we are unable to
correlate the reduction in systemic IL-8 levels to the other findings in the study.
Immunomodulatory effects of statins have been studied in other chronic lung conditions. Wang et al
were able to demonstrate that in COPD, prior statin use was associated with reduced exacerbations
requiring hospitalization.26 In addition, long term (>2 years) statin use was associated with a 39%
decrease in risk of death in COPD patients.27 In a large study of 501 lung transplant patients, Li et al
demonstrated a strong association between postoperative statin administration and improvement of
survival, maintenance of graft lung function and slowing of the onset of bronchiolitis obliterans.28
In our study, there was an increase in number and proportion of apoptotic neutrophils, decrease in the
proportion of viable neutrophils and a reduction in the total number of neutrophils, obtained from
sputum of patients at the end of 6months of atorvastatin treatment. We therefore hypothesize that this
decrease in the overall number of neutrophils may be related to the altered lifespan of the neutrophils in
response to statin treatment. In bronchiectasis, there is prolonged neutrophil persistence that promotes
excess airways inflammation.18 It has been well established that there is a key role for apoptosis, or
programmed cell death, in the regulation of inflammation and the host immune response.29 Although
neutrophils appear to be committed to death via apoptosis, it is now clear that the life span and
functional activity of mature neutrophils can be extended significantly by proinflammatory cytokines,
including granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor,
interferon gamma, TNF-a and IL-2.29 In contrast, we have shown that neutrophil apoptosis can be
induced by treatment with agents such as cyclin-dependent kinase (CDK) inhibitor drugs, with
consequent pro-resolution effects.30 31 In addition, studies using in vivo models of pneumococcal
infection, have demonstrated that inducing apoptosis of neutrophils improved resolution of
inflammation and accelerated recovery.32 Several reports have found that statins reduce the levels of
the anti-apoptotic protein Bcl-2 and increased apoptosis and cell death, in human cancer cell lines and
murine non-cancer cells.33 There is also evidence demonstrating that statins enhance efferocytosis in
vitro and in vivo, and that they may play an important therapeutic role in diseases where efferocytosis,
a key regulator of inflammation is impaired.34
The role of statins in promoting apoptosis in airway neutrophils or the mechanism by which statins
increase apoptotic neutrophils in sputum in bronchiectasis remains to be explored. However, it is clear
that "switching off' of the activated neutrophils and inducing apoptosis has therapeutic potential in
bronchiectasis by promoting the resolution of inflammation.
Studies using animal sepsis models have also demonstrated that statins reduce endothelial dysfunction
and have anti-thrombotic effects that improve outcome.35 We found no adverse effect on viable
bacterial load in the sputum of the statin treated patients. Fewer patients on statin therapy had two or
more and three or more exacerbations compared to patients on placebo. This exacerbation reduction
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however did not reach statistical significance but the study was not powered for this end point. Larger
multicentre studies are needed to assess exacerbations as the primary endpoint.
Surprisingly, there was no reduction in sputum MPO or neutrophil elastase as might be expected. It is
expected apoptotic neutrophils would maintain membrane integrity until clearance and have reduced
ability to degranulate, generate a respiratory burst, or undergo shape changes in response to external
stimuli.36 However, release of these granule contents could occur before the induction of apoptosis.
These results are similar to a study by Llewellyn-Jones et al, where indomethacin 75 mg per day was
given to 9 patients with clinically stable bronchiectasis/7 Pre-treatment with indomethacin, led to a
reduction in neutrophil chemotaxis but had no effect on sputum MPO or free elastase activity,
suggesting that these measurements in sputum may not accurately reflect airway neutrophil numbers.
Further mechanistic studies will be needed to assess the immunomodulatory effects of statins on
neutrophils.
The literature supports long-term anti-infective therapies in bronchiectasis and possibly anti¬
inflammatory therapies using macrolides. Four RCTs using macrolides (3 studies with azithromycin; 1
study with erythromycin) as an anti-inflammatory agent in bronchiectasis have been recently
published.38"41 All studies showed that 6-24 month use of macrolides, either in full dose or lower
maintenance dose, led to reduced exacerbation frequencies in bronchiectasis. To the authors' best
knowledge, this is the first study exploring the role of statins as a potential anti-inflammatory therapy
in bronchiectasis. With 6months statin treatment, there was significant improvement in cough
reduction, a decreased serum IL-8 and an increase in airways neutrophil apoptosis. While the
mechanism for cough reduction is not entirely clear, we hypothesize that long term statins will enhance
apoptosis of sputum neutrophils thereby promoting resolution of inflammation.
The major risk factor of long term statin use is myositis and deranged liver function tests.42 In our
study we used the maximum dosage of statin and hence more side effects were anticipated. 5 (17%) did
not tolerate statins due to headache, diarrhoea and deranged liver function tests.
There were more dropouts in the statin group compared to the group on placebo (6 (20%) compared to
1 (3%) in the placebo), the most common cause for dropout was headache and diarrhoea. There were
no dropouts due to myositis but deranged liver function tests necessitated withdrawal of one patient.
The only dropout from the placebo group was due to personal reasons.
24 (80%) in the statin group were able to tolerate the high dose statins and complete the full 6-month
treatment. Baseline liver functions need to be recorded when starting patients on statins. Liver function
tests need to be checked at 3months and at lyear after commencing treatment or earlier if there is any
indication to do so. Although there were no cases of withdrawal due to myositis in the study, patients
should be encouraged report symptoms of myositis necessitating monitoring of creatinine kinase once
reported.42
Limitations
This is a small proof of concept study that was not powered for any of the secondary end points. There
was not an exact matching of the active treatment and placebo. The researchers were all blinded to
treatment and the study pharmacist dispensed the study medications. We have no reason to believe that
the patients were not blinded. Although there was fixed block randomization of four that was used, the
investigators were not aware of the treatment, as the allocation was done by an external source. Some
patients had a smoking history but we excluded patients with greater than 15 pack year smoking history
and evidence of significant emphysema on CT of the chest, making significant COPD unlikely.
Conclusions
Six months of atorvastatin improved cough in bronchiectasis patients. There was an increase in the
number of airways apoptotic neutrophils suggesting a possible reduction of inflammation and
promotion of resolution, thereby impacting on cough.
Multi-centered studies are now needed to assess whether long-term statin therapy can reduce
exacerbations. In addition, further studies are needed to assess statin treatment in severe bronchiectasis
in patients chronically colonized with Pseudomonas aeruginosa.
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Research in context panel
Systematic Review
Bronchiectasis is a chronic disabling respiratory condition characterized by chronic cough, chronic
sputum production and recurrent chest infections. There is evidence from in vitro studies to suggest
that statins have immunomodulatory properties. In particular statins have been shown to reduce
neutrophil activation in healthy volunteers challenged to sterile inflammation. International cohort
studies in COPD, pneumonia and lung transplantation have demonstrated that prior statin therapy was
associated with improved outcome. Bronchiectasis is a neutrophilic inflammatory disease where the
driver for persistent inflammation remains unknown but infection is hypothesized to play a major role.
There has been an international interest in anti inflammatory therapy in bronchiectasis. Available
evidence suggests that statins may have a role in modulating the inflammatory response in
bronchiectasis. A systematic review was carried out on any paper before November 2010 on Pubmed,
Medline and Embase using the terms 'bronchiectasis,' 'COPD', 'emphysema', 'pneumonia' and
'atorvastatin' or 'statin' and 'randomized control trial' before conducting the study. Only articles in
English were taken. There were no positive results. To the authors best knowledge, no previous studies
assessing the role of statins in bronchiectasis have been carried out.
Interpretation
Six months of atorvastatin improved cough, a major symptom in patients with bronchiectasis. A
potential mechanism found was that there was an increase in the number of airways apoptotic
neutrophils, suggesting a possible reduction of inflammation and promotion of resolution, thereby
impacting on cough. Although not statistically significant, there was also a relative risk reduction for 2
or more exacerbations and 3 or more exacerbations. This proof of concept study however was not
powered to address exacerbations and multi-centered studies are now needed to address whether long-
term statin therapy can reduce exacerbations.
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Figure la&b: Reduction of cough in the statin group, as measured by LCQ; *p=0.01 for comparison of
reduction in cough between both groups, at the end of 6months.
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Appendix 1. Increased levels of sputum neutrophil apoptosis following atorvastatin. Figure shows
neutrophils (XI000) from sputum (per 400 cells counted) in a patient after 6-months statins. Apoptotic
























BMI (Kg/m2) 28.8 (8) 28.1 (6.3) -
Aetiology -
Idiopathic 21 (70%) 21 (70%)
Post infectious 4 (13%) 4(13%)




IgG2 deficiency 0 1 (3%)
High BMI >30Kg/m2 11 (37%) 10(33%)
IHD 2 (7%) 1 (3%)
Asthma 19(63%) 17(57%)
Previous malignancy 1 (3%) 1 (3%)
Diabetes mellitus 1 (3%) 1 (3%)
Respiratory physiology -
Pre therapy FEVi (L) 2.1 (0.8) 2.2 (0.9)
FEV,
(% predicted)
78.3% (23.8%) 73.9% (24.5%)
Pre therapy FVC (L) 3(1.1) 3.2(1.1)
FVC (%predicted) 94.8% (4.2%) 86.4% (25.6%)
FEV, /FVC 69% (0.13%) 69.6% (0.12%)




Neutrophils (X109/L) 4.3 (1.9) 3.9(1.1)
ESR (mm/hr) 15.1 (11.7) 14.8 (10.7)










Mixed normal flora 13 (43%) 17(57%)
No sputum produced - 1 (3%)




Oral steroids 0% 2 (7%)
Long term antibiotic
for chest (penicillin)




Leicester Cough Questionnaire -
Units 13.1 (4.0) 15.1 (4.4)
Table 1. Baseline characteristics of study population. BM1 = body mass index; CRP= C-reactive
protein; FEV,= Forced expiratory volume in 1 second; FVC= Forced vital capacity; IgG2=
Immunoglobulin G2; IHD=ischemic heart disease.
# Breakdown ofmicroorganisms isolated at baseline (*Statin group, **Placebo group)
Haemophilus influenzae *8(27%); **6(20%); Streptococcus pneumoniae *4(13%); **1(3%);
Staphylococcus aureus *3(10%); **2(7%); Other enteric gram negative organisms *3(10%); **2(7%);
Pseudomonas aeruginosa *2(6%); Moraxella catarrhalis **1(3%). Some patients isolated more than 1
organism.
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Sputum differential count (per 400 cells counted) 1
Apoptotic neutrophil 5.5 (0.0, 15.0) 0.5 (0.0, 3.0)
Apoptotic neutrophil
(% difference of apoptotic
neutrophils)






(% difference of viable
neutrophils)


























































*3 5 (21%) 10(34%)
Systemic inflammation 3

























































































Table 2. Summary statistics of secondary end points and adverse effects. ALT= alanine
aminotransferase; CK= creatinine kinase; CRP= C-reactive protein; ESR= erythrocyte sedimentation
rate; FEVi= Forced expiratory volume in 1 second; FVC= Forced vital capacity; SGRQ= St. George's
Respiratory Questionnaire.




Leg pain 2 (7%) 0
Raised CK 1 (3%) 2 (7%)
Headache 3 (10%) 0
Diarrhea 3 (10%) 0
Abdominal discomfort 1 (3%) 1 (3%)
Deranged LFTs 1 (3%) 0
Haematutria 1(3%) 0
Table 3. Adverse events during the study.
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